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Cyanobactins are peptide natural products that fall under the broad class of 
the ribosomally synthesized and posttranslationally modified peptides (RiPPs). Since 
they are synthesized by the ribosome, the biosynthesis of these peptides is 
genetically encoded. A precursor peptide gene carries the primary amino acid 
sequence of the natural product. The precursor peptide is surrounded by other genes, 
which encode posttranslational enzymes that decorate the primary sequence with 
elaborate structural motifs. Due to the genetically encoded origins of the 
cyanobactins, simple manipulations at the peptide sequence level are tolerable and 
lead to the creation of a diversity of natural products. The roots to this tolerance lie 
in the innate extreme broad-substrate nature of the posttranslational enzymes. Here, 
we explore the biochemical basis of this promiscuity and in vitro methodologies to 
create structurally elaborate peptidic motifs. In addition, the cyanobactin 
biosynthetic machinery is a rich source of enzymes capable of performing a wide 
array of intriguing chemistry and here we probe into some of these mechanisms. Put 
together, the broad-substrate nature coupled with the unique enzymology of the 
cyanobactin biosynthetic machinery provides a toolkit for the creation of designer 
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1.1 What are cyanobactins? 
Cyanobactins are peptide natural products isolated from cyanobacteria, the 
first of which were the ulicyclamide and ulithiacyclamide from the marine ascidian 
Lissoclinum patella from Palau.1 This was followed by discovery of the patellamides 
A-C from the same L. patella organism.2 More than two decades later, it was shown 
that the patellamides originally isolated from ascidians were actually produced by 
symbiotic cyanobacteria harbored by the ascidian.3 An obligate cyanobacterial 
symbiont, Prochloron didemni, was found to carry genes that could be responsible 
for the biosynthesis of patellamides. The subsequent transfer of the putative 
biosynthetic genes to E. coli for heterologous production of patellamides confirmed 
the source of the natural product to be a result of marine symbiosis, in one of the 
first pioneering studies of connecting chemistry to a symbiont producer via gene 
transfers.3 At the time of discovery, these compounds were called “small cyclic 
peptides”, but the observation that common structural features are conserved across 
many small cyclic peptides, all of which are specific to cyanobacteria, led to the 
formal proposal of the term “cyanobactins” for this class of compounds.4 The 
structures of a few representative cyanobactins are drawn out in Figure 1.1.  
 
1.2 The biosynthetic machinery to cyanobactins 
If we overlook the structural details, the most universal feature of 
cyanobactins is that they all carry a peptide backbone. A precursor peptide gene 
carries the primary amino acid sequence of this backbone, which is embedded as a 
“core” sequence within the larger precursor peptide. Genes for tailoring enzymes 
that carry out elaborate structural modifications on the core sequence are present 
along with the precursor peptide gene in a single gene cluster. Since the primary 
	 3 
sequence is genetically encoded, the peptide backbone is synthesized by the ribosome, 
and tailoring enzymes decorate this backbone via posttranslational modifications. 
Figure 1.2A demonstrates a simple schematic of this biosynthetic route, which aligns 
the cyanobactins with the larger class of the ribosomally synthesized and 
posttranslationally modified peptide natural products (RiPPs). Among the RiPPs, 
differences in the identity of the posttranslational modifications and homology 
between the enzymes and substrates help classification of different peptide products 
into the different RiPP families.5 
All genes from the cyanobactin biosynthetic cluster are named as abcX, 























































































Figure 1.1 The structures of a few representative cyanobactins are shown. 
Common structural features such as presence of heterocyclic rings and isoprene 
units on the peptide backbone, which are shared across many cyanobactins, are 






example, the pat pathway produces patellamides,3 the tru pathway produces 
trunkamide,4 the pag pathway produces prenylagaramides,6 the lyn pathway 
produces aestuaramides,7,8 etc. “X” is the name given to each gene in the 
biosynthetic cluster. A minimal cyanobactin biosynthetic pathway comprises the 






















Figure 1.2 Biosynthesis of cyanobactins: (A) A simple schematic of the biosynthetic 
route to cyanobactins is shown. The genes responsible for synthesis of the final 
cyanobactin natural product are present as a single gene cluster. The gene in black 
represents the precursor peptide gene, which carries an embedded core sequence 
(blue) that has the primary amino acid backbone sequence of the natural product it 
is destined to be. The precursor gene is in turn flanked by different enzyme genes 
(grey) that are responsible for transforming the core backbone into elaborate 
structural motifs via posttranslational modifications. This is a general route to 
biosynthesis of not only the cyanobactins but also the larger class of the RiPP 
natural products. This figure is adapted from Sardar and Schmidt, Curr. Opin. 
Chem. Biol., 2016. (B) A minimal cyanobactin biosynthetic machinery is outlined 
which comprises the precursor peptide (E) that carries the core sequence, which is 
transformed into the final cyanobactin natural product by the action of two 
proteases (A and G). They proteolytically separate the core from the rest of the 





the action of at least two enzymes: an N-terminal protease (A) that cleaves off the N-
terminus of the core and a C-terminal protease (G) that cleaves off the C-terminus of 
the core in tandem with N-C macrocyclization of the free ends, to yield the final 
cyclic peptide (Figure 1.2B). There are often further modifications appended by 
additional posttranslational enzymes (see later). For example, for the pat pathway, 
patE is the precursor peptide gene that encodes the sequence of the final 
patellamide natural product. This is modified by the action of patD (heterocyclase), 
patA (N-terminal protease), patG (C-terminal protease/macrocyclase) and patOx 
(oxidase).3 The biochemical characterization of various posttranslational enzymes 
that are responsible for cyanobactin biosynthesis is detailed later. 
 
1.3 Plasticity of biosynthetic machinery 
The core sequence is a small stretch of amino acids embedded into the larger 
precursor peptide. The core is transformed into the final cyanobactin. Often, 
multiple copies of the precursor peptide are present within a single pathway. Within 
each copy, nearly the entire peptide sequence is highly conserved, but with the 
exception of hypervariability in the core sequence. This variety allows a single 
pathway to produce a multitude of natural products.9 The phenomenon of 
hypervariability in core sequence as the mechanism of creation of combinatorial 
libraries was described first in the conotoxin class of RiPPs.10,11 The cone snails that 
are the producers of these RiPPs synthesize a mixture or ‘cabal’ of toxins, instead of 
a single toxin. This ‘cabal’ of toxins acts synergistically to hunt prey. Apart from the 
cyanobactins, this feature of hypervariability has since then been explored in other 
RiPPs such as in the lanthipeptide family of prochlorosins.12  
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In addition to having multiple precursor peptides with variable cores, an 
extra layer of diversity is introduced in many cyanobactin pathways by the use of 
multiple cores in a single precursor peptide. For example, the ten pathway 
(teneucyclamide) carries up to four core sequences in a single precursor TenE.9 
Other than in cyanobactins, this feature of multiple cores has been observed only in 
plant-derived RiPPs such as cyclotides and orbitides13,14 and the fungal-derived 
RiPPs ustiloxins.15,16 
The strategy of using multiple variations of the core explains the immense 
substrate diversity leading to cyanobactin combinatorial libraries in nature. This 
raises the question whether the corresponding posttranslational enzymes are also 
changing to keep up with this substrate variation. This is not the case since the 
same set of biosynthetic enzymes is capable of producing the observed diversity. This 
can be explained by the example of the pat pathway. As of 2006, the pat pathway 
was known to produce 7 natural products. As shown in Figure 1.3, the pat pathway 
is capable of using a single set of 4 enzymes (patD, patA, patG and patOx) to carry 
out 62 different posttranslational modification reactions to create the 7 pat natural 
products. 9 The number of posttranslational reactions is expected to be even larger 
since many more pat natural products have been discovered after. This remarkable 
promiscuity of the enzymes is also reflected by their utility in the creation of 
artificial cyanobactin derivatives carrying non-proteinogenic amino acids17 and in 
the creation of artificial libraries, which demonstrated the potential of the tru 
pathway to produce >300 compounds.18 The noteworthy feature that stands out is 
that it is not one enzyme, but each and every posttranslational enzyme from the 
pathway that is extremely broad-substrate, such that the pathway as a whole unit is 




































































































































Figure 1.3 The concept of hypervariable cores leading to product diversity is 
explained with the help of the pat pathway. The pat gene cluster is shown, wherein 
the gene in black is the precursor peptide gene. Diversity is introduced in two ways: 
(i) multiple precursors with different core sequences and (ii) single precursor with 
multiple core sequences, with sequence variation in the core. PatE precursors 
(PatE1-7) that encode natural products (1, patellamide C; 2, patellamide A; 3, 
ulithiacyclamide; 4, lissoclinamide 2/3 that differ in stereochemistry; 5, 
lissoclinamide 4; 6, lissoclinamide 5; 7, patellamide B) are shown. These 7 
compounds carry 62 different modifications comprising heterocyclization, 
proteolysis, macrocyclization and oxidation at different sites, all of which are carried 
out by the same set of 4 enzymes (PatD, PatA and PatG fused to PatOx). Each 
modification site of heterocyclization is shown by a grey highlight in the core 
sequence (blue). The core is flanked by conserved recognition sequences (red) that 




The highly conserved elements in the precursor peptide that surround the 
core and are eventually removed during product maturation were proposed to act as 
recognition sites for the posttranslational enzymes. The recruitment of 
posttranslational enzymes by these recognition sequences would explain the innate 
promiscuity of these enzymes, since it allows recognition of the substrate to be 
separated from the actual site of catalysis, which lies in the core. This would allow 
the enzymes to encounter a diversity of substrates successfully for product
formation.3,4,9 This phenomenon has been explored with biochemical characterization 
and is the theme of Chapter 2 of this dissertation,19 and elements of this have been 
validated in a subsequent crystal structure report on a cyanobactin heterocyclase.20 
Described below is the enzymology of different members of the cyanobactin 
biosynthetic machinery with focus on the broad-substrate nature of each. 
 
 
1.4 Enzymology of biosynthetic machinery 
The detailed posttranslational events of cyanobactin biosynthesis are 
outlined in Figure 1.4. The first modification enzyme is a heterocyclase (designated 
as “D”), followed by the N-terminal protease (designated as “A) and C-terminal 
protease/macrocyclase (designated as “G”). Oxidases (designated as “Ox”) and 
prenyltransferases (designated as “F”) act after macrocyclization. The modifications 
of heterocyclization, oxidation and prenylation are present in only a subset of 
cyanobactins in different combinations. Efforts to identify and characterize new 
enzymes are also being uncovered. Given below are details of each characterized 




1.4.1 Heterocyclase (D) 
The heterocyclase acts on cysteine, serine or threonine residues enabling the 
attack of the amino acid thiol or hydroxyl group to the carbonyl of the preceding 
amide bond, to morph the peptide backbone into a heterocycle. Since the 
heterocyclases act on the full-length precursor peptide, this is the first step of the 
cyanobactin biosynthesis pathway if heterocyclization is present as a 
posttranslational modification. The first cyanobactin heterocyclases to be reported 
were PatD and TruD from the pat and tru pathways.21 PatD could modify both 
cysteine and serine/threonine residues, whereas TruD was chemoselective for 
cysteine. The reaction was found to be ATP dependent and the order of 
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1.4 Enzymology of biosynthetic machinery 
The detailed posttranslational events of cyanobactin biosynthesis are 
outlined in Figure 4. The first modification enzyme is a heterocyclase 
(designated as “D”), followed by the N-terminal protease (designated as “A) 
and C-terminal protease/macrocyclase (designated as “G”). Oxidases 
(designated as “Ox”) and prenyltransferases (designated as “F”) act after 
macrocyclization. The modifications of heterocyclization, oxidation and 
prenylation are present in only a subset of cyanobactins in different 
combinations. Efforts to identify and characterize new enzymes are also being 











Figure 4 A simple schematic of cyanobactin biosynthetic steps are shown. If 
heterocycles are present, this is the first step of the pathway. Proteolysis and 
macrocyclization are the subsequent steps, which is followed by oxidation and 
prenylation in certain pathways. 
Figure 1.4 A simple schematic of c nobactin biosynthetic steps is shown. If 
heterocycles are present, this is the first step of the pathway. Proteolysis and 
macrocyclization are the subsequent steps, which is followed by oxidation and 




heterocyclization was shown to proceed from the C-terminus end of the core 
sequence. TruD was found to have two domains, the N-terminal domain that 
contains zinc binding double CxxC motif and a C-terminal YcaO domain.22 Studies 
with YcaO domains from related RiPP heterocyclases had identified this domain to 
be catalytic and carrying the ATP binding site.23 Subsequently, the crystal structure 
of TruD was reported,24 followed by that of LynD (TruD homolog) from the lyn 
pathway,20 both of which reinvestigated the ATP usage by TruD.  
The broad-substrate nature of PatD/TruD were first demonstrated by studies 
that showed PatD could modify tru pathway substrates in addition to its native pat 
pathway substrates, a feature exhibited by TruD too.21 Sequence observation of 
precursor peptides from pathways that carried heterocyclization versus those that 
did not helped to identify a short sequence motif of LAELSEEAL in precursors of 
only those pathways that had a PatD homolog enzyme. This was proposed to be the 
putative recognition site of PatD-like enzymes,6 which was later shown to be true in 
three contemporary studies,19,24,25 one of which is a part of Chapter 2 of this 
dissertation.19 These studies also explored the broad-substrate nature of the 
heterocyclases demonstrating that almost no sequence limitation exists in what core 
sequences PatD homologs can accept. 
 
1.4.2 N-terminal protease (A) and C-terminal protease/macrocyclase (G) 
All cyanobactin pathways carry two proteases that cleave off the ends of the 
core sequence, separating it from the rest of precursor peptide. The N-terminal 
protease proteolytically cleaves the N-terminus of the core and the C-terminal 
protease acts on the C-terminus. The C-terminal protease additionally seals the free 
ends into a N-C macrocycle, such that it is also a macrocyclase. The first proteases to 
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be functionally characterized were PatA and PatG.26 This study also gave a peek at 
the broad-substrate nature of the enzymes since both could be used in the creation of 
the non-native natural product eptidemnamide, a homolog of the rattlesnake-
derived anticoagulant eptifibatide.  
Further studies demonstrated the true broad-substrate nature of PatG by 
creation of a small library of cyclic peptides, some of which carried non-canonical 
amino acids and polyketide insertions.27 Sequence analysis of the amino acid stretch 
flanking the core and observations from biochemical studies led to the identification 
of a GVDAS-like sequence flanking the N-terminus of the core to be the recognition 
site for PatA homologs. Similarly, an AYDGE-like sequence flanking the C-terminus 
of the core was identified as the recognition for PatG homologs. In addition, PatG 
and homologs require a C-terminal heterocycle for functional activity.3,4,26,27 Both 
cyanobactin proteases are serine proteases that carry the canonical Ser-His-Asp 
catalytic triad. Molecular details of recognition and catalysis have been explored 
with subsequent crystal structure reports of both PatA and PatG.28-30 
 
1.4.3 Oxidase (Ox) 
An oxidase enzyme is responsible to convert thiazoline, oxazoline and methyl 
oxazoline heterocyclic rings in cyanobactins into the corresponding azoles. Related 
RiPP pathways that carry heterocyclization modification usually require the oxidase 
and heterocyclase in an associated unit to be functional, as in the case of microcin 
B17.31 The cyanobactin oxidase on the other hand has a greater degree of freedom in 
that it is never found associated with the heterocyclase. It can exist as a stand-alone 
enzyme (tri pathway to trichamides),32 fused to the C-terminal 
protease/macrocyclase in many cases (pat) or be absent altogether (tru). The 
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oxidases carry an FMN-binding site and are postulated to require FMN to be the 
electron donor for oxidation. Due to difficulty in purification of the oxidases, it was 
previously uncharacterized. A recent report studied the oxidase activity of two 
enzymes (Thcoxi and Apoxi) from the thc and art pathways that produces the 
cyanothecamides and arthrospiramides, respectively.30 Both the oxidases were found 
to be FMN-dependent. Thcoxi could only act on heterocycles that were conformed into 
the N-C macrocycle, and failed to be active on linear peptide sequences carrying 
heterocycles, whereas Apoxi could oxidize heterocycles in both linear and cyclic 
peptides. As with the other enzymes from the cyanobactin biosynthetic machinery, 
the Thcoxi and Apoxi were also found to be tolerant of substrates from non-native 
pathways.33 
 
1.4.4 Prenyltransferase (F) 
Prenylation is a feature unique to the cyanobactins, and found to be present 
in only one other RiPP called ComX involved in quorum sensing.34 The first to be 
characterized from this enzyme class was LynF (lyn pathway producing 
aestuaramides) that is responsible for the reverse O-prenylation of tyrosine hydroxyl 
side group, which undergoes a spontaneous Claisen rearrangement to yield forward 
C-prenylated tyrosine products.7 The crystal structures of a LynF homolog called 
PagF (pag pathway producing prenylagaramides) that forward O-prenylates 
tyrosine hydroxyl group is currently under study. The first forward O-
prenyltransferase of serine/threonine hydroxyl was TruF1 (tru pathway), which is 
characterized in a part of Chapter 3 of this dissertation.35 More recently, a C-
prenyltransferase KgpF (kgp pathway to kawaguchipeptin) has been characterized 
that is involved in C-prenylation of tryptophan residues.36 
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Like the other members of the cyanobactin biosynthetic machinery, all of the 
above prenyltransferases exhibit promiscuity in that they can accept both native and 
non-native substrates. The characterized prenyltransferases prefer cyclic peptide 
substrates. This establishes prenylation as the final step of cyanobactin biosynthesis 
occurring after macrocyclization. Interestingly, apart from various cyclic peptide 
substrates, these prenyltransferases are also capable of accepting various lengths of 
linear peptides. Additionally, both LynF and PagF have been shown to accept boc-
tyrosine residues and derivatives, leading to creation of small molecule libraries 
with prenylation motifs. 
 
1.4.5 New enzymology 
The cyanobactin biosynthetic machinery is a treasure trove of new 
enzymology. Many more enzymes are awaiting discovery. Many natural products 
exist with cyanobactin-like structures with new chemical motifs, but lack of 
biosynthetic information precludes characterization of the corresponding 
enzymology. The reverse is also true, in that there are many new cyanobactin-like 
gene clusters with new proteins in public genome databases, but lack of structural 
data of the final natural products disables connecting enzymology and chemistry. 
Some recent genome mining stories have connected new cyanobactins to 
identification of new enzymes. For example, the pir cluster to piricyclamides was 
identified, and the natural products were found to be geranylated, indicating that 
the PirF prenyltransferase homolog in the cluster is actually a geranyltransferase.37 
This is a rare posttranslational modification among the RiPPs, and this enzyme is 
currently awaiting functional biochemical characterization. 
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Another study reported that small linear peptide natural products, 
aeruginosamide B-C and viridisamide with N-terminal prenylation and C-terminal 
methylation, are actually cyanobactins. These are the first linear cyanobactins to be 
reported in literature. Analysis of the biosynthetic gene cluster showed clear 
homology to cyanobactin enzymes and precursor peptide.38 Interestingly, this gene 
cluster identified a new enzyme, a single enzyme with a prenyltransferase and 
methyltransferase domain fused. The biochemical characterization of this enzyme is 
a focus of Chapter 5 of this dissertation. 
 
1.5 Questions addressed in this dissertation 
With the above background information, the questions we asked in this 
dissertation are the following. The first question that arises is that of the 
biochemical basis of the extreme promiscuity of the cyanobactin biosynthetic 
enzymes, which is the focus of Chapter 2 of this dissertation.19 This chapter 
identifies the recognition sequence for the heterocyclase enzyme, and coupled with 
the previously known recognition sequences of the cyanobactin proteases, 
demonstrates how these elements can explain the extreme flexibility of cyanobactin 
biosynthesis. With this understanding of what governs selectivity in these enzymes, 
the next question was how we could use different enzymes in combinations for the 
synthesis of cyanobactin natural products and novel derivatives. This led to 
development of an in vitro toolkit for the creation of modified cyclic peptide motifs, 
which is the focus of Chapter 3.35 Chapter 4 describes the principles and methods for 
the production of cyanobactins and derivatives both in vitro and in vivo through the 
use of heterologous expression host E. coli.39 Chapters 5 and 6 delve deeper into the 
intriguing enzymology of specific enzymes from the cyanobactin biosynthetic 
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machinery. Chapter 5 provides the first biochemical characterization of a fused 
methyl-prenyl transfer enzyme capable of performing dual chemistry on peptide 
substrates, whereas Chapter 6 explores the mechanism of action of the heterocyclase 
TruD with regard to its ATP usage. It is fascinating how a biosynthetic pathway 
from the marine environment is intrinsically rich in interesting enzymology, which 
holds immense engineering potential in the field of creation of peptide-derived 
biologically important chemical scaffolds. This is the theme of Chapter 7,40 which 
describes the principles that allow combinatorial chemistry not only in the 
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ABSTRACT: Ribosomally synthesized and posttranslationally modiﬁed peptide (RiPP) natural
products are of broad interest because of their intrinsic bioactivities and potential for synthetic
biology. The RiPP cyanobactin pathways pat and tru have been experimentally shown to be
extremely tolerant of mutations. In nature, the pathways exhibit “substrate evolution”, where
enzymes remain constant while the substrates of those enzymes are hypervariable and readily
evolvable. Here, we sought to determine the mechanism behind this promiscuity. Analysis of a
series of diﬀerent enzyme−substrate combinations from ﬁve diﬀerent cyanobactin gene clusters, in
addition to engineered substrates, led us to deﬁne short discrete recognition elements within
substrates that are responsible for directing enzymes. We show that these recognition sequences
(RSs) are portable and can be interchanged to control which functional groups are added to the
ﬁnal natural product. In addition to the previously assigned N- and C-terminal proteolysis RSs, here we assign the RS for
heterocyclization modiﬁcation. We show that substrate elements can be swapped in vivo leading to successful production of
natural products in E. coli. The exchangeability of these elements holds promise in synthetic biology approaches to tailor peptide
products in vivo and in vitro.
KEYWORDS: cyanobactins, posttranslational modiﬁcations, ribosomally synthesized and posttranslationally modiﬁed peptides (RiPP),
recognition sequences, substrate evolution
Ribosomally synthesized and posttranslationally modiﬁed
peptides (RiPPs) are ubiquitous natural products found in all
branches of life. The resulting compounds are chemically
diverse, and their biological activities are equally varied. For
example, some RiPPs are cofactors, while others are secreted
antibiotics, cytotoxins, or quorum sensing molecules, among
many other activities.1 Despite the many types of possible
posttranslational modiﬁcations (PTMs) in RiPPs, RiPP path-
ways share some nearly universal features.2,3 First, the natural
products are encoded on a precursor peptide, which is
ribosomally translated. Within the precursor peptide, a core
peptide represents the sequence of the active natural product.
Recognition sequences (RSs) often ﬂank the core peptide,
where they direct enzymes that modify the core, and are often
found on a leader peptide, which serves several diﬀerent
purposes.4 Ultimately, the leader peptide and the RSs are
proteolytically cleaved, leaving the core that results in the
mature natural product (Figures 1 and Supporting Information
S1-A).
It has long been known that RiPP biosynthetic machinery
can tolerate mutations in the core sequence, enabling the
engineering of novel “unnatural natural products.”5−11 This
factor, coupled with the great variety of PTMs, makes the
RiPPs good candidates for synthetic biology. The ultimate goal
is to be able to gain control of PTMs so that they are portable;
leading to the ability to design highly derived peptide materials
in organisms and in vitro. The ﬁeld is still a long way from
achieving this goal.
We have selected a highly plastic RiPP platform, in which
nature already models aspects of this exchange. These are
Received: January 16, 2014
Published: March 13, 2014
Figure 1. Typical cyanobactin precursor peptide is shown containing
leader sequence (green), core peptide sequence (blue), and
recognition sequences RS (red) that ﬂank the core. The core
sequence eventually matures into the ﬁnal natural product after
proteolytic removal of the rest of the precursor. In a subset of
pathways, additional PTMs occur on the core sequence. There are
three classes of RS for the PTM enzymes: RSI that directs
heterocyclases as deﬁned in this study, and RSII and RSIII that direct
the N-terminal and C-terminal protease/macrocyclase, respectively.
The structure of the natural products prenylagaramide (left) and
trunkamide (right) is shown with the heterocycle modiﬁcation in
trunkamide circled in blue.
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cyanobactin pathways, often found in symbiotic bacteria within
marine animals. For example, there are about 50 known natural
products produced by the pat cyanobactin pathway.12 Within
this pathway, the enzymes are essentially identical, and yet, the
sequences represented in the natural products are highly
diverse.13,14 The resulting compounds are found in great
abundance in the animals, and work on their coevolution with
animals clearly shows that the selection for these diverse
products is at the level of the whole animal.15 Thus, identical
enzymes modify many diﬀerent hypervariable precursor
peptides with diverse sequences, with selection operating at
the level of the ﬁnal product. Previously, we showed that only
the core peptides are hypervariable, while the remainder of the
precursor peptides remains identical, providing a mechanism by
which this diversity can be achieved.7,14 It should be
emphasized that the hypervariable regions are truly variable
and do not just have a point mutation here or there. Sequences
with 0% identity across the 6- to 8-amino acid lengths of the
products can be accepted and processed by the pathway. Here,
we have named this phenomenon, where pathways are identical
in their native contexts but the substrates and products evolve,
“substrate evolution”. This name does not imply that the
substrates are better (faster) substrates for the enzymes, but
instead captures the process observed in nature.
In addition to pat, the related tru pathway is found in
symbionts of animals, where it is responsible for synthesizing an
additional 12 known cyanobactin compounds.14 Beyond the
native compounds produced by pat and tru, we have reported
an additional 20 unnatural derivatives that we synthesized in
Escherichia coli using recombinant technology.9 In both pat and
tru, the core peptide sequences are hypervariable, while all
other elements of the pathway remain identical.
Interestingly, when comparing pat and tru across multiple
samples, there is a position where crossovers occur. pat and tru
are identical in their 5′ and 3′ regions, but there is a swap in the
middle section of the pathways that encodes diﬀerent
functionality. For example, pat products are heterocyclic at
Ser and Thr, while tru products are prenylated in these
positions.14 The swap between pat and tru involves an exchange
of genes that encode these diﬀerent modifying enzymes. The
natural swap in function, along with the natural ability to
encompass potentially millions of derivatives, makes the
cyanobactin pathways ideal for understanding how to achieve
the synthetic biology goal of creating a designer posttransla-
tional toolkit.
Cyanobactins are initially encoded on a precursor peptide,
represented by PatE. In many cyanobactins, PatE and its
homologues are modiﬁed by a heterocyclase such as PatD to
Table 1. Sequences of All Peptide Substrates Used in This Studya
aSubstrates 1 and 12−15 are native precursor peptides from diﬀerent pathways. Substrates 1−3 and 8−15 were expressed as His-tagged constructs.
Substrates 8−11 were mutated (green highlights) to probe RS requirements. The shorter substrates 4−7 were synthesized chemically on resin.
Succeeding lines within a single substrate have been used to represent multiple cores. Where required, dashes have been used to align sequences into
the speciﬁc regions of RSI (yellow), RSII−RSIII (red) and core (blue). Substrates 16, 3, and 8 were used for heterologous production of
cyanobactins in E. coli.
ACS Synthetic Biology Research Article
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produce thiazoline and oxazoline rings from Cys and Ser/Thr
residues.16 Subsequently, a PatA-like protease cleaves the N-
terminal sequence of PatE, and a PatG-like protease removes
the C-terminus and performs a macrocyclization reaction to
yield an N−C circular product.13,17 Further tailoring, such as
prenylation by LynF-like enzymes and oxidation by PatG
oxidase domain-like enzyme,18 is also possible (Figures 1 and
Supporting Information S1-B). A recent study revealed C-
terminal methylation of linear products as a further
modiﬁcation in this compound series.19 Therefore, when a
cyanobactin pathway accepts a new substrate, it eﬃciently
passes through not only one, but through all of the enzymatic
steps in the pathway.
Previously, we showed that the macrocyclization of
cyanobactins is accomplished using a series of “recognition
sequences” (RSs), here named RSII and RSIII.13,17 When these
sequences are present, two proteases recognize them and
collaboratively excise and macrocyclize extremely sequence
diverse substrates in vivo and in vitro. We also previously
proposed that a third recognition sequence (RSI) element
directs the heterocyclization events.20 Here, we show that this
RSI is indeed the primary element responsible for recruiting
heterocyclases, which then modify extremely diverse core
peptide sequences. More importantly, we show that these RSs
act independently of surrounding context, and therefore
provide rules for their portability and application in creating
new compounds. This result has implications in applying RiPP
machinery for advances in synthetic biology.
■ RESULTS AND DISCUSSION
Expression and Puriﬁcation of Diverse Cyanobactin
Enzymes and Substrates. Cyanobactin gene clusters have
been grouped into four distinct genotypes that produce distinct
and varied natural products with diﬀerent PTMs.19,20 Here, we
further examined the previously described tru and pat pathways,
which fall into cyanobactin Genotype I and produce the
patellamide and trunkamide cyanobactins. We focused on
TruA/PatA N-terminal proteases, which are 95% identical and
PatD/TruD heterocyclases, which are 88% identical. To
explore biosynthetic pathways that had not been previously
analyzed, we expressed precursor peptides from the following
pathways: the lyn pathway (produces the aestuaramides),21
which also occupies Genotype I but only exhibits on average
60% protein sequence identity with pat/tru pathways; the pag
pathway (produces the prenylagaramides),20 which is in
Genotype II and is highly divergent from other pathways;
and the thc pathway,22 which is in Genotype IV and the
chemotype of which was unknown at the time we initiated this
study.20 In addition to pat/tru enzymes, we expressed protease
thcA and heterocyclase thcD, both from the thc pathway that
produces the cyanothecamides. ThcA was expected to perform
N-terminal proteolysis, and ThcD was expected to transform
Cys and/or Ser/Thr residues into thiazoline and oxazoline,
respectively. Multiple precursor peptides are present in each
pathway, and only 1 or 2 from each set of precursors were
selected for study, as designated by the diﬀerent numbers. A
series of engineered precursor peptides was also made that were
a hybrid of two or more pathways (described later), further
adding to the substrate diversity of this study. A detailed list of
all substrates used in this study is given in Table 1. Proteins
were expressed in E. coli as His-tagged constructs and puriﬁed
using standard methods (Supporting Information Figure S2).
Biochemical Analysis of thc Pathway Enzymes. The thc
pathway was characterized to add to the repertoire of the
previously studied pat and tru pathways. ThcE4 (1) was chosen
as the precursor peptide substrate. Putative heterocyclase ThcD
and putative N-terminal protease ThcA were used in enzymatic
assays. Using optimized reaction conditions, ThcD was
incubated with ThcE4 (1) and the reaction was analyzed by
MS methods. High-resolution FT-ICR ESI MS/MS (FTMS)
has previously been used to localize the position of
heterocyclization.16,23,24 The method identiﬁes sites of
dehydration via the 18 Da mass diﬀerence, and further, it is
possible to determine the type of dehydration (whether
reverse-Michael or cyclodehydration) by fragmentation pat-
tern.25 The ThcD/ThcE4 reaction was digested with
chymotrypsin to yield easily detectable fragments. MS/MS
analysis showed that all heterocycles were thiazolines derived
from Cys and clearly localized them to SCDCSLYGGCESC,
where C stands for thiazoline ring modiﬁcation (Figures 2A and
Supporting Information S3). Detailed analysis of MS spectra is
given in Supporting Information.
ThcA was incubated both with the ThcE4 precursor peptide
and with the product of the ThcD reaction, which is
presumably its native substrate. In both cases, ThcA was active,
as observed by SDS-PAGE (Figure 2B inset). In addition, ESI-
MS analysis showed that the precursor peptide was cleaved at
the RSII encoded by AVLAS (Figure 2B). This RSII is
homologous to the previously described PatA RSII sequence of
GL(V)E(D)AS.12 Since the C-terminal core sequence boun-
dary could be easily assigned based on the C-terminal
conserved Cys residue,20 determination of this RSII helped
assign the boundary of the ThcE4 core sequence. Figure 2
Figure 2. Biochemical characterization of thc pathway enzymes. (A)
ThcE4/ThcD: FTMS spectra of chymotryptic digests ASSCDCSLY
and GGCESCSYEGDEAE of ThcE4 modiﬁed by ThcD. Each [M
+2H]2+ mass peak corresponds to the peptide sequence given in a gray
box, and a heterocycle PTM is indicated by a C (in red) within the
sequence. (B) ThcE4/ThcA: Deconvoluted ESI-MS spectrum of the
ThcE4/ThcA reaction. The [M-H]− mass peak 7098.0 Da is
unmodiﬁed ThcE4 (His-tag removed) and 4915.0 Da corresponds
to the leader after ThcA proteolysis at the AVLAS RSII site. The inset
shows SDS-PAGE visualization of the same reaction, where the left
lane is ThcE4 only and the right lane is ThcE4 in presence of ThcA.
The smaller band in the right lane indicates the ThcA cleaved product.
A schematic representation of results is shown where (X38) represents
the 38-residue leader sequence before RSI, RSII (red) and core (blue)
sequences.
ACS Synthetic Biology Research Article
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shows a schematic representation of both of these PTMs of
heterocyclization and N-terminal proteolysis of ThcE4.
Eﬃcient Heterocyclase Activity Is Driven by RSI.
Before exploring the portability of RS elements, we ﬁrst
needed to identify the heterocyclase RS. It was previously
speculated that a LAELSEEAL-like sequence that is conserved
in pathways carrying heterocycles is a recognition element for
this modiﬁcation.19,20 By contrast, when a pathway lacks
heterocycles, the corresponding LAELSEEAL-like sequence is
absent.20,26 A similar element is also seen in non-cyanobactin
RiPP families such as bottromycins27−29 and YM-21639130
(Supporting Information Figure S4). To test this hypothesis, a
series of substrates was either synthesized or heterologously
expressed that contained intact leader sequence, various
fragments thereof, or mutations in the putative RSI (Table 1,
Supporting Information Figure S5). These substrates were used
in tandem with heterocyclases ThcD, TruD, and PatD. While
TruD/PatD share high identity, the newly characterized ThcD
is about 60% identical to both enzymes. The native substrates
of each enzyme are very diﬀerent from each other, although in
all cases the putative RSI element is well conserved. Reactions
were analyzed by a combination of techniques as detailed in
Methods. Brieﬂy, precursor peptide modiﬁcation was followed
by SDS-PAGE and ESI-MS. The synthesized peptides 4−7
could be analyzed by HPLC, followed by ESI-MS and/or
MALDI-MS. In certain cases, FTMS was used to further
conﬁrm the identity of products. Substrates 4−7 had core
sequences from pat and tru precursors.
Full-length precursor peptides 2 (TruLy1, chimera of TruE1
leader up to its ﬁrst core cassette fused to LynE core) and 3
(TruLy2, chimera of TruE2 leader up to its ﬁrst core cassette
fused to LynE core) containing all RSs were reactive with
ThcD, TruD and PatD (Supporting Information Figure S6). In
comparison, a short substrate (4) containing only a core
peptide sequence was not reactive with any enzyme (data not
shown). Short substrates containing RSIII (5 and 6) were
slowly reactive, with reactions reaching only a little more than
50% completion with ThcD after 24 h, although reactions with
TruD were comparatively faster (Supporting Information
Figures S7−S9 and Table S2). Reaction progress was judged
from comparison of HPLC traces of the substrate and product
peaks relative to each other. By contrast, synthetic substrate 7,
which included RSI, was highly reactive (Supporting
Information Figure S10), with reactions complete within 15
min with ThcD (Figures 3 and Supporting Information S11).
These results showed that although RSI was not absolutely
essential for enzymatic reaction, the inclusion of RSI led to a
reaction that was >150 times faster with respect to the time
taken for reaction completion. Note that modiﬁcation of 7 was
even faster than full-length precursors 2−3, which showed
roughly 70% reaction completion after 3 h (Supporting
Information Figure S12), but the comparison should be treated
with caution for reasons including diﬀerences in solubilities and
the presence of multiple heterocyclizable residues in the
precursor.
We proposed that the slow reactivity of 5 and 6 might be
caused by poor enzyme recognition due to the absence of RSI.
Obtaining good kinetic data is challenging with this series
because of the limits of substrate solubility. Therefore, to test
this hypothesis, we used competition experiments (see
Methods) in which the fastest substrate 7 underwent reaction
with ThcD in competition with substrate 3, which contains RSI,
and 5-6, which lack RSI (Figure 4A). All substrates were
maintained at the same concentrations in these reactions, and it
was seen that despite the eﬃciency of 7 the full-length substrate
3 inhibited modiﬁcation of 7, such that no product was seen
after the 15-min time point. In contrast, the RSI-lacking
substrates 5−6 did not inhibit this reaction (Figures 4C and
Supporting Information S13). These data indicated that RSI
was likely responsible for eﬃcient binding of core peptide to
the enzyme.
To conﬁrm that RSI was solely responsible for this eﬀect and
not other elements embedded in the substrate or leader
peptide, a series of full-length precursors (8−11) was
constructed. RSI motifs were aligned using WebLogo31
(Supporting Information Figure S14-A), and it was seen that
three Glu and three Leu residues were the most conserved.
Since the microcin B17 leader peptide is known to adopt a
helical conformation,32 a model of the RSI residues using a
helical wheel arrangement was drawn, and it was seen that the
conserved Glu and Leu residues were on opposite faces of the
helix (Supporting Information Figure S14-B). Hence, the Glu
residues were simultaneously converted into Ala residues in
triple mutant 8. The (3[Glu→Ala]) mutant 8 could still be
heterocyclized (Supporting Information Figure S15) although
with reduced eﬃciency since only up to double dehydration
was observed in comparison to wild-type TruLy2 (3) that
showed triple dehydration. Since the TruLy2 mutants were
harder to purify, the Leu to Ala mutations were made in a
diﬀerent precursor that carried the same leader peptide as
TruLy2 but carried pag core instead (substrate 9). In contrast
to 8, the (3[Leu→Ala]) mutant 9 was no longer an eﬃcient
substrate (Supporting Information Figure S16). These results
indicate that a Leu-rich hydrophobic patch may serve a critical
function.
Peptide 10 is a derivative of a natural precursor peptide
PagE6 from the non-heterocyclizing pag family that lacks the
Figure 3. (A) Summary of reactivities of substrates 2−7 with ThcD,
TruD, and PatD. Full-length precursors 2−3 and substrate 7 that lacks
most of the leader, but contains RSI, were reactive with all tested
enzymes. By contrast, 4 that lacked any RS was unreactive and 5−6
that lacked both leader and RSI was a very slow substrate. (B) Using
the same assay conditions containing 2 μM ThcD and 200 μM
substrate 7 or 5, a time-course was followed. Substrate 7 was
completely modiﬁed to give product (1264.16 [M+2H]2+) within 15
min of reaction (ESI-MS on left), whereas 5 was very slow, and the
reaction was far from complete even after 21 h (HPLC trace on right).
Similar results were obtained with substrate 6, and an expanded
reaction time-course is given in Supporting Information Figure S11.
ACS Synthetic Biology Research Article
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RSI element intrinsically. To make it a potential substrate for
heterocyclases, we introduced a Cys residue in the requisite
position (with tru RSII and RSIII). In addition, peptide 11 was
made, in which RSI was inserted into the backbone of peptide
10 (Table 1). Our results showed that 10, which lacked RSI,
was not a substrate for heterocyclases, although it carried a
heterocyclizable residue (only a minor product peak was seen
that equaled <10% of product even after 18-h reactions), while
11, which carried RSI insertion, was fully competent for
reaction and essentially equal to other full-length precursors
(Supporting Information Figure S17). This demonstrates the
portability of RSI to import heterocyclization in a completely
non-native core peptide sequence.
In addition, competition experiments similar to those
described earlier were performed using ThcD and competent
substrate 7 versus 8−11. Only substrate 11 with intact RSI
competed with 7, while the RSI mutants 8−10 did not (Figures
4 and Supporting Information S18). This further reiterated that
RSI is responsible for eﬃcient heterocyclization.
Leader Peptide Coevolves with Cyanobactin Mod-
iﬁcation Enzymes. To ﬁnd out the extent of conservation of
non-RS elements of the leader sequence, we constructed
phylogenetic trees of cyanobactin precursor peptides. We
speculated that such an analysis might help us to identify
important non-RS elements, if any, which could make
portability of PTMs a physiologically and synthetically relevant
process. Previously, the hypervariability of core peptides made
the tree-building process diﬃcult. This led us to construct trees
composed solely of the leader peptide in the absence of the
hypervariable cores, both with and without RSI (Figures 5 and
Supporting Information S19). Surprisingly, in both cases, the
tree topology was identical and split precursor peptides into
two groups. Group I peptides contain RSI, and Group II
peptides lack RSI. As expected, Group II peptides are derived
from pathways that also lack heterocyclases. Note that presence
or absence of RSI did not deﬁne this branch point since trees
made either way were identical.
Furthermore, within Group I, the tree topology is similar to
that made using cyanobactin heterocyclase sequences (Support-
ing Information Figure S20).20 These observations suggested
that the heterocyclases and leader sequences are coevolving,
and because of this relationship, we speculated that
heterocyclases might prefer their cognate (or native) leader
sequences. In that event, not only RSI, but also the remainder
of the leader peptide may be needed to enable portability of
heterocyclization PTM. To understand this, we took a diﬀerent
approach, where instead of carrying out exhaustive mutations of
the leader sequence, we took advantage of the diversity of
cyanobactin biochemical components we already had in our
hands, as described below.
Noncognate Leaders Do Not Hinder Heterocyclase
Reactivity. To test the requirement of cognate leader peptide
sequence, ThcD, TruD, and PatD were assayed with a series of
both native and non-native substrates from Groups I and II
(Figure 6). Group I included the native substrates of these
three enzymes, ThcE4 (1), TruE2 (12), and PatE (13), in
addition to LynE (14) from a diﬀerent Group I pathway, and
TruLy 1 and 2 (2) and (3), which contain tru leaders and
hybrid tru-lyn cores and were designed in our lab as robust
Figure 4. Competition reactions: (A) Substrates 3 and 11 (containing
RSI), 5−6 (lacking RSI) and 8−10 (RSI mutants) were made to
compete with ThcD (2 μM) reaction on substrate 7, which has RSI
but lacks the leader before it. Only 3 and 11 inhibited modiﬁcation of
7, while 5−6 and 8−10 did not. All substrates were maintained at
concentrations of 50 μM (in reactions with 3, 11, and 8−10) or 200
μM (in reactions with 5−6) under the same assay conditions. (B)
MALDI-MS of competition with 3 and 11, which completely inhibit
modiﬁcation of 7. The mass of 2566 corresponds to [M+Na]+ of 7.
(C) On the left is ESI-MS of competition with 6, which does not
inhibit modiﬁcation of 7 (product mass 1264.11 [M+2H]2+), and
substrate 6 is unmodiﬁed (1121.58 [M+H]+). On the right is MALDI-
MS of competition with 9 that does not aﬀect modiﬁcation of 7. The
mass peak of 2548.38 corresponds to [M+Na]+ of 7 product, while
only a minor peak of unmodiﬁed 7 was observed (2566.35 [M+Na]+).
Similar results were obtained from competition with 5, 8, and 10,
which is shown in Supporting Information Figures S13 and S18 along
with necessary controls.
Figure 5. Phylogenetic tree of cyanobactin precursor peptide leader
sequences. Group I pathways carry RSI, heterocycle PTM and the
corresponding heterocyclase enzyme, whereas Group II pathways lack
the same. Only a subset of peptides is shown here, with the ones used
in this study highlighted in yellow. See Supporting Information Figure
S19 for a complete tree with all known cyanobactin precursors.
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substrates for TruD. Group II included PagE6 (15) from the
pag pathway, which is divergent from all of the other pathways
used in this study. Since the PagE6 core lacked heterocyclizable
residues, a Pag/Tru chimera (11), which carries a Pro to Cys
mutation and RSI, was used.
To our surprise, instead of exhibiting selectivity for cognate
leaders as would be expected from the phylogenetic analysis, all
heterocyclases were active on all substrates as long as RSI was
present (Figure 6). Detailed product characterization is given in
Figures S21−24 and Tables S3−S7 (see Supporting Informa-
tion). As has been reported earlier, TruD was chemoselective
for Cys and PatD diﬀered in that it could modify Ser/Thr
residues as well.24 ThcD as characterized in this study
resembles TruD in chemoselectivity. Diﬀerences in precursor
peptide sequences, and even hybrids of diﬀerent types of
precursors, did not alter chemoselectivity or regioselectivity of
the resulting products.
Precise kinetic measurements of heterocyclization reactions
are complex due to the solubility issues alluded to above and
distributive processing by the enzymes, such that the substrate
is released from the enzyme after each residue is heterocyclized.
Despite these factors, we performed a semiquantitative analysis,
wherein the amount of enzyme was varied and reaction
completion after an 18-h time-point was monitored based on
the SDS-PAGE band-shift (Supporting Information Figure
S25). Substrates 14 (LynE), 2 (TruLy1), and 12 (TruE2) were
analyzed in this way because of the clear visibility of their band-
shifts due to heterocyclization. TruD and ThcD were essentially
identical in apparent reactivity, whereas our PatD enzyme
preparation was relatively less eﬃcient, such that a higher
amount of enzyme was required to allow reaction completion at
the same time-point.
Additionally, experiments were performed in which reactions
of 14 with TruD and ThcD were competed with substrates 2
(TruLy1), 8 (TruLy2 RSI mutant), and 15 (PagE6), using the
same methods that were employed earlier to deﬁne RSI. As
determined by SDS-PAGE analysis (Supporting Information
Figure S26) and conﬁrmed by MS (Supporting Information
Figure S27), only 2 carrying intact RSI could compete with 14.
Taken together, these results showed that the native leader
peptide was not necessary for reactivity and that leader
sequences with <50% sequence identity are recognized by all
three heterocyclases as long as RSI is present.
Importance of RSII and Insigniﬁcance of the Native
Leader Peptide for N-terminal Proteolysis. We wished to
see if the above observation with RSI could also be extended to
RSII. Beyond PatD-like heterocyclase proteins, the reactivity of
PatA and PatG is essential in cyanobactin maturation.20 PatA
and relatives act on full-length heterocyclized precursor
peptides. Here, we examined the cross-reactivity of RSII
elements with PatA-like proteases. Despite the comparatively
lower sequence identity of PatA and ThcA (Supporting
Information Figure S2), both could recognize GVDAS-like
RSIIs (Figures 6 and Supporting Information S28, Supporting
Information Table S8) in native and non-native substrates. The
reactivity of TruA was examined in vivo (see below). It
processed both substrate 3, which carried native leader, and
substrate 16, which carried a Group II non-native leader. In
short, the proteases require RSII for activity, which exhibits the
same portability as observed for the heterocyclase RSI.
Finally, PatG and relatives act after N-terminal proteolysis on
short substrates carrying the AYDGE-like RSIII. The RSIII-
protease interaction has already been extensively studied.17,33,34
Therefore, with this study and resting on previous work, the
selectivity requirements for the major PTM enzymes in the
cyanobactin family have been explored. Next, we aimed at
testing the portability of all RSs in the context of the complete
cyanobactin pathway in vivo.
Portability of RSs to Produce Cyanobactins In Vivo.
The above results with heterocyclases and proteases implied
that conserved elements within precursor peptides are virtually
interchangeable. Therefore, it should be possible to swap PTMs
by importing enzymes and their RSs into preexisting precursor
peptides. To test this hypothesis in the context of a whole
pathway in vivo, we formed hybrid precursor peptides
comprising sections of tru, lyn and pag precursors (Supporting
Information Figure S29). These were coexpressed with our
previously described tru production vector in E. coli
(Supporting Information Figure S29).9 The resulting cyano-
bactin products were extracted from the E. coli cell pellet and
analyzed by ESI-MS (see Methods). Robust expression of
patellins from the parent tru pathway served as internal controls
for cyanobactin expression.
Unfortunately, lyn and pag core sequences did not lead to
detectable products. This could be for any number of reasons,
including toxicity to E. coli, degradation in vivo, etc. Two of the
Figure 6. Native leader peptide is not required for cross-selectivity of
cyanobactin PTM enzymes. Substrates were grouped based on the
type of leader, where Group I are from heterocyclase containing
pathways and Group II are from those without. Heterocyclases ThcD/
TruD/PatD and proteases PatA/ThcA are reactive with both native
and non-native substrates in vitro as long as RSI or RSII is present.
TruA reactivity was analyzed in vivo only on substrates 3 and 16. (Xn)
represents leader peptide where n is the number of residues before
RSI. Dashes have been used to align sequences to the color-coded RS
and core regions. Regioselectivity of each individual enzyme is shown
by speciﬁc symbols at the modiﬁed residues. Nonﬁlled symbols
represent partially characterized PTMs (Supporting Information).
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designed precursors did lead to cyanobactin products. The ﬁrst
precursor contained the TruE2 leader peptide (TruLy2; 3),
while the second contained the same TruE2 RSs as 3, but fused
to the PagE6 leader instead (Pag/TruLy; 16). A TruLy2
mutant (8) was also made, carrying a (3[Glu→Ala]) mutated
RSI sequence. Our results showed that, irrespective of leader,
the tru pathway processed both 3 and 16 (Figure 7) to produce
the macrocyclized product TFPVPTVC. In comparison, the
mutant 8 failed to produce compounds, as would be expected
from the earlier established in vitro result that the substrate 8
could not compete with full-length precursors. In the context of
the whole tru pathway in E. coli, where tru precursors were
present as internal controls (producing patellins), the mutant 8
was not expected to be a substrate. Both nonprenylated and
prenylated forms of the compound TFPVPTVC were observed,
indicating that the TruF group of prenyltransferase PTM
enzymes were also active.
Conclusions. Here, we experimentally deﬁne RSI, which we
previously proposed to exist based upon extensive sequence
analysis. In the presence of an RSI, peptides are eﬃciently
heterocyclized, while in its absence heterocyclization is
extremely ineﬃcient or completely abolished. In native
cyanobactin precursors lacking RSI, introduction of the element
from other pathways enables access to the RS and eﬃcient
heterocyclization. Mutations to RSI lead to a greatly diminished
enzyme activity when the acidic side of this helical sequence
was modiﬁed, while activity was abolished on the hydrophobic
side of the helix. These results indicate that potentially the
hydrophobic helical face is crucial for the interaction with the
enzyme. Taken together, we show that RSI is necessary for the
eﬃcient reaction required in vivo.
It was recently proposed that the sequence identiﬁed as RSI
here is not responsible for recognition but instead is required
just in order to access interior Cys residues.35 This
interpretation does not provide a good evolutionary rationale
to maintain RSI because the native substrates of TruD lack
interior Cys residues within single cassettes. The results here
clearly disprove that idea, showing deﬁnitively that RSI is
required for eﬃcient synthesis under native conditions. While a
slow reaction occurs in vitro, this is likely not relevant to the
natural reaction.
These add to the previously known RSII and RSIII in
cyanobactin biosynthesis. Although these were previously
known, here we add to the understanding of RSII function,
showing that diﬀerent sequences can be interchanged. Here, we
also show how RSI, RSII, and RSIII function in the context of
whole pathways. Previously, precise elements involved in
recognition have been determined for individual enzymes and
precursor peptides largely through mutagenesis studies in the
lanthipeptides and several microcins.32,36 Additional advances
include the in trans use of leader peptides and core peptides,
rather than the normal fusion products found in nature. This
has been especially advantageous, with the covalent fusion of
leader peptides with enzymes, providing robust catalysis of, for
example, lanthionine bond formation.37 On the other hand, the
lack of importance of the leader has also been demonstrated
with the Balh heterocyclases in vitro.38
Here, we hoped to learn how switching leader peptides
would enable us to recruit PTM enzymes. Instead, and to our
surprise, we found that quite diﬀerent leader sequences were
still fully functional with noncognate enzymes, and that those
leader sequences could be swapped with no impact on activity.
The only critical sequences are the three short RS elements,
which are necessary to obtain products. The ﬁnding that RS
elements recruit PTMs has implications for RiPP engineering.
Such elements are inherently interchangeable and will thus
aﬀord a simple method for mixing diﬀerent types of PTMs in a
rational manner.
Importantly, these noncognate enzymes enabled us to
change the pattern of PTMs, leading to the introduction of
unnatural modiﬁcations in vitro. By combining these enzymatic
elements at will, novel compounds can be synthesized. Here,
we demonstrate the synthesis of some of these compounds in
vitro by combining PatA and PatD-like enzymes with various
substrates. We provide the ﬁrst example of how this might be
applied in vivo using a swap where a wholly unnatural precursor
peptide still is functionally modiﬁed in the context of the tru
pathway, validating the ability to functionally swap cassettes.
On the basis of this technological advance, work is underway in
the lab to synthesize libraries of derivatives, which will be
reported in due course. The underlying technology, however,
should be applicable to other types of RiPP pathways for which
recognition elements have been deﬁned.
We used the observation of natural “substrate evolution” and
real-time pathway crossovers to inspire the creation of portable
synthetic biology tools. Although very precise substrate
evolution has still been described only in cyanobactins found
within coral reef animals, it is likely that this will be found in
many other RiPPs as well, as shown by initial evidence in some
other pathway types.39 Not all RiPPs exhibit this feature, as
others that have been studied exhibit fairly narrow substrate
selectivity, where more than a small number of mutations are
not accepted in the ﬁnal products. The accumulation of natural
RiPP pathways in which substrate evolution is occurring will
thus be very valuable in achieving the long-term goal of
Figure 7. Production of cyanobactins from engineered peptides in E.
coli. Hybrids of TruE2 and LynE with core peptides TFPVPTVC and
ACMPCYP were made. The latter was not detected, but expression of
the cyclic TFPVPTVC product was robust. Expression was maintained
even when PagE6 leader (purple) replaced the native TruE2 leader.
Product formation was abolished when the RSI-mutated precursor was
used.
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precisely controlling posttranslational modiﬁcations and small
peptide design.
■ METHODS
Genes and Cloning. The ThcA, ThcE4, ThcD, TruLy2,
and Pag/Tru genes were obtained from GenScript and cloned
into the pET28 vector between NdeI and XhoI sites for protein
expression and/or into our previously described pRSF-lac
vector9 between NdeI and KpnI sites for compound expression
in E. coli. The mutants 3[Glu→Ala], 3[Leu→Ala] and the RSI
deletion mutants of TruLy2 and Pag/Tru constructs were made
by site-directed PCR mutagenesis.
Protein Expression, Puriﬁcation, and Synthesis.
Precursor peptides ThcE4, LynE, PagE6, TruLy2 and Pag/
Tru along with their mutants were made by overexpression (3 h
at 37 °C with 1 mM IPTG induction) to drive the protein into
inclusion bodies, in R2D-BL21 cells in 2xYT medium.
Puriﬁcation was performed by Ni-NTA aﬃnity chromatography
under denaturing conditions. ThcD and ThcA were expressed
under similar conditions as the precursor peptides except that
milder expression conditions were used (18−21 h at 18 °C with
0.1 mM IPTG induction), and the proteins were puriﬁed using
native conditions. All proteins were dialyzed, aliquoted, ﬂash-
frozen, and stored at −80 °C till used. Enzymes were
additionally stored in 10% (v/v) glycerol. The precursor
peptides TruE2, PatE, TruLy1, and the enzymes TruD, PatD,
and PatA were made as described previously.15,24 The synthetic
substrates 4−7 were made at the University of Utah Peptide
Synthesis Core Facility.
ThcE4 PTM Assay Conditions. For characterization of thc
pathway enzymes, ThcE4 (30 μM) was incubated with 0.4 μM
of ThcD in optimized additive mixtures containing 50 mM Tris
buﬀer pH 7.5 along with 7.5 mM DTT, 4 mM MgCl2, and 1
mM ATP in a ﬁnal reaction volume of 50 or 100 μL. The N-
terminal cleavage assay was carried out by incubating 40 μM of
ThcE4 with 6 μM of ThcA in optimized additive mixtures
containing 50 mM Tris buﬀer pH 7.5 along with 4 mM DTT
and 10 mM CaCl2 in a ﬁnal reaction volume of 50 or 100 μL. In
certain cases, cleavage assays were performed after hetero-
cyclization by adding protease to the ThcD/ThcA reaction
mixture while maintaining the same ﬁnal concentration as
detailed above. Assays performed in absence of enzyme and/or
absence of ATP were used as negative controls. The reactions
were incubated at 34 °C for 18 h in a MJ Research Minicycler.
Each reaction was done at least in triplicate and was quenched
by immediately freezing at −80 °C until used for SDS-PAGE
and MS analysis.
Precursor Peptide Assay Conditions and Product
Characterization. Reactions were carried out under con-
ditions similar to ThcE4 assays as given above, with 25−50 μM
peptide and 0.5−2 μM heterocyclase or 5 μM protease, for 18 h
at 34 °C, unless otherwise speciﬁed. Products were analyzed in
two steps. First, preliminary results were obtained by
visualization of modiﬁcation on SDS-PAGE. Second, reactions
were analyzed by ESI-MS, which indicated the number of
dehydrations (in case of heterocyclization) or a smaller
molecular weight mass (in case of proteolysis). In most cases,
identity of the product was further conﬁrmed by high-
resolution FTMS and MS/MS fragmentation pattern. See
Supporting Information for detailed interpretation of MS data.
Synthetic Substrate Assay Conditions and Product
Characterization. Reaction conditions were identical to those
for precursor peptide assays, except that up to 200 μM
substrate was used with 2 μM heterocyclase, for 18 h at 34 °C,
unless otherwise speciﬁed. Reactions were quenched with 1 M
guanidine hydrochloride, centrifuged, and the supernatant was
analyzed by RP-HPLC on a LaChrom Elite System (Hitachi). A
214MS C4 5 μ column (Grace-Vydac) was used and run on a
linear gradient from 99% of buﬀer A (H2O/0.1% TFA) to
100% ACN over 45 min with a ﬂow rate of 1 mL min−1.
Because of the presence of Tyr residues in 5−7 a 276 nm UV
absorbance maximum was clearly observed for the starting
substrate. Thiazoline modiﬁcation introduces an additional 254
nm shoulder,40 such that product formation can be easily
detected. Further conﬁrmation was provided ESI-MS and/or
FTMS. Note that for substrate 7, it was diﬃcult to attain HPLC
separation of substrate and product peaks. Hence, reactions
were followed by ESI-MS and/or MALDI-MS. Samples to be
analyzed by MALDI were desalted and concentrated using C18
Zip-Tips (Millipore). See Supporting Information for detailed
interpretation of MS data.
Competition Reaction Assay Conditions and Product
Characterization. Identical reaction conditions were main-
tained for each competition reaction series. For competition of
7 with precursor peptides 3, 11, and 8−10, 50 μM of each
substrate was used, since attaining higher concentrations of
precursor peptide was diﬃcult, and the reactions were followed
by MALDI-MS. For competition of 7 with synthetic peptides
5−6, 200 μM of each substrate was used, and the reactions
were followed by ESI-MS. For competition of precursor
peptides 14 with other precursor peptides 2, 8, and 15, 25
μM of each substrate was used, and reactions were followed by
SDS-PAGE and ESI-MS at increasing time points. All enzymes
were used at a concentration of 1 μM, unless otherwise
speciﬁed.
SDS-PAGE Band-Shift Assay. Comparison of modiﬁed
peptide with unmodiﬁed peptide on SDS-PAGE was used to
visualize PTM modiﬁcation, since heterocyclized peptides
showed greater mobility and cleaved peptides resulted in a
smaller band in most cases. 18% gels were used to analyzed 15
μL of each reaction by standard SDS-PAGE conditions. In all
cases, MS methods conﬁrmed results seen on SDS-PAGE gels.
Mass Spectrometric Methods. ESI-MS and FT-ICR
analyses were performed at the University of Utah Mass
Spectrometry and Proteomics Core facility. ESI was done using
a Micromass Quattro-II (Waters), and analysis of spectra was
carried out using predicted masses obtained from Monoisotopic
Mass calculator. FT was performed following cleavage of
heterocyclized peptide by chymotrypsin or PatA protease, using
a LTQ FT Ultra Hybrid Mass Spectrometer (Thermo
Scientiﬁc) and analyzed both manually using predicted masses
from Monoisotopic calculator and using Mascot from Matrix
Science. MALDI-TOF samples were mixed with 1-cyano-4-
hydroxycinnamic acid (10 mg mL−1 in 50:50 water: methanol
with 0.1% triﬂuoroacetic acid) and analyzed using a Micromass
MALDI micro MX (Waters) using an automated targeting
protocol.
Construction of Phylogenetic Trees. Alignments were
done based on ClustalW2 output results. The precursor peptide
sequences shown in Supporting Information Figure S19 along
with the known/predicted N-terminal protease recognition
sequences RSII were obtained from previously published
studies7,16,17,21,23,24,26,41,42 and our present analysis of the thc
pathway. MEGA5.1 was used to construct the Maximum
Likelihood phylogenetic tree using the JTT model.
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Expression of Hybrid Precursor Peptides in E. coli.
This was based on our previously described tru pathway-based
expression system.9 A two-plasmid system was coexpressed in
E. coli, one plasmid carrying the precursors for expression of
patellins 2 and 3, and the other carrying the engineered hybrid
precursor. The hybrids created for this study were obtained
from GenScript before subcloning into our previously described
pRSF-lac expression vector. Single colonies were picked to
make seed cultures, and at least ﬁve seed cultures were pooled
the next day and inoculated into optimized 2xYT medium
supplemented with antibiotics. Cultures were grown for 5 days,
after which the cells were harvested. Their acetone extract were
isolated, dried, redissolved in methanol, and analyzed by LC/
ESI-MS using an Agilent Eclipse C18 column (4.6 mm × 150
mm, 5 μm) on a Waters Micromass ZQ mass spectrometer.




Experimental details and additional data. This material is
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Macrocyclases and other posttranslational enzymes
afford derived peptides with improved properties for
pharmaceutical and biotechnological applications.
Here, we asked whether multiple posttranslational
modifications could be simultaneously controlled
and matched to rationally generate new peptide
derivatives. We reconstituted the cyanobactin pep-
tide natural products in vitro with up to five different
posttranslational enzymes in a single tube. By
manipulating the order of addition and identity
of enzymes and exploiting their broad-substrate
tolerance, we engineered the production of highly
unnatural derivatives, including an N-C peptide
macrocycle of 22 amino acids in length. In addition
to engineering, this work better defines the macro-
cyclization mechanism, provides the first biochem-
ical demonstration of Ser/Thr posttranslational
prenylation, and is the first example of reconstitution
of a native, multistep RiPP pathway with multiple
enzymes in one pot. Overall, this work demonstrates
how the modularity of posttranslational modification
enzymes can be used to design and synthesize
desirable peptide motifs.
INTRODUCTION
Cyclic peptides are of particular interest among the various
bioactive macrocyclic scaffolds known so far. Their stability,
coupled with their ability to access hard to reach targets
such as protein-protein interactions, has led to significant
enthusiasm concerning their therapeutic potential (White and
Yudin, 2011). Most cyclic peptide drugs approved by the US
Food and Drug Administration, such as cyclosporine and
daptomycin, are synthesized by non-ribosomal multienzyme
assembly lines (Sieber and Marahiel, 2003), but an increasing
number of related cyclic compounds are also ribosomally
synthesized (Arnison et al., 2013). The chemical synthesis of
macrocyclic scaffolds has been well explored, but many draw-
backs exist including those of specific sequence requirements,
length restrictions, poor yield, and high cost (Yu and Sun,
2013). In contrast, enzyme-catalyzed peptide macrocyclization
offers many advantages over the conventional synthetic chem-
istry methods.
Well-studied enzymatic N-C macrocyclizations include those
mediated by subtiligases, sortases, and inteins (Zhang et al.,
2014; Scott et al., 1999). In contrast to these unnatural pro-
cesses, PatG-like enzymes from cyanobactin pathways are
serine proteases that natively form macrocycles (Lee et al.,
2009; McIntosh et al., 2010; Agarwal et al., 2012; Koehnke
et al., 2012). The macrocyclases creating the cyclotide and
amanitin natural products are also being explored (Craik and
Malik, 2013; Luo et al., 2012, 2014; Barber et al., 2013; Nguyen
et al., 2014). In addition, a wide array of enzymes cyclizing prod-
ucts via side chains (rather than asmain-chain N-Cmacrocycles)
is also known (Arnison et al., 2013). Beyond simple synthesis of
macrocycles, it is desirable to introduce tailoring reactions,
which greatly modify the pharmacological properties of the
peptides. In light of this, the aim of this study was to exploit
a series of cyanobactin tailoring enzymes to produce highly
modified cyclic peptides in vitro, using hybrid biosynthetic
machineries comprising mixtures of enzymes from different
pathways.
The cyanobactins are a class of natural products first isolated
frommarine ascidian animals (Ireland and Scheuer, 1980), where
they are produced by symbiotic cyanobacteria (Schmidt et al.,
2005). Cyanobactins are found in approximately 10%–30% of
all cyanobacteria on Earth (Leikoski et al., 2013), creating an
enormous wealth of enzymes and substrates that can be ex-
ploited in synthetic biology. They are ribosomally synthesized
and posttranslationally modified peptides (RiPPs) that aremostly
cyclic, although some linear derivatives have been reported
recently (Leikoski et al., 2013; Donia and Schmidt, 2011). The
biosynthetic pathway involves a linear precursor peptide
substrate, containing a core sequence that matures into the final
natural product. The enzymes that modify the core sequence
include at least two proteases, PatA and PatG and their homo-
logs, which proteolyze the N and C termini of the core sequence,
respectively (Lee et al., 2009). PatG also carries out N-C macro-
cyclization of the core in tandem with proteolysis (Lee et al.,
2009; Schmidt et al., 2005). Often, multiple core peptides are
encoded in a single precursor, such that multiple cyclic peptides
are derived from single substrates. Further modifications such
as heterocyclization, oxidation, prenylation, and/or methylation
may be carried out by additional enzymes (Figure 1).
In nature, cyanobactins exist as large combinatorial libraries,
leading to hundreds of known natural products and probably
thousands of unknown compounds. This diversity arises in
part from hypervariable core sequences, which are tolerated
by exceptionally broad-substrate biosynthetic enzymes (Donia
et al., 2006; Sardar et al., 2014). Broad-substrate tolerance
is possible because the precursor contains specific recognition
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sequences (RSs) directing enzymes to otherwise hypervariable
cores. RS conservation therefore explains, at least in part, the
observed promiscuity of the posttranslational enzymes (Donia
et al., 2006; Sardar et al., 2014). As elucidated from earlier
work, RSI recruits a heterocyclase enzyme (PatD homolog)
that acts on cysteine, serine, or threonine in a regio- and chemo-
selective manner. RSII and RSIII recruit proteases related to
PatA (N-terminal protease) and PatG (C-terminal protease/
macrocyclase), respectively. Proteolysis cleaves RSs from
the core peptide, enabling ‘‘scarless’’ formation of the desired
cyclic peptide with the recognition elements removed. The only
exception in RS requirements lies in the final enzymatic step
of prenylation, which does not seem to need RSs and instead
recognizes cyclic peptides with diverse sequences (McIntosh
et al., 2011) (Figure S1).
Our previous in vitro effort in cyclic peptide production used
a combination of PatA and PatG to generate eptidemnamide
(an analog of the anticoagulant eptifibatide) (Lee et al., 2009).
Subsequent work focused only on PatG activity using short syn-
thetic substrates as starting material (McIntosh et al., 2010;
Agarwal et al., 2012; Koehnke et al., 2012). These substrates
carried a proline residue at the C terminus of the core, since a
heterocycle at this position was observed to be required for
PatG activity (McIntosh et al., 2010), although natural PatG
substrates carry thiazole at this position. We have also synthe-
sized small libraries in vitro using discrete substrates for the
prenyltransferase enzymes (McIntosh et al., 2011). Despite hav-
ing the ability to reconstitute individual enzymatic steps in vitro,
the combination of multiple enzymatic steps to generate modi-
fied cyclic peptides has been much simpler in Escherichia coli
in vivo (Ruffner et al., 2014; Tianero et al., 2011). Using this
methodology, the single tru pathway has been used to encode
libraries that potentially synthesize millions of ‘‘unnatural natural
products.’’ While in vivo libraries are extremely powerful in drug
discovery, not all types of compounds are readily synthesized.
For example, compounds toxic to E. coli are unlikely to be pro-
duced, and substrates that are degraded faster than they are
modified by enzymes would not be observable.
Recent advances in heterocyclization chemistry using PatD
and homologs (Sardar et al., 2014; Koehnke et al., 2013; Goto
et al., 2014) enabled us to make short heterocycle containing
peptides, which provided a simple method to generate native-
like substrates for downstream enzymes in vitro. This in turn
allowed us to optimize the conditions necessary to exploit the
chemistry of a combination of these enzymes. Here, our efforts
involved the coupling of PatD-like enzymes along with a mixture
of other posttranslational enzymes to produce modified cyclic
peptides. We based this work on the hypothesis that the RS
elements act independently both from each other and from
the core peptides. Therefore, appropriately embedded RS ele-
ments would universally and predictively recruit posttransla-
tional modification enzymes, even when mixed from different
biosynthetic pathways. We tested this hypothesis by designing
and synthesizing a series of modified cyclic peptides, both
natural and unnatural, using enzymes, precursors, and RS ele-
ments from the trunkamide, prenylagaramide, cyanothecamide,
patellamide, and aestuaramide cyanobactin families.
RESULTS
Sequential Enzymatic Reactions Reconstitute
Full Pathway Activity
Synthetic substrate 1, which carries the trunkamide core
sequence TSIAPFC (Figure 2), was selected for initial studies
because it exhibited promising biological activity (Salvatella
et al., 2002). In addition, we have developed substantial technol-
ogy around this sequence (Ruffner et al., 2014; Tianero et al.,
2011). In place of the complete precursor peptide, substrate 1
was previously engineered to contain solely RS elements I, II,
and III (Sardar et al., 2014), such that 1 represents aminimal sub-
strate. Precursor 1 was only 25 amino acids in length, enabling
chemical synthesis, whereas the native substrates are >50–80
amino acids and require more cumbersome methods. The
enzymes used included heterocyclase ThcD from the recently
characterized cyanothecamide thc pathway (Donia and
Schmidt, 2011; Houssen et al., 2012; Sardar et al., 2014),
N-terminal protease PatA (Lee et al., 2009), the C-terminal prote-
ase/macrocyclase PatG and TruG (Lee et al., 2009; McIntosh
et al., 2010; Agarwal et al., 2012; Koehnke et al., 2012), and
the prenyltransferase TruF1 (McIntosh et al., 2011), from the
well-characterized patellamide pat and trunkamide tru path-
ways. Although ThcD is not from the tru pathway, it exhibits
the same chemoselectivity as TruD (Sardar et al., 2014).
In addition, PatA and TruA are virtually sequence identical
(Lee et al., 2009).
We investigated the action of enzymes on substrate 1 by
sequentially adding the enzymes into the same tube along with
the necessary enzyme cofactors at each step (see Experimental
Procedures). Since heterocyclization requires RSI, the ThcD
reaction was performed first, leading to the thiazoline-containing
product 2 (Sardar et al., 2014). Subsequent addition of PatA
excised both RSI and the PatA recognition sequence RSII, lead-
ing to products 3 and 4. Since 4 carries thiazoline, it is a substrate
for PatG. Addition of PatG macrocyclase domain to the reaction
Figure 1. Simplified Schematic of Cyanobactin Biosynthesis
A schematic of cyanobactin biosynthetic machinery showing the leader pep-
tide, core peptide, recognition sequences (RSs), and the posttranslational
enzymes used in this study. ThcD is a heterocyclase that uses RSI to modify
Cys residues to thiazoline. This is followed by the action of proteases PatA
and PatG (or TruG) that use RSII and RSIII to cleave off the N and C termini
of the core peptides, respectively. PatG (or TruG) also carries out macro-
cyclization in tandemwith proteolysis. The prenyltransferases TruF1 and PagF
add isoprene units to the cyclic peptide scaffold and do not require RSs.




mixture cleaved the RSIII element in tandem with cyclization to
provide the cyclic peptide 5. The addition of prenyltransferase
TruF1 provided the monoprenylated product 6 (Figures 2 and
S2A). In our hands, only about 30% of 5 (as judged from area
of integrated chromatogram) was converted to the prenylated
product 6, and the doubly prenylated product was not detected
(Figure S2A). The same products 5 and 6were observedwith full-
length protein TruG in place of the macrocyclase/protease
domain of PatG (Figure S2B). The structure of 5 was further
confirmed by nuclear magnetic resonance (NMR) characteriza-
tion (Figure S2C).
The substrate 1 was quantitatively consumed in the reaction,
and less than 5% was converted to side products as detected
by liquid chromatography-mass spectrometry (LC-MS) (Fig-
ure S2D). In the subtiligase and sortase systems, a yield of
67% and 85%, respectively, has been reported (Zhang et al.,
2014), whereas with PatG, as shown here, it is possible to
achieve nearly complete conversion to cyclic product in the
reaction mixture.
Biochemical characterization of each posttranslational
enzyme from previous studies has shown that each enzyme is
fully functional independently, and no protein-protein interac-
tions were detected between enzymes (McIntosh and Schmidt,
2010a, 2010b; McIntosh et al., 2010). Here, we reinvestigated
the possible requirement for protein interactions. Reactions
were carried out where intermediates from each step were
purified by high-performance liquid chromatography (HPLC)
and used as a substrate for the next modification step.
These pure intermediates (2 and 4), free from enzymes and
cofactors from the previous modification reaction, were fully
competent substrates for the next enzymatic reaction in that
they could be completely processed to the respective products
(Figure S2E).
Previous studies reported extremely slow reaction rates for
PatG such that in many cases reaction was complete by 24 hr
only with a 50% catalyst load (McIntosh and Schmidt, 2010b;
McIntosh et al., 2010; Agarwal et al., 2012), although the rate
could be modified by adjusting buffer conditions (Koehnke
et al., 2012). In contrast, in this study PatG was comparatively
faster in the formation of product 5 such that complete conver-
sion to product was observed by 24 hr using an enzyme to
substrate ratio of 1:5. To test if the presence of a thiazoline
heterocycle instead of a proline could be responsible for this
acceleration, we synthesized a variant of substrate 1 containing
the same core sequence with a single point mutation of TSIAPFC
to TSIAPFP (1a). Reactions were carried out with PatG to give
the expected cyclic product 5a. A time-course comparison of
amount of proline-containing product 5a formed versus the thia-
zoline-containing product 5 showed that formation of 5a was
significantly slower (up to 4-fold), indicating that presence of
A B C
Figure 2. In Vitro Synthesis of Trunkamide Derivatives
(A) Schematic representation of the step-by-step reaction starting from the linear unmodified substrate 1 carrying the trunkamide core sequence TSIAPFC along
with the necessary RSs. Action of ThcD heterocyclizes the Cys in the core to lead to 2, followed by proteolysis by N-terminal protease PatA to release the in-
termediate 4, which is further processed by the C-terminal protease/macrocyclase PatG to lead to the cyclic product 5. The addition of the prenyltransferase
TruF1 further prenylates 5 to 6.
(B) Mass spectra showing the masses of each reaction intermediate: 1, 1272.8 Da [M + 2H]2+ and 849.0 Da [M + 3H]3+; 2, 1264.2 Da [M + 2H]2+ and 843.1
[M + 3H]3+; 4, 1084.8 Da [M + H]+ and 543.1 Da [M + 2H]2+; 5, 702.3 Da [M + H]+; and 6, 770.4 Da [M + H]+. See Figure S2 for structures and higher resolution MS
of each species.
(C) Mass spectrum of the [M + H]+ of the product 5 resulting from a one-pot addition of enzymes ThcD, PatA, and PatG. The structure of 5 is given with the
thiazoline modification circled in yellow. See Figure S2G for high-resolution mass spectrum of 5 with a mass error of <2.5 ppm.
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the thiazoline at the C-terminal end improved PatG activity
(Figure S2F).
One-Pot Synthesis of Cyanobactins
When all enzymes, cofactors, and the substrate 1 were added
together in one pot rather than sequentially, the cyclic product
5 was readily synthesized (Figures 2 and S2G). As observed for
the sequential reaction, an essentially quantitative conversion
to 5 was measured (Figure S2H). The reaction was sensitive
to the concentration of protease PatA, which could produce
the non-heterocyclized N-terminally cleaved product 7 as a
side product (Figure S2I). Without heterocyclization, 7 is not a
substrate for the macrocyclization reaction. When prenyltrans-
ferase TruF1 was added, the monoprenylated product 6 was
produced (Figure S2J), although as in the sequential reactions
the complete conversion to 6 was not observed. Analysis of
the one-pot reaction showed that the PatG step is the limiting
step in that it is much slower in comparison with either
the ThcD or PatA step (Figure S2K). To our knowledge, this
is the first demonstration of reconstitution of a complete,
multistep RiPP biosynthetic pathway with multiple enzymes in
a single pot.
Unprecedented Macrocycle Size Plasticity
For several years, the ability to perform one-pot reactions eluded
us and has also proved challenging in other hands, where prote-
ases other than PatA were required (Houssen et al., 2014). Here,
we showed that this was due to differential redox sensitivity of
various enzymes in the pathway. Neither ThcD nor PatG require
the addition of reducing agent for activity, but PatA showed a
significant decrease in activity if DTT was used in the assay.
DTT has usually been added to these reactions because of the
prevalence of disulfide bonds in the precursor peptide. Hence,
both the sequential and one-pot reactions described above to
yield 5 were carried out in absence of DTT.
To our surprise, in one-pot reactions with 1 where PatA was
inhibited by DTT, a macrocyclic product (8, m/z = 1,072 Da,
Figure 3. Synthesis of 22-Ring Size
Macrocycle
Using ThcD and PatG only, macrocycle 8
comprising 22 residues was synthesized from 1.
The structure of 8 is given with the thiazoline
modification shown in yellow along with the high-
resolution FT-ICR mass spectrum showing the
[M + 2H]2+ with an error of <1.5 ppm.
[M + 2H]2+) was observed, resulting from
macrocyclization of 2 (Figure S3A). This
product could also be recapitulated in
reactions containing solely ThcD and
PatG. The PatG macrocyclase domain
could also be replaced with full-length
TruG, again affording the same product
8 (Figure S3B). Complete conversion of 1
to the product 8 was observed, whether
the reactions were performed in a single
one-pot step (Figure S3C) or via stepwise
addition of enzymes (Figure 3). As with the
cyclic peptide 5, the linear derivative of 8 (8 + H2O) was present
only in barely detectable trace amounts.
The structure of 8 was anticipated by high-resolution Fourier
transform ion cyclotron resistance (FT-ICR) tandem mass spec-
trometry (MS/MS) of 8 in comparison with 2, and further
confirmed by purification and NMR analysis (Figures S3D and
S3E; Table S1). Ring opening of the macrocycle as detailed in
the next section provides further evidence confirming the struc-
ture of 8. Purified 8 was quantified by NMR using boc-tyrosine
as a standard (Tianero et al., 2011). This in turn was used to
draw a standard curve of 8, which was used to compute the
yield of the reaction as 81% (Figure S3F). A time course of
the formation of 8 in comparison with 5 in one-pot reactions
is given in Figure S3G. Since this unusually long substrate
2 was macrocyclized, we also examined a short substrate 9,
comprising only 5 amino acids in the core peptide. Substrate 9
was also processed to the cyclic product 11, although with a
lower yield (<40%) (Figure S3H).
Here, we show that pat and tru enzymes can synthesize
macrocycles in a size range of 5–22 amino acids in length.
Previously, natural macrocycles from these pathways were
known to comprise 6–8 amino acids, while artificial substrates
had been 6–11 amino acids long (McIntosh et al., 2010). Beyond
the pat and tru pathways, cyanobactins exist varying from sizes
of as small as 3 residues (the linear products, viridisamides) (Lei-
koski et al., 2013) to up to 20 residues in cyclic products (Leikoski
et al., 2012). A 43-residue macrocycle could be a possible
product in Calothrix sp. PCC 7103 (Figure S3I). However, the
22-residue 8 is the largest confirmed product of a cyanobactin
pathway.
Enzymatic Reactions in Designed Unnatural Synthesis
RiPPs carry enormous potential for designer synthesis of deriv-
atives. As an initial examination of this process, we noted that
the large macrocycle 8 carries the PatA recognition sequence,
RSII. Recognition motifs within cyclic peptide scaffolds have
been shown to hold potential in stabilizing these scaffolds for
910 Chemistry & Biology 22, 907–916, July 23, 2015 ª2015 Elsevier Ltd All rights reserved
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enhanced protein-protein interactions (Davidson et al., 2009;
de Vega et al., 2007). Thus, we expected that the macrocyclic
product 8 might be proteolyzed by PatA, which in turn would
produce a derivative with the thiazoline residue in an abnormal
position. The HPLC-purified product 8 (Figure S4A) was used
in assays with PatA, and the expected linear product 13 was
indeed observed (Figure S4B). A complete conversion to the
linear product 13was observed, as judged by the disappearance
of 8 in the mass spectrum. High-resolution FT-ICR MS/MS
confirmed the sequence of the product 13 (Figure S4B; Table
S2). In addition, PatA cleavage of both the cyclic substrate 8
and the linear substrate 2was comparable in that both reactions
were complete by 30 min (Figure S4C). Thus, proteolysis within
the cyclic peptidemotif shifts the position of the heterocycle (Fig-
ure 4). This holds potential for engineering thiazoline-containing
peptides, wherein heterocycles can be introduced readily in any
desired position within a linear peptide.
Cyclic Peptides from Full-Length Artificial
Precursor Peptides
Using the tru pathway in E. coli, we have synthesized many
peptides with highly artificial sequences (Ruffner et al., 2014;
Tianero et al., 2011). However, many sequences were not
accepted. Here, we asked whether these failures were due to
the cyanobactin enzymes, or to some limiting factor in E. coli.
We previously sought to use 14 in vivo, but no products were
detected. Peptide 14 encodes a precursor peptide sequence
derived from the natural pag pathway (Donia and Schmidt,
2011), but where the native INPYLYP has been replaced with
INPYLYC. Peptide 14 was a substrate for heterocyclization
in vitro but not macrocyclization in vivo (Sardar et al., 2014).
Many tru precursor peptides contain exceptionally strong
intra- or intermolecular disulfide bonds (McIntosh and Schmidt,
2010a, 2010b), necessitating use of the PatA-inhibiting DTT.
Therefore 14 and ThcD were allowed to react in the presence
of DTT, affording 14a, which was purified by HPLC. Addition of
PatA led to production of 14b, which was then HPLC purified
and used with PatG, affording the expected cyclic product 14c
(cyc-INPYLYC*) (Figure 5). Minor amounts of the linearized
precursor (14c + H2O) were also produced. However, the yield
of 14cwas quite low in comparison with that from other reactions
performed in this study. The limiting factor was observed to be
macrocyclization by PatG (Figure S5). Therefore, at least in this
case, the factor limiting in vivo production appears to be the
macrocyclization reaction, since in vivo linear intermediates
would likely be non-specifically proteolyzed in the 5-day fermen-
tation time course.
Synthesis of Multiple Modified Cyclic Peptides in a
Single Reaction Batch from a Precursor Peptide
Carrying Multiple Cores
SomeRiPPpathways containmultiple core sequences in a single
precursor peptide. Apart from cyanobactins in which multiple
core sequences are very common, this feature has been
observed only rarely, such as in the cyclotide and orbitide family
of plant RiPPs (Arnison et al., 2013; Condie et al., 2011; Jennings
et al., 2001), and also the ustiloxins, fungal cyclic peptides that
havebeen recently reported tobe ribosomally synthesized (Ume-
muraet al., 2014; Tsukui et al., 2015).We therefore askedwhether
a precursor peptide (15) containing multiple cores could be pro-
cessed in vitro. Precursor15 is ahybrid containing core sequence
TFPVPTVC from the tru pathway and core sequence ACMPCYP
from the lyn pathway (McIntosh et al., 2013). Using the stepwise
methods applied to substrate 14, the expected products cyc-
TFPVPTVC* 15c and cyc-AC*MC*YP 15d (where C* is thiazoline)
were observed (Figures 6 andS6). As foundwith substrate 14, the
PatG reactionwas slow, and intermediates 15a and 15bwere not
fully cyclized within 24 hr. The linear derivatives of 15c and 15d
(15c-d + H2O) were not detectable in the reaction mixture. Cyclic
peptide 15d previously was not synthesized in vivo (Sardar
Figure 4. Manipulation of Reaction Order Alters Position of Heterocycle
In native cyanobactin biosynthesis, the order of enzymatic reactions starts with heterocyclization followed by N- and C-terminal proteolysis/macrocyclization,
such that in this study ThcD would act first followed by PatA and PatG. Here, we changed the order of the reaction such that proteolysis by PatA was carried out
after PatG macrocyclization of 2 to 8. This provided the linear product 13, which has its thiazoline ring (shown in yellow) shifted toward the N terminus from the
original C-terminal end position in the precursor 2.
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et al., 2014), again likely because of the slow reaction with PatG.
Overall, it is clear that application of the in vitro system comple-




RiPP prenylation has been found in the cyanobactins and
the quorum sensing ComX derivatives, where there are
many otherwise unprecedented posttranslational modifications
(Arnison et al., 2013; McIntosh et al., 2011; Okada et al., 2005).
We aimed to cross prenyltransferases between pathways,
Figure 5. Synthesis of Thiazoline-Contain-
ing pag Derivative from Full-Length Linear
Precursor
ThcD modification on 14 adds a thiazoline to
the core to yield 14a, which is followed by PatA
to yield 14b, which undergoes PatG processing
to lead to 14c. The structure of 14c is shown along
with its mass spectrum. The FT-ICR mass
spectrum is given in Figure S5 with a mass error
of <4.5 ppm. Structures and mass spectrum of
intermediates are also given in Figure S5. The
yellow circle represent thiazoline modification. It is
noteworthy that natural prenylagaramide (pag)
pathway products lack thiazolines, unlike the
unnatural derivative 14c.
Figure 6. Multiple Cyclic Peptides Produced
in a Single Reaction Batch from a Hybrid
Precursor Peptide Carrying Multiple Core
Sequences Derived from the tru and lyn
Pathways
As detailed for substrate 14, processing of 15 by
ThcD, PatA, and PatG led to the cyclic peptides
15c and 15d. The yellow circles represent thiazo-
line modifications. The schematics of the reaction
series are given along with the mass spectra of the
products. See Figure S6 for mass spectra and
structures of intermediates.
swapping TruF1, from the trunkamide tru
pathway, and PagF, from the prenylagar-
amide pag pathway. Based on the natural
products of these pathways, one would
expect that TruF1 would reverse preny-
late serine and threonine, while PagF
would forward prenylate tyrosine.
The cyclic peptides 15c and 15d were prenylated in a single
batch reaction containing both TruF1 and PagF, which led to
prenylated products cyc-TFPVPTVC* and cyc-AC*MPC*YP
(where the underlined threonine or tyrosine residue represents
prenylation and C* represents thiazoline). In the case of 15c
both singly and doubly prenylated products were observed on
the two threonine residues. For 15d carrying one tyrosine resi-
due, the expected single prenylation event was observed. In
addition, cyclic peptide 14c, which carries two tyrosine residues,
was doubly prenylated to yield 14d. In both cases the prenylation
reaction was complete in that the cyclic peptide substrate was
not detectable after 18 hr of reaction. The natural product analog
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of 14d (prenylagaramide B) does not carry a thiazoline modifica-
tion and is only singly prenylated, whereas in vitro exploitation of
these enzymes allows us to make this unnatural derivative.
These results show that it is possible to cross multiple posttrans-
lational modifications to create unusual products representing
hybrids of natural biosynthetic pathways (Figures 7 and S7).
DISCUSSION
Macrocycles are an underrepresented drug class, and their
potential is gradually being recognized. They exhibit unique
stability, membrane permeability, and ability to access difficult
targets such as protein-protein interactions. The cyanobactin
class of macrocyclic natural products provides access to an
unprecedented diversity of broad-substrate enzymes that can
be used for synthetic biology. The natural tru pathway has
previously been shown to be capable of producing millions of
macrocyclic derivatives using just proteinogenic amino acids
in vivo in an E. coli expression platform. Non-proteinogenic
amino acids have also been incorporated, greatly adding to




(A) Prenylation of cyclic peptides 15c and 15d by
a combination of the prenyltransferases TruF1
and PagF to yield the products 15e and 15f, and of
14c by PagF to yield the product 14d. Note that
15e is a natural product (patellin 6 from the tru
pathway), whereas 15f is a derivative of the lyn
pathway lacking thiazoline oxidation. The product
14d is an unusual derivative of the pag pathway
carrying thiazoline and double prenylation that is
natively absent in the parent pag natural product
(prenylagaramide B). The yellow and green circles
represent thiazoline and prenylation modifications
respectively.
(B) Mass spectrum of the product 14d.
See Figure S7 for the mass spectra of products
15e and 15f.
Here, we define practical methods
to make derivatives using mixtures
of cyanobactin enzymes in vitro. Both
natural and unnatural derivatives of the
patellamide, trunkamide, aestuaramide,
and prenylagaramide pathways were
successfully made. Moreover, the reac-
tions using 14 and 15 showed that these
are competent substrates, and that
a former lack of detection in E. coli
expression experiments (Sardar et al.,
2014) was not due to incompetency of
the tru pathway enzymes to accept
these substrates. Thus, in total the
enormous chemical potential of cyano-
bactin pathways determined through
in vivo work greatly underestimates the
potential products that can be synthe-
sized by this highly plastic biosynthetic
pathway.
This work is complementary to a recent report wherein simple
derivatives of the patellamide core sequence were synthesized
in vitro (Houssen et al., 2014). The work described here synthe-
sizes highly distant sequences using the same set of enzymes,
including a hybrid of modifications from different pathways. In
addition, this work exploits the prenylation posttranslational
modifications, macrocycle size plasticity, and use of a one-pot
methodology. A combination of these technologies will find
use in the generation of important cyclic peptides other than cy-
anobactins. For example, the Suga laboratory produced hetero-
cyclic precursors to the telomestatins using an in vitro translation
system (Goto et al., 2014). Perhaps in combination with the
methods developed here more advanced telomestatin analogs
could be synthesized.
The cyanobactin macrocyclase PatG is a serine protease (Lee
et al., 2009; McIntosh et al., 2010; Agarwal et al., 2012; Koehnke
et al., 2012); its mechanism is similar to that of other serine pro-
teases in first creating a covalently tethered ester intermediate,
which is then displaced by a nucleophile. In the case of PatG,
that nucleophile is the N terminus, leading to macrocycle forma-
tion. In contrast, most serine proteases use water as the
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nucleophile. A remaining question was how this selectivity for
macrocyclization instead of hydrolysis is achieved. One proposal
is that a capping helix that binds to RSIII also excludes water
from the active site (Koehnke et al., 2012). However, nucleo-
philes readily enter the PatG active site (McIntosh et al., 2010;
Agarwal et al., 2012). For example, transamination can occur
via both side-chain and main-chain amines (McIntosh et al.,
2010), as well as from short dipeptides in the reaction buffer
(Agarwal et al., 2012). A peptide with a glycolate terminus
(containing OH in place of NH2 at the terminus) is hydrolyzed
efficiently by water (McIntosh et al., 2010). PatG could function
by exploiting native substrate preorganization that would
hold the amine terminus in proximity to the ester intermediate
(Milne et al., 2006). However, PatG has been used to cyclize
hundreds of vastly different substrates (Lee et al., 2009;
McIntosh et al., 2010; Agarwal et al., 2012; Koehnke et al.,
2012; Schmidt et al., 2005; Donia et al., 2006; Ruffner et al.,
2014; Tianero et al., 2011; Houssen et al., 2014). Here, PatG
efficiently macrocyclizes a 22-amino-acid precursor containing
much of the leader peptide. This peptide necessarily adopts a
shape very different from that of the small, natural substrates,
which is at odds with the idea of substrate preorganization.
Therefore, PatG itself likely scaffolds peptides for macro-
cyclization, preferring nitrogen to oxygen nucleophiles. The
role of protein-substrate interactions in promoting cyclization
versus hydrolysis is reminiscent of that found in non-ribosomal
peptide thioesterases, and should be further explored (Jiang
et al., 2011).
SIGNIFICANCE
Posttranslationally modified peptides are found in all forms
of life, and are increasingly important as drug leads and
biochemical tools. Nature provides an enormous diversity
of peptide products and posttranslational modifications.
Here, we demonstrate howenzymes frommultiple pathways
can be combined in vitro to produce new natural products
with tailored posttranslational modifications. Because cya-
nobactin enzymes are exceptionally promiscuous, these
combined enzymes could be applied to highly unnatural
substrates to design the synthesis of new compounds.
Such a strategy holds promise in applying the many RiPP
enzymes to the synthesis of drug-like compounds. Finally,
application of these enzymes provided new insights into
important and novel posttranslational modifications.
EXPERIMENTAL PROCEDURES
Genes and Cloning
The genes for the enzymes ThcD, PatA, PatG protease/macrocyclase domain,
and TruG, along with those for the substrates 14 and 15, were made previously
(Lee et al., 2009; Sardar et al., 2014). The codon-optimized version of TruF1
was obtained from GenScript. All enzymes and peptides were expressed as
histidine-tagged constructs in pET-28b (+) expression vectors.
Protein Expression, Purification, and/or Synthesis
Peptides 1 and 9were obtained from the Peptide Core facility at the University
of Utah. Precursor peptides 14 and 15 were made as described previously,
whereby R2D-BL21 cells were electroporated with the respective plasmid,
a seed culture grown overnight in 2xYT media, an aliquot of which was inocu-
lated the next day in 1 l of 2xYT cultures. The cultures were grown at 37!C until
an OD600 of about 0.4 was achieved, followed by 1 mM isopropyl-b-D-thioga-
lactopyranoside (IPTG) induction for 3 hr at the same temperature. The
enzymes PatA, PatG, TruG, TruF1, and PagF were expressed such that all of
the conditions were maintained the same as above, except that 0.1 mM
IPTG induction was carried out overnight at a lower temperature of 18!C.
The cells were harvested and purified by Ni-NTA affinity chromatography
under denaturing (for 14 and 15) or native (for all modification enzymes) condi-
tions, according to the manufacturer’s protocol (Qiagen). All peptides were
dialyzed, aliquoted, flash-frozen, and stored at "80!C until use. The enzymes
were additionally stored in 10% (v/v) glycerol.
Assay Conditions for Sequential Enzyme Addition
In all assays a substrate concentration of 50–100 mMwasmaintained in 50mM
Tris buffer of pH 7.5. The heterocyclization reactions used 2 mM of the enzyme
in reaction mixtures containing 1 mM ATP and 5 mM MgCl2. The N-terminal
proteolysis reactions with PatA used 2–5 mM of the enzyme in reaction mix-
tures carrying 10 mM CaCl2, and C-terminal proteolysis/macrocyclization
with PatG or TruG used 10–20 mM of the enzymes with 5 mM MgCl2. Prenyla-
tion with TruF1 and PagF used enzyme at 10 mM in optimized reactionmixtures
containing 10 mM dimethylallyl pyrophosphate (DMAPP). A temperature of
37!C with variable time points was used for all reactions. Reactions with sub-
strate 1 were carried out for 2 hr with ThcD, 2 hr with PatA, and overnight with
PatG/TruG and TruF1/PagF. With substrates 14 and 15, each step was carried
out for 18 hr (sometimes longer in reactions with PatG).
Assay Conditions for One-Pot Reactions
All reagents and enzymes were maintained at the same concentrations as
above, such as 50 mM Tris buffer (pH 7.5), 5 mM MgCl2, 10 mM CaCl2,
1 mM ATP, 2 mM ThcD, 2 mM PatA, and 10 mM PatG at 37!C. If prenyltransfer-
ase was used, 10 mM of the enzyme was used with 10 mM DMAPP. Reactions
were carried out for 18 hr in most cases.
HPLC Purification of Reaction Intermediates
Reaction mixtures were centrifuged and the supernatant was used for purifi-
cation of intermediates by reverse-phase HPLC on a LaChrom Elite System
(Hitachi). A semi-preparative Supelco Discovery HS C18 column (25 cm 3
10 mm, 5 mm) was used for purification of the ThcD and PatA products of sub-
strate 1 (intermediates 2 and 4), and also for ThcD products of full-length sub-
strates 14 and 15, and PatA product of substrate 14a (intermediate 14b). A
gradient of 99% H2O/1% acetonitrile (ACN) to 1% H2O/99% ACN was used
over 20 min at a flow rate of 3.0 ml min"1 with 250-ml injection volumes. No tri-
fluoroacetic acid was used in the mobile phase because of the possibility of
thiazoline ring opening. For PatA product intermediates of substrate 15 (inter-
mediates 15a, b) an analytical Agilent Eclipse XDB-C18 column (4.6 3
150 mm, 5 mm) was used. The same gradient as above was maintained, with
the exception of adding 0.05% formic acid to the aqueous mobile phase. Re-
actions were dried down to 100 ml for injection, and a flow rate of 0.7 ml min"1
was used.
Characterization and Yield of Compounds
The reactions leading to 8were performed using the same reagent concentra-
tions described above, but were scaled up to 2 ml to guarantee sufficient
amounts of 1 (2 mg) for characterization. The product was purified as
described above to afford #1-mg quantities of pure 8, which was character-
ized by NMR and high-resolution MS. 1H NMR and 1H-1H COSY spectra
were obtained using a Varian INOVA 500 (1H 500 MHz) NMR spectrometer
with a 3-mm Nalorac MDBG probe. HSQC spectra were recorded on a Varian
INOVA 600 (1H 600 MHz and 13C 150 MHz) NMR equipped with a 5-mm 1H
[13C,15N] triple resonance cold probe with a z axis gradient, utilizing residual
solvent signals for referencing. The amount of isolated 8 was measured using
NMR standards consisting of varying concentrations of boc-tyrosine. Both
sample and standard were dissolved in 3:2 D2O/ACN-d3. To determine the
yield of 8 in enzyme reactions, the isolated, quantified standard was used to
generate a standard curve with HPLC on an analytical C18 column (Kinetex,
250 3 4.5 mm, 5 mm) over a gradient of 100% H2O-0.5% formic acid/0%
ACN-0.5% formic acid to 0% H2O-0.5% formic acid/100% ACN-0.5% formic
acid for 40 min at a flow rate of 1.0 ml min"1.
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PatA Proteolysis Reaction on Macrocycle 8
HPLC-purified 8 was lyophilized and an aqueous stock solution of 1 mM was
made. PatA cleavage of 8 was carried out using 7 mM of the enzyme, 200 mM
purified 8, 4 mMMgCl2, and 10 mMCaCl2 at 37!C for 18 hr. A reaction without
PatA was used as a negative control.
LC-MS-Based Product Characterization
All product characterization was based on LC-MS analyses. Low-resolution
LC/ESI-MS was done using a Micromass Quattro-II (Waters) instrument on
an analytical Agilent Eclipse XDB-C18 column (4.6 3 150 mm, 5 mm) with a
linear gradient of 1%–99% B over 20 min, where the mobile phase consisted
of solvent A (H2Owith 0.05% formic acid) and solvent B (ACN). High-resolution
mass spectra were recorded using the same LC conditions on a Micromass
Q-TOF Micro Mass Spectrometer (Waters) in positive ion mode. FT-ICR/MS
was performed using an LTQ FT Ultra Hybrid Mass Spectrometer (Thermo
Scientific) at the University of Utah Mass Spectrometry Core Facility. See
Tables S3 and S4 for a complete list of all substrates, intermediates, and prod-
ucts made in this study along with their expected masses.
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The increasingly rapid accumulation of genomic information is revolutionizing natural
products discovery. However, the translation of sequence data to chemical products
remains a challenge. Here, we detail methods used to circumvent the supply problem
of cyanobactin natural products, both by engineered synthesis in Escherichia coli and by
using purified enzymes in vitro. Such methodologies exploit nature's strategies of com-
binatorial chemistry in the cyanobactin class of RiPP natural products. As a result, it is
possible to synthesize a wide variety of natural and unnatural compounds.
1. INTRODUCTION
Natural products remain a major component of drug discovery efforts
(Newman & Cragg, 2012), but such efforts are still hindered by the need to
synthesize a sufficient supply and to create analogs. Mimicking biosynthesis
has emerged as a powerful tool to overcome these problems, providing a
tractable alternative to traditional chemical synthesis. The key advance
Methods in Enzymology # 2016 Elsevier Inc.






















































that has aided this is the explosion in genomic data, which has allowed con-
necting natural products to their corresponding genes (Walsh & Fischbach,
2010). In turn, rapid gene identification enables heterologous expression of
enzymes to perform total synthesis in vivo or in vitro. Connecting genes to
molecules has thus aided discovery based on sequencing, overcoming
limitations of conventional natural products discovery, which relies on
actual physical isolation of compounds, often from far-reaching locations
of the earth. In addition, assigning genes to specific chemical modifica-
tions allows exploitation of enzyme function to modify nature’s arsenal
of chemistry far beyond, by technologies such as directed evolution
(Renata, Wang, & Arnold, 2015).
This chapter focuses on directing biosynthesis using the cyanobactin bio-
synthetic machinery to engineer synthesis. Cyanobactins are natural prod-
ucts found in marine animals or in relatively slow-growing cyanobacteria.
Due to the rare and variable distribution of the producing organisms, supply
is an issue hindering cyanobactin development. An advantage is that several
cyanobactin pathways are exceptionally broad-substrate tolerant, which
allows cyanobactin enzymes and pathways to be used in the synthesis of
thousands of derivatives. Recent advances enable such synthesis at scale in
Escherichia coli and in vitro using purified enzymes. Later, we describe
methods enabling the practical synthesis and engineering of cyanobactin
pathways.
2. DISCOVERY OF CYANOBACTIN PATHWAYS
The cyanobactins belong to RiPP (ribosomally synthesized and post-
translationally modified peptides) class of natural products and are present in
about 30% of all cyanobacteria (Arnison et al., 2013; Sivonen, Leikoski,
Fewer, & Jokela, 2010). The first cyanobactins, patellamides, were isolated
from marine ascidian animals (Ireland & Scheuer, 1980), and related com-
pounds have also been found in both ascidians and free-living cyanobacteria.
Subsequently, biosynthetic genes for cyanobactins were discovered. A small
sample (several grams) of the ascidian Lissoclinum patella was obtained near
breaking surf on the reef flat above Blue Corner, Palau. Metagenome
sequencing of the marine animal and its symbiotic bacteria led to identifica-
tion of a RiPP pathway, pat in symbiotic cyanobacteria, Prochloron. pat car-
ried a gene encoding the amino acid sequence of patellamide. Heterologous
expression of pat in E. coli confirmed the symbiont Prochloron as the source of




















































the cyanobactin. This was an early application of whole (meta)genome
sequencing to identify a natural product source, leading to successful transfer
of the producing pathway from a noncultivable producer in the ocean to a
model host in the laboratory (Schmidt et al., 2005).
Due to the ribosomal nature of the cyanobactin pathway, subsequent
genome mining efforts were focused on discovery through screening of
homologous sequences, leading to identification of a new cyanobactin,
trichamide (Sudek, Haygood, Youssef, & Schmidt, 2006), heralding the
era of genome-based RiPP discovery. In RiPP pathways, a precursor
peptide is modified by enzymes to yield natural products. In the case of
cyanobactin pathways, further analysis revealed that the precursor peptides
exist as natural combinatorial libraries (Donia et al., 2006; Donia, Ravel, &
Schmidt, 2008). Many more new pathways were discovered in this way by
genome mining (Donia & Schmidt, 2011; Leikoski, Fewer, & Sivonen,
2009; Martins, Leao, Ramos, & Vasconcelos, 2013; Ziemert et al., 2008),
including the noteworthy discovery of a new class of cyanobactins that were
linear with the ends protected by N-terminal prenylation and C-terminal
methylation (Leikoski et al., 2013).
Ascidians contain a wide array of different cyanobactins with different
structures and posttranslational modifications. However, across time and
space in the oceans the ascidian-derived cyanobactin pathways are very
closely related, being nearly 100% gene-sequence identical across their bio-
synthetic pathways. The exception is in precise regions that encode new
sequence variants or new posttranslational modifications. This natural pre-
cision mutation has greatly aided studies of biosynthetic mechanism and
engineering (Donia et al., 2008; Fig. 1). The most conserved genes are
the N- and C-terminal proteases, a feature that can be exploited to discover
new cyanobactin pathways by blast searching (Donia & Schmidt, 2011). By
contrast, more variable regions and enzymes have allowed us to understand
the rules that govern combinatorial biosynthesis (Donia et al., 2006;
Sardar & Schmidt, 2015), which was subsequently exploited for engineering
as described later.
3. ELUCIDATING NATURAL RULES OF ENGINEERING IN
CYANOBACTIN PATHWAYS
Across multiple cyanobactin pathways, two kinds of genetic recom-
bination events can be observed. First, the precursor peptide substrate is
shuffled. Only a small number of amino acids in the precursor peptide




















































(the core sequence) encode the final natural product; these are hypervariable.
By contrast, the core peptide is flanked by highly conserved sequences that
largely serve as recognition sequences (RSs) for enzymes (Sardar, Pierce,
McIntosh, & Schmidt, 2015; Schmidt et al., 2005). Often, multiple copies
of the core or multiple precursors with different cores are present in the same
biosynthetic gene cluster. This results in the observed natural combinatorial
chemistry in the cyanobactins (Donia et al., 2008). Second, the modifying










































truB truC truD truE truF1 truF2 truG
patB patC patD patE patF patOx-patG
Fig. 1 Evolution of cyanobactin pathways in ascidians. The pat and tru cyanobactin
gene clusters are shown, where the precursor peptide gene patE/truE is in black. The
red (dark gray in the print version) bars within the precursor peptide gene represent
the variable core sequences that encode the final natural products, whereas the
remaining sequence (black) share>80% identity. The genes flanking the precursor code
for posttranslational enzymes and other functions. Outside the precursor gene, regions
in gray are similar in sequence, whereas the colored segments represent variation in
sequence. The most variability apart from the core sequence corresponds to hetero-
cyclization (yellow, white in the print version), prenylation (green, gray in the print
version), and oxidation (blue, gray in the print version) posttranslational chemistry
(purple (light gray in the print version) box). This variation translates clearly to structural
variability in the pat and tru natural products as shaded in the same corresponding color
as the genes. The pat pathway products carry both thiazolines and oxazoline/
methyloxazolines (yellow (white in the print version) circles), whereas tru products carry
only thiazoline (yellow (white in the print version) circle). In addition, tru products are
prenylated (green (gray in the print version) circles) corresponding to presence of the
TruF1 prenyltransferase that is absent in pat. Similarly, tru products lack oxidation of
thiazolines, since the corresponding oxidase domain (blue, gray in the print version)
is absent in them, in contrast to pat products.




















































correspond to new chemistry in the final natural product. For example, the tru
pathway produces prenylated natural products, a feature endowed by the
prenyltransferase TruF1 (Sardar, Lin, & Schmidt, 2015). In contrast, the pat
pathway that lacks prenylated natural product does not carry a functional
TruF1 homolog in its cluster. These principles of nature to introduce new
sequences into the natural peptide backbone (by shuffling precursor peptides)
followed by introducing new chemistry on the peptide scaffold (by shuffling
posttranslational modification enzymes) have been recapitulated in the
laboratory to produce desired novel peptide derivatives.
The question that arises is how do the same posttranslational modifica-
tion enzymes deal with this immense precursor peptide substrate diversity?
The enzymes must be extremely promiscuous. This promiscuity is enabled
by highly conserved sequences within the precursor peptide, the RSs that
serve to guide the posttranslational enzymes (Donia et al., 2008; Sardar,
Pierce, et al., 2015). This enables the core peptides, encoding the natural
product, to vary without losing affinity for the enzyme. This evolutionary
mechanism creates a unique natural engineering strategy that allows synthe-
sis of novel derivatives in the laboratory as detailed later (Fig. 2).
4. HETEROLOGOUS EXPRESSION OF CYANOBACTIN
PATHWAYS IN E. coli
The patellamides were the first cyanobactins to be heterologously
expressed (Long, Dunlap, Battershill, & Jaspars, 2005; Schmidt et al.,
2005). Due to their ribosomal origins, and the unique engineering rules
of the cyanobactin biosynthetic route, specific mutations could be easily
made within the pathway to encode nonnative cyanobactin derivatives
(Donia et al., 2006). For cyanobactin production, we designed an E. coli
expression platform that now uses a pUC-based vector pTru-SD
(Symbion Discovery, Inc.), which carries the tru pathway under control
of the lac promoter. This includes the biosynthetic enzymes TruA (N-
terminal protease), TruB/TruC (hypothetical proteins), TruD
(heterocyclase), TruF1 (prenyltransferase), TruF2 (prenyltransferase of
unknown function), TruG (C-terminal protease/macrocyclase), and the
precursor peptide substrate TruE that encodes the natural products patellins
3 and 2 (patellin 3¼diprenylated cyc-TVPVPTLC* and patellin
2¼diprenylated cyc-TVPTLC*, where C* is thiazoline). A typical expres-
sion experiment involves the following steps (Fig. 3):




















































• Day 1: Transform vector pTru-SD into E. coli DH10β and plate on LB
agar supplemented with ampicillin (50 μg mL!1).1
• Day 2: Pick six colonies into six wells in a 24-well plate containing liquid
2xYTmedium (3 mL) with ampicillin (50 μg mL!1). Grow overnight at
30°C with shaking at 150 rpm.
• Day 3: Pool the cultures. Use the pooled cultures (20 μL of pooled cul-
ture per 6 mL final volume) to inoculate wells in a 24-well plate
(rounded ends). Each well contains 2xYT (6 mL) and ampicillin
(50 μg mL!1). In addition, several other media components can be
added (described later as “yield optimizing additives”). Cover each
24-well plate with foil (sealing), and use a sterile needle to poke a small
Fig. 2 Combinatorial libraries using tru. The tru pathway gene cluster is shown, and the
precursor peptide variant TruE (black) is magnified to its translated amino acid
sequence. Observation of this sequence clearly demarcates the hypervariable regions
(blue, dark gray in the print version) that represent the core encoding the final natural
products. In contrast, the rest of the precursor is highly conserved and correspond to
recognition sequences (RSs, red, dark gray in the print version) that direct specific post-
translational enzymes. This phenomenon of substrate evolution, wherein the substrates
evolve to maintain a balance between variations in the core (creates diversity) and con-
servation of the flanking RSs (maintains modification chemistry) allows the creation of
natural combinatorial libraries.
1 Note: Other cyanobactin vectors, or even libraries containing multiple cyanobactin precursor variants,
use roughly the same protocol. Some details vary. For example, the yield is much lower with vectors
that are not codon-optimized.




















































hole directly above each well to enable gas exchange. Grow cultures at
30°C with shaking at 150 rpm. Optimum harvest time varies by condi-
tion, but as described here 5 days is usually best.
• Day 8: Harvest the cells by centrifuge using either the 24-well plates or
combined cultures from multiple wells.2 Wash the resulting pellet twice
with either 100 mM NaCl or phosphate-buffered saline. At this stage,
the cell pellets can be extracted immediately or stored at!80°C for later
extraction.
• To extract cells, resuspend the pellets (fresh or frozen) in acetone
(2–3 mL) and place in a sonicating bath for 30 min. Remove cell debris
Fig. 3 Schematic for heterologous expression in E. coli. There are three basic steps: (1)
transformation of E. coli with the pTru-SD vector that carries the tru pathway. At this
step, the sequence of the precursor can be manipulated to add desired motifs to the
final product; (2) expression in E. coli for an optimum of 5 days. At this step, addition
of cysteine or cysteine with mevalonate results in higher yields of compounds; and
(3) extraction of compounds from the E. coli cell pellet and mass spectrometry-based
detection.
2 Note: The yield is best if cells are grown in individual wells rather than combined in a flask. It is trivial to
aliquot seeded media into multiple wells, which can then be combined and extracted at the end of the
experiment. Because yield is not affected by stacking 24-well plates, this method optimizes use of
shaker space, and the entire volume of a shaking incubator can be occupied. Yield is reasonable in flasks
or in a fermentor under some conditions when using “yield optimizing additives,” but it is still less
reliable than 24-well plates.

























by centrifugation, and the acetone extract is processed (later) for further
analyses.
• Example use 1: The acetone layer is extracted, air-dried, and
resuspended in liquid chromatography mass spectrometry (LC–MS)
grade methanol, which is directly injected into the HPLC–mass spec-
trometer for analysis.
• Example use 2: The acetone layer is passed through a plug containing
C18 resin, and fractions containing desired cyanobactins are further puri-
fied by HPLC.
• The yield of cyanobactins varies, but is generally !10 μg L"1 under
these conditions. “Yield optimizing additives” described later improve
yield by 3000-fold but add complexity.
Over the years, this platform has been extensively optimized to engineer
both for production of derivatives and improve yields. The synthesis of non-
native cyanobactin was reported first in the creation of eptidemnamide, an
analog of the rattlesnake derived anticoagulant eptifibatide. This was
achieved by replacing the core sequence of patellamide precursor peptide
with the eptifibatide sequence designed to carry an amide bond instead of
a disulfide linkage (Donia et al., 2006). This feat was furthered by synthesis
of cyanobactin derivatives containing nonproteinogenic amino acids like
chlorinated and brominated tyrosine residues. Using methodologies devel-
oped by the Schultz group (Young et al., 2011), incorporation of non-
proteinogenic amino acids in the core sequence was carried out (Tianero,
Donia, Young, Schultz, & Schmidt, 2012). Production of patellins 3 and
2 from the parent precursor pTru-SD serves as internal controls of expres-
sion ensuring that the tru pathway is functional. A typical procedure for the
incorporation of unnatural amino acids in cyanobactins is as follows:
• Clone the precursor peptide truE into pRSF vector under the control of
a lac promoter and create mutants replacing the codons of amino acids in
one or multiple positions with the amber stop codon, TAG. Select for
the mutants using kanamycin (50 mg mL"1) and purify the plasmids.
• Cotransform the resulting pRSF plasmid containing the truE with TAG
codon(s) with the pTru-SD containing the tru operon and pEvol/
pCNF3 which contains the tRNA/aaRS pair to incorporate the unnat-
ural amino acids into the TAG/stop codon position. Plate in LB agar
3 pEvol/pCNF plasmid contains arabinose-inducible copy of the aaRS. In our hands, successful incor-
poration of the unnatural amino acids was achieved without induction.




















































containing kanamycin (50 μg mL!1), ampicillin (50 μg mL!1), and
chloramphenicol (25 μg mL!1). Grow at 30°C and 150 rpm overnight.
• Pick colonies and start seed cultures in 2xYT broth containing the three
antibiotics (kanamycin, ampicillin, and chloramphenicol) as described
earlier. After overnight growth, inoculate a fresh 2xYT broth (6 mL)
containing the antibiotics with 20 μL of the pooled seed culture. To this,
add the prepared unnatural amino acid (2 mM) and “yield optimizing
additive.”
• Grow the cultures for 5 days in a shaking incubator at 30°C and 150 rpm.
Extract the cultures as described earlier and analyze the extracts for both
the cyanobactin(s) containing the unnatural amino acids and patellins
2 and 3.
• This procedure can also be performed using amber mutations within the
tru operon, rather than having a second copy encoding TruE.
In addition to creating nonnative cyanobactin derivatives, recently a tru
pathway library was made in E. coli, revealing an ability to make potentially
millions of compounds. The same method as described earlier was fol-
lowed, and the library helped elucidate rules of core sequence selectivity
and amino acid residue preferences at each position in the core sequence,
leading to creation of >300 new compounds (Ruffner, Schmidt, &
Heemstra, 2015).
5. OPTIMIZATION FOR INCREASED YIELD OF
CYANOBACTINS IN E. coli
Although the strategies described earlier allowed production of both
natural and unnatural cyanobactins in E. coli, a significant gap still existed in
that heterologous expression often led to low compound yield. Although we
had the technological expertise to create combinatorial libraries in the E. coli
factory for drug discovery, downstream applications such as drug develop-
ment were hindered by the yield problem.
Conventional protocols such as transcriptional activation, varying media
conditions, or using different strains led to no significant improvement to
yield (Donia & Schmidt, 2011). We then resorted to a novel metabolite-
directed approach with the hypothesis that certain reagents can affect the
metabolic flux in E. coli, which may result in increased compound yields.
A screen of such metabolites led to the identification of the amino acid cys-
teine (yield optimizing additive), which provided a 150-fold increase in
compound production (Tianero et al., 2016).




















































The addition of cysteine is identical to that described earlier except
on Day 3:
• Day 3: Pool the cultures. Use the pooled cultures (200 μL of pooled cul-
ture per 6 mL final volume) to inoculate wells in a 24-well plate. Each
well contains 2xYT (6 mL), cysteine (5 mM),4 and ampicillin
(50 μg mL!1). Cover with foil, and poke a small hole directly above each
well to enable gas exchange. Cultures are grown at 30°Cwith shaking at
150 rpm. Harvest after 5 days.
• This condition provides up to about 2 mg L!1 of cyanobactins.
Further investigation revealed that hydrogen sulfide, the breakdown prod-
uct of cysteine in E. coli, was the actual mediator of increased cyanobactin
production. The cysteine effect could be recapitulated by introducing
hydrogen sulfide to the media as described later. In addition, the mechanism
of sulfide action has been elucidated (Tianero et al., 2016).
The protocol is identical to that described earlier, except for Day 3:
• Day 3: Pool the cultures. Use the pooled cultures (20 μL of pooled cul-
ture per 6 mL final volume) to inoculate a glass test tube containing
2xYT (6 mL) and ampicillin (50 μg mL!1). Place the test tube inside a
50 mL conical Falcon tube containing sodium phosphate buffer pH
8 (0.2 M, 10 mL) and Na2S (10 mM). Seal the Falcon tube with a rubber
cap allowing a little open headspace above the glass culture tube. This
generates low doses of hydrogen sulfide that can diffuse into the culture
tube through the headspace.
• Sulfide can also be applied at other scales and other vessel combinations.
A second metabolite was also identified along with cysteine that could drive
increased compound titers: the isoprene precursor mevalonate, which is
converted into dimethylallylpyrophosphate (DMAPP; Tianero et al.,
2016). Addition of the mev pathway and mevalonate to E. coli cultures
not only increases the degree of prenylated products but also increases total
compound production, although the effect of mevalonate was only pro-
nounced in the presence of cysteine. A typical expression platform involving
mevalonate is as follows:
• Day 1: Transform vector pTru-SD5 and pMBI6 (Martin, Pitera,Withers,
Newman, & Keasling, 2003) carrying the mevalonate pathway into
4 Note: Optimum cysteine concentration varies between 1 and 20 mM depending upon the exact con-
dition, but 5 mM provides a good, standardized dose that works.
5 Note: Other cyanobactin-encoding vectors, including those for libraries of compounds or for other
pathways such as pat, are effectively produced in this protocol.
6 Note: In addition to pMBI (Martin et al., 2003), it is possible to use vectors that encode mevalonate
synthesis from acetate instead, but cyanobactin yields are lower and more variable.




















































E. coli DH10β and plate on LB agar supplemented with ampicillin
(50 μg mL!1) and tetracycline (5 μg mL!1).
• Day 2: Pick six colonies into six wells in a 24-well plate containing liquid
2xYT medium (3 mL) with ampicillin (50 μg mL!1) and tetracycline
(5 μg mL!1). Grow overnight at 30°C with shaking at 150 rpm.
• Day 3: Pool the cultures. Use the pooled cultures (20 μL of pooled cul-
ture per 6 mL final volume) to inoculate wells in a 24-well plate
(rounded ends). Each well contains 2xYT (6 mL), cysteine (5 mM),
mevalonate (20 mM)7, ampicillin (50 μg mL!1), and tetracycline
(5 μg mL!1).
• Cultures are otherwise treated as described earlier. This condition pro-
vides up to about 30 mg L!1 of cyanobactins.
6. SYNTHESIS OF CYANOBACTINS IN VITRO
In many events, certain sequences exist that can be fully processed
in vitro, yet fail to be produced in E. coli. This can be caused by any number
of reasons, such as toxicity and/or degradation (Sardar, Lin, et al., 2015). In
such cases, having a robust in vitro synthetic platform at hand is necessary for
drug discovery.
Since discovery of the first cyanobactin gene cluster (Schmidt et al.,
2005), a series of biochemical studies characterized representatives of the
most ubiquitous cyanobactin enzymes, including the heterocyclase (TruD
and homologs; Koehnke et al., 2013; McIntosh, Donia, & Schmidt,
2010; McIntosh & Schmidt, 2010; Sardar, Pierce, et al., 2015), the N-ter-
minal and the C-terminal protease/macrocyclase (TruA and TruG homo-
logs; Agarwal, Pierce, McIntosh, Schmidt, & Nair, 2012; Houssen et al.,
2012; Koehnke et al., 2012; Lee, McIntosh, Hathaway, & Schmidt,
2009; McIntosh, Robertson, et al., 2010), and the prenyltransferase
(TruF1 and homologs; McIntosh, Donia, Nair, & Schmidt, 2011; Sardar,
Lin, et al., 2015). An elegant alternative in vitro approach to probing enzyme
activity was recently reported by Goto et al., using a cell-free translation sys-
tem. Interestingly, unprecedented heterocyclic motifs were generated,
including a sequence with tandem thiazoline rings, a feature not observed
in nature (Goto, Ito, Kato, Tsunoda, & Suga, 2014).
7 Note: In general, the more mevalonate added, the better. However, mevalonate toxicity is apparent
above about 40 mM, so that 20 mM as the upper limit is usually safe. Doubling time of E. coli is delayed
to "400 min in this condition.




















































Despite extensive exploitation of individual cyanobactin enzymes to cre-
ate unnatural derivatives, the use of a combination of these enzymes for reca-
pitulation of the entire multistep biosynthetic route was achieved only
recently (Sardar, Lin, et al., 2015). A key finding enabling this event was that
the N-terminal protease is inhibited by the reducing agent dithiothreitol
(DTT). This required that if the preceding heterocyclization required
DTT, then the heterocyclized product had to be purified for subsequent
proteolysis. Alternatively, the protease cleavage site could be replaced to
include a commercial protease cleavage site (Houssen et al., 2014), although
this is not advantageous for one-pot synthesis. In addition, certain substrates
that did not carry intramolecular disulfides could be easily processed by the
heterocyclase without the need for reduction, and such substrates could be
used in one-pot reaction schemes that could be modified to the final natural
product carrying up to at least four posttranslational modifications (Sardar,
Lin, et al., 2015). A typical in vitro pathway reconstitution method is
described later (Fig. 4).
The cyanobactin proteins are expressed and purified as follows:
• All expression constructs are cloned into pET-28(b) vector backbone
within the NdeI and XhoI restriction sites, which maintains an N-ter-
minal His-tag.
• Day 1: Transform desired construct into BL21(DE3) or R2D-BL21
cells, and plate on LB agar supplemented with kanamycin (50 μg mL!1).
Add chloramphenicol (25 μg mL!1) if R2D-BL21 cells are used.
• Day 2: Pick 4–5 colonies into LB broth (40 mL) supplemented with
kanamycin (50 μg mL!1), with addition of chloramphenicol
(25 μg mL!1) if R2D-BL21 cells were used, for an overnight seed
culture.
• Day 3: Inoculate either LB or 2xYT media supplemented with the nec-
essary antibiotics as above with the overnight culture from day 2, using
10 mL L!1. Incubate at 30°C with shaking at 200–225 rpm, until the
OD600 reaches 0.4–0.6 units. For precursor peptide expression, induce
cultures with IPTG (1 mM) and raise temperature to 37°C for an addi-
tional 3 h. This drives the precursor peptide into the pellet and improves
expression. For expression of enzymes, lower the expression tempera-
ture to 18°C and induce cultures with 0.1 mM IPTG for 18 h. Typically,
6–8 L culture scales are used for each protein.
• After completion of induction time, harvest cells by spinning at
4000 rpm for 10 min. The pellets are collected and stored at !80°C till
processed for purification.




















































• All precursor peptides are purified using denaturing conditions and all
enzymes are purified under native conditions using nickel column affin-
ity chromatography, following standard purification protocols. All pro-
teins are aliquoted and flash frozen (the enzymes are stored with 5%
glycerol). The precursor peptides are stable and can be thawed multiple
times or stored at 4°C for long time periods, whereas with the enzymes, a
fresh aliquot is used every time.
A typical in vitro reaction setup is as follows:
• We use the enzyme ThcD from the thc pathway for introducing thia-
zolines. TruD from tru pathway also exhibits the same chemoselectivity
as ThcD (Sardar, Pierce, et al., 2015). Heterocyclization reactions are
set up with enzyme (2 μM), substrate (typically 50–100 μM), MgCl2
Fig. 4 Schematic for in vitro synthesis of cyanobactins. (A) The purified enzymes and
substrate are mixed in a reaction tube under optimum conditions, and the products
detected by mass spectrometry. It is essential to maintain the necessary recognition
sequences (RSs) in the substrate for posttranslational chemistry. (B) A detailed reaction
scheme is shown with each modification step. The representative substrate carries the
trunkamide core sequence, flanked by the required RSs. The heterocyclase ThcD
(directed by RSI) modifies the cysteine residue in the core to thiazoline. This is followed
by N-terminal proteolysis by the protease PatA (directed by RSII). It is helpful to keep the
reaction medium free of reducing agents for PatA action. The subsequent protease/
macrocyclase PatG (directed by RSIII) cleaves off the RSIII and joins the ends to generate
the cyclic product. Further modification of prenylation is appended on the backbone by
the enzyme TruF1.




















































(5 mM), DTT (if present, 7.5 mM), and ATP (1 mM) in Tris buffer pH
7.5 (50 mM). If DTT is present, the reaction is purified for subsequent
steps by HPLC. Alternatively, a similar method can be used with PatD
to simultaneously heterocyclize cysteine and serine/threonine.
• The second step after heterocyclization is N-terminal proteolysis. We
use the enzyme PatA from the pat pathway for this purpose. The purified
heterocyclized product is subjected to N-terminal proteolysis with
enzyme (2–5 μM), MgCl2 (5 mM), and CaCl2 (10 mM, this is not nec-
essary and can be left out) in Tris buffer pH 7.5 (50 mM). If no DTTwas
used in the previous step, these components can be directly added to the
heterocyclization reaction mix.
• N-terminal proteolysis is followed by C-terminal cleavage in tandem
with macrocyclization. We have used both PatG protease domain (pat
pathway) and TruG full-length construct (tru pathway) for this. Addition
of the C-terminal protease/macrocyclase can be done either with or
without purification of the N-terminal proteolytic product, although
HPLC purification usually yields a cleaner subsequent reaction. The
C-terminal protease/macrocyclase (10–20 μM) is added to the previous
reaction maintaining MgCl2 (5 mM) in Tris buffer pH 7.5 (50 mM).
• In certain pathways, isoprene is appended on the cyclic peptide backbone.
We have used the prenyltransferases TruF1 (a Ser/ThrO-prenyltransferase
from the tru pathway), PagF (a Tyr O-prenyltransferase from the pag
pathway) and LynF (a reverse Tyr O-prenyltransferase from the lyn
pathway). For prenylation, the enzyme (10 μM) is added to the mac-
rocyclization reaction mix with DMAPP (10 mM) as the prenyl donor.
Due to the high cost of commercially available DMAPP, we chemically
synthesize it in the laboratory using previously established protocols
(Davisson et al., 1986; Woodside, Huang, & Poulter, 1988).
• All reactions are carried out at 37°C in a PCR cycler with a heated lid to
prevent evaporation within the reaction tubes. Typically, both the
heterocyclization and N-terminal proteolysis reactions are complete
within 2 h, whereas the C-terminal proteolysis/macrocyclization usually
runs for 24 h or more, and the subsequent prenylation step even longer
and never reaches completion in our hands.
• A one-pot synthetic route to cyanobactin derivatives using the enzymes
ThcD, PatA, and PatG (or TruG) was also reported (Sardar, Lin, et al.,
2015). For one-pot reaction schemes, the same concentrations and
conditions as detailed earlier are maintained in a single reaction tube
for 7.5–10 h.














































Purification and characterization of reaction intermediates and products is
done as follows:
• If it is desirable to stop the reaction at an earlier time point, boiling for
15 min quenches the reactions. The tubes are then centrifuged briefly to
pellet precipitated material, and the supernatant is analyzed.
• HPLC purification: A semipreparative C18 column is used with a
mobile phase comprising H2O/ACN gradient from 1% to 99% ACN
over 20 min. Note that no acid is used in the HPLC mobile phase since
it renders the thiazoline prone to ring opening. Typically, fractions are
collected every minute, dried under vacuum, and the fractions with UV
absorbance are analyzed by mass spectrometry to detect the desired
species. A 255-nm shoulder in the UV spectrum indicates presence of
thiazoline ring.
• C18 purification: In certain cases, an alternative to HPLC purification is
a rapid purification by C18 resin (Sigma). A small C18 plug is made in a
Pasteur pipette. The resin is equilibrated with 100% ACN followed by
H2O. The reaction solution is added to the resin, which is washed twice
with water, and elutions are collected at 25%, 50%, and 100% ACN.
Typically, the desired products elute at 50% and/or 100% ACN.
• Product characterization: All intermediate and product species are char-
acterized by LC–MS analysis. A C18 or C4 analytical column is used in
all cases, and a C4 column results in negligible column bleed-through in
case of larger peptides >1000 Da mass. A mobile phase of H2O (0.1%
formic acid)/ACN is used, with an ACN gradient of 1–99% over
20 min.
• If reactions are done in large scale, purity of products is further assessed
byNMR spectroscopy. Typically, the cyclic peptides are dissolved in 3:2
D2O/ACN-d3 for best results.
Alternative routes to generate products and derivatives in vitro have also
been reported, such as use of commercial protease cleavage sites in addition
to cyanobactin enzymes (Houssen et al., 2014), use of posttranslational
enzymes fused to substrate leader sequence (Oueis et al., 2015), and use
of an in vitro translation platform (Goto et al., 2014). A unique feature of
cyanobactin RiPP pathways that has enabled in vitro synthesis of
cyanobactin derivatives is their modularity (Sardar, Lin, et al., 2015). This
implies that parts of the pathways can be mixed and matched with parts
of other pathways to create hybrid natural products. Thus, different enzymes
from varied cyanobactin families can successfully process nonnative sub-
strates from other families, or even chimeric substrates that carry cores from




















































different families. The only requirement necessary to allow such hybridiza-
tion is the maintenance of the conserved RSs that act as docking sites for the
respective posttranslational modification reaction (Fig. 5; Sardar, Pierce, et
al., 2015).
7. CONCLUSIONS
This chapter details the methods that demonstrate the powerful
ability of rerouting biosynthetic routes for synthesis. Since the cyanobac-
tins carry a peptide backbone, research in this area provides tools for the
synthesis of desirable peptide motifs. An advantage of such tools is that
they require simple manipulations at the genetic level for the creation of
derivatives. In contrast, a chemical synthetic route is tedious with com-
plicated scope for combinatorial chemistry. For example, the total synthesis
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Fig. 5 Modularity of cyanobactin pathways. Enzymes and substrates from different
pathways can be mixed and matched to create hybrid natural products for combinato-
rial chemistry. For example, the unnatural cyanobactin shown on the right is derived
from elements belonging to four different pathways pat, thc, pag, and tru. The specific
elements involved from each gene cluster for the creation of this hybrid are highlighted
in red (dark gray in the print version). The cyclic peptide sequence is derived from pagE
precursor sequence INPYLYP (red (dark gray in the print version) bar in pagE), wherein
the proline is mutated to cysteine to allow introduction of a heterocycle. The recogni-
tion sequences in the precursor substrate were derived from truE (red (dark gray in the
print version) bars in truE) to direct the enzymes heterocyclase (thcD, from the thc
pathway), the N-terminal protease (patA, from the pat pathway), and the C-terminal
protease/macrocyclase (patG, from the pat pathway). Additional modification of
prenylation was introduced by pagF (from the pag pathway). This resulted in a deriva-
tive of the natural product prenylagaramide B, carrying chemistry not found in nature
such as thiazoline ring (yellow, white in the print version) and double prenylation (blue,
gray in the print version).




















































of trunkamide and derivatives with the use of our optimized E. coli
expression system and in vitro platform requires far lesser effort with
maximized yields.
We have detailed methods for synthesis in vivo and in vitro. Such syn-
thesis is possible based on an understanding of nature’s engineering rules of
modularity in the cyanobactin RiPPs. This has allowed creation of unique
peptide scaffolds, a few examples of which include cyclic peptides with
halogenation, azide functionality, polyketide insertions, and large macrocy-
clic ring size. In addition, pathway hybrids with nonnative patterns of
heterocyclization and prenylation and linear peptides with heterocycles at
unexpected positions are among few of the nonnative chemical motifs that
have been captured in the laboratory, expanding nature’s array of chemistry
using nature’s tools (Fig. 6).
Fig. 6 Representative examples of modified peptide motifs not found in nature created
using the cyanobactin RiPP machinery both in vivo and in vitro. (1) Eptidemnamide that
resembles the rattlesnake derived anticoagulant eptifibatide, (2) macrocyclic peptides
with polyketide insertions, (3) macrocyclic peptides with nonproteinogenic amino acid
insertions, (4) small molecules carrying isoprene units, (5) thiazoline containing cyclic
peptides, (6) linear peptide with the thiazoline heterocycle at desirable positions,
and (7) an unusually large macrocycle of 22 ring size.





















































Although this chapter is focused primarily on the cyanobactin story,
similar features of promiscuity that allows combinatorial biosynthesis are also
beginning to be observed in other RiPP families (Sardar & Schmidt, 2015).
The most notable of this is the lanthipeptide family of RiPPs, which include
the marine compounds called the prochlorosins (Zhang, Yu, Velasquez, &
van der Donk, 2012). Apart from the cyanobactins and the lanthipeptides, it
is likely that similar stories and strategies will be found among the ubiquitous
and widespread families of RiPPs.
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USE OF IN VITRO TOOLKIT TO RECAPITULATE NEW CHEMISTRY 
 









The cyanobactins are modified peptide natural products that belong to the 
larger class of the ribosomally synthesized and posttranslationally modified peptides 
(RiPPs).1 They were previously defined as small cyclic peptides, due to the fact that 
all cyanobactin natural products reported ever since its first discovery in 19802 until 
2008 were macrocyclized peptides.3 Modified peptides are ubiquitous natural 
products, but the biosynthetic origins of many of these compounds remain unknown. 
A key step that enables study of the enzymology responsible for the creation of many 
unique chemical motifs seen in natural products is to be able to know the identity of 
the corresponding producer genes, connecting genes to molecules.4 
The utility of connecting genes to molecules is exemplified by the natural 
product aeruginosamide. It is a small tetrapeptide (Ile-Val-Pro-Cys), and the C-
terminus Cys residue is modified to a thiazole. It is protected at its N-terminus by 
two isoprene units and at the C-terminus with a methyl ester. It was first isolated in 
1999 from the cyanobacterium blooms of Microcystis aeruginosa and was found to be 
biologically active with cytotoxicity against human ovarian tumor cells and leukemia 
cells.5 This compound shares certain structural features common to cyanobactins 
such as heterocyclization, oxidation of heterocyclic rings and prenylation, in addition 
to a cyanobacterial producer source. The linear nature of the natural product made 
it doubtful for it to be classified as a cyanobactin. A recent study reported discovery 
of aeruginosamide-like compounds, and genome analysis led to the identification of 
the biosynthetic genes of these compounds, which clearly resembled that of known 
cyanobactins. These compounds were named as aeruginosamide B-C and 
viridisamide A (Figure 5.1), expanding the chemical diversity of the cyanobactins to 
include linear modified peptides.6 Additionally, analysis of the biosynthetic gene 
	 66	
cluster allowed identification of the enzymology that would be responsible for 
introducing this new chemistry of linearity in the cyanobactin class.  
A comparison of the aeruginosamide pathway (aer) and the well-known pat 
pathway to the patellamide cyanobactins (from Prochloron didemni)7 is a clear 
demonstration of the phenomenon of substrate evolution described in Chapter 2.8 
Despite the different source organisms of the aeruginosamide and patellamide class 
of natural producer, the posttranslational enzymes are homologous. In contrast, 
variation exists only at two points in the biosynthetic gene cluster. The first is at the 
substrate level in the substrate core sequence. The rest of the substrate flanking the 
core is similar in its leader and recognition sequences, which allows recruitment of 
the same type of posttranslational enzymes. This is an example of substrate 
evolution, wherein variation in the core lends diversity and conservation of 
recognition elements maintains posttranslational chemistry. The core sequence 
! 70!
reported discovery of aeruginosamide-like compounds, and genome analysis 
led to the identification of the biosynthetic genes of these compounds, which 
clearly resembled that of known cyanobactins. These compounds were named 
as aeruginosamide B-C (similar to the originally isolated aeruginosamide) 
and viridisamide A, expanding the chemical diversity of the cyanobactins to 
include linear modified peptides6 (Figure 1). Additionally, analysis of the 
biosynthetic gene cluster allowed identification of the enzymology that would 
be responsible for introducing this new chemistry of linearity in the 










Figure 1 The structures of the originally isolated aeruginosamide, and the 
recently discovered natural products aeruginosamide B-C and viridisamide A 
are shown. The latter were demonstrated to be cyanobactins. The 
modifications of heterocyclization, N-terminal prenylation and C-terminal 








































Figure 5.1 The structures of the originally isolated aeruginosamide, and the 
recently discovered natural products aeruginosamide B-C and viridisamide A are 
shown. The latter were demonstrated to be cyanobactins. The modifications of 
heterocyclization, N-terminal prenylation and C-terminal methylation are 




differences encode the different primary peptide backbone sequence of patellamides 
and aeruginosamide. For example, as shown in Figure 5.2, the patellamide core is 
VTACITFC, whereas that of aeruginosamide is FFPC. The second difference 
between the pathways is at the enzyme level. All enzymes between the two 
pathways are homologous with the exception of a new posttranslational enzyme 
gene (aerMTPT) in the aer pathway. This gene shares homology to 
methyltransferases (MT) at its N-terminal domain and prenyltransferases (PT) at 
its C-terminal domain. This enzyme was proposed to carry out the addition of the 
observed methyl-prenyl groups on aeruginosamide B-C. This would explain the 
major structural difference of linearized versus macrocyclized chemistry between the 
aeruginosamides and patellamides, since aerMTPT would block the peptide 
backbone from cyclizing by protection of the peptide termini by methylation and 
prenylation. 
The existence of bi-functional enzymes carrying two separate catalytic 
domains is common in enzymology. For example, within the cyanobactin pathway 
itself, certain pathways carry the peptide macrocyclization enzyme fused to an 
oxidase (as in the pat pathway to patellamides).7 Certain oxidases can also be mono-
domain proteins in some other pathways and are fully functional.9 Similarly, an 
analysis of biosynthetic gene clusters across several cyanobacterial genomes 
identified a few stand-alone methyltransferases or in some cases, 
methyltransferases fused to the cyanobactin protease homolog.6 Posttranslational 
modifications of N-terminus prenylation and C-terminus methylation was previously 
unknown in the cyanobactin class of natural products and a bi-domain prenyl-
methyl transferase is unique and previously unreported in enzymology. This led us 
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Figure 5.2 The biosynthetic gene clusters of aer and pat cyanobactin pathways are 
shown. The genes in grey represent posttranslational enzymes and other proteins 
that are homologous between the two pathways that explain the common structural 
features of heterocyclization, proteolytic release of core and oxidation of heterocycles 
between the aer and pat compounds. There are two major differences between these 
compounds. The precursor peptide gene (black) carries the first difference, which lies 
in the sequence of the primary peptide backbone encoded in the variable cores (blue). 
The conservation of recognition sequences (red) maintains posttranslational 
chemistry in these varied cores. The second difference, which is that of linearized 
versus macrocyclized structure, is attributed to the presence of the new aerMTPT 
enzyme gene in the aer cluster. This bi-domain gene product is expected to N-
prenylate (blue circle) and C-methylate (green circle) the peptide termini, blocking 




5.2 Results and discussion 
5.2.1 Proposed biosynthetic route of aeruginosamide B-C (aer pathway) 
The aeruginosamide precursor peptide (called as AerE) carries three core 
sequences of which core I and III encode aeruginosamide B, whereas core II encode 
aeruginosamide C. The core sequence is flanked by canonical cyanobactin 
recognition sequences of heterocyclization (RSI), N-terminal proteolysis (RSII) and 
C-terminal proteolysis/macrocyclization (RSIII).8 The corresponding enzyme 
homologs in the aer pathway would be AerD (heterocyclase), AerA (N-terminal 
protease) and AerG (C-terminal protease/macrocyclase). The AerG is also fused to 
the oxidase domain (AerOx). The pathway also encodes the methyl-prenyl 
transferase enzyme AerMTPT (MT= methyltransferase; PT= prenyltransferase). 
The proposed biosynthetic pathway would be as follows: AerE is the peptide 
substrate that carries the core sequence amino acid stretch of the final products. 
AerD recognizes the RSI (LAELSEEAL) to heterocyclize cysteine residues to 
thiazolines (C*= thiazoline), which is followed by action of AerA that recognizes the 
RSII homolog (GMDAS/GADAS) to proteolytically remove the N-terminus. Since 
AerE carries three cores, N-terminal proteolysis will release three intermediates 
carrying the core and RSIII (SYD). The expected fate of one of the intermediates 
FFPC*SYDDGDA (C*= thiazoline) is shown in Figure 5.3. The timing of action of 
the AerG and AerMTPT is speculated to be either of two possibilities. First, AerG 
acts to proteolytically release the core, after removal of its C-terminal recognition of 
RSIII (SYD). AerG shares homology to other cyanobactin macrocyclases and would 
be expected to macrocyclize the core, but the small size of the core (4 residues) 
makes macrocyclization unlikely, since known macrocyclized cyanobactins are at 
least six-membered rings. This would leave the termini of the core free for N-
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prenylation and C-methylation by AerMTPT (shown as route 1 in Figure 5.3). 
Another possibility is that the PT domain of AerMTPT acts first to N-prenylate the 
AerA product. The C-terminus RSIII of this intermediate is then proteolytically 
removed by AerG, which would be unable to N-C cyclize the core because of 
protection afforded by the N-terminal prenylation. This would be the subsequent 
substrate for the MT domain of AerMTPT to yield the final product (shown as route 
2 in Figure 5.3). The AerOx domain of the pathway can act either after or before 

























Figure 3 The proposed biosynthetic route to aeruginosamide B (grey box) is 
shown. AerE is the precursor peptide with three core sequences (blue) and 
the canonical recognition sequences RSI-RSIII (red) for the heterocyclase 
(AerD) and proteases (AerA and AerG). The expected activity of heterocyclase 
AerD (where C* is the thiazoline heterocycle) and N-terminal protease AerA 
is shown. Due to the presence of the new enzyme AerMTPT, the timing of the 
C-terminal protease/macrocyclase AerG can be either of two ways as shown 
in two possible routes. Posttranslational modifications of N-terminal 
prenylation and C-terminal methylation expected from AerMTPT are shown 







Figure 5.3 The proposed biosynthetic route to aeruginosamide B (grey box) is 
shown. AerE is the precursor peptide with three core sequences (blue) and the 
canonical recognition sequences RSI-RSIII (red) for the heterocyclase (AerD) and 
proteases (AerA and AerG). The expected activity of heterocyclase AerD (where C* is 
the thiazoline heterocycle) and N-terminal protease AerA is shown. Due to the 
presence of the new enzyme AerMTPT, the timing of the C-terminal 
protease/macrocyclase AerG can be either of two ways as shown in two possible 
routes. Posttranslational modifications of N-terminal prenylation and C-terminal 





In other words, the difference between both these possibilities is that in the 
first case, AerG is unable to macrocyclize AerE core due to its small size of 4 
residues, whereas in the second case, AerG is unable to carry out macrocyclization 
due to N-terminal protection of the core by prenylation. In both cases, failure of 
macrocyclization explains the observed linearity of the final cyanobactin products. 
Another possibility is that AerG is intrinsically incapable of macrocyclization, 
although this is unlikely since AerG shares homology to PatG domains that are 
involved in C-terminal proteolysis and macrocyclization (Supporting Figure 
S5.1).11,12 An additional difference between the two proposed routes is that in route 1, 
AerMTPT acts in a single step to carry out the dual reactions of methyl-prenyl 
transfer, whereas route 2 entails that AerMTPT act in two separate steps to carry 
out each reaction of methyl-prenyl transfer. Thus, in route 2, AerMTPT would 
behave in a distributive manner wherein the PT domain product is released to be 
the subsequent substrate for AerG, the product of which in turn is the substrate for 
the MT domain. This would be a unique route to biosynthesis for fusion enzymes, 
where the whole enzyme binds two structurally different substrates twice to carry 
out two different chemical reactions. To explore the working of this novel AerMTPT 
enzyme, we used the in vitro toolkit described in Chapter 3,10 to probe into the 
biosynthesis of aeruginosamide B. 
 
5.2.2 Modularity of biosynthetic machinery enables in vitro  
recapitulation of putative AerD heterocyclase activity 
The first step in the reconstitution of AerMTPT activity is the production of 
the relevant substrate for the enzyme. This would require the use of the native aer 
pathway enzymes AerD, AerA and AerG. The promiscuity and modularity of 
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cyanobactin pathways implies that elements from non-cognate cyanobactin 
pathways can be used in a rationally designed combination to yield the desired 
substrate for AerMTPT, which would bypass the need of acquiring the native aer 
pathway enzymes.8,10 To this end, we selected the sequence FFPCSYD, which carries 
the core aeruginosamide B sequence of FFPC. Since it lacks the N-terminal leader, 
use of this substrate precludes use of a N-terminal protease, and requires only the 
heterocyclase and C-terminal protease. The heterocyclase has been previously shown 
to be able to process substrates lacking RSI,8,13,14 although with much lower 
efficiency. We used the FFPCSYD 1 substrate in a reaction with heterocyclase TruD 
from the tru pathway,15 which shares 79% identity with AerD, the heterocyclized 
product 2 was observed, and the reaction had low efficiency as expected. To 
overcome this, we used a TruD variant (RSI-TruD), wherein the RSI sequence is 
fused to the N-terminus of TruD (Supporting Figure S5.2A). The methodology of 
using enzyme variants to process stand-alone cores was first demonstrated for a 
lanthipeptide synthetase and later for a cyanobactin heterocyclase.16,17 The RSI-
TruD had higher efficiency and led to complete conversion of 1 to its heterocyclized 
product 2 (Figure 5.4A). Interestingly, apart from the increased efficiency of RSI-
TruD, we also observed that RSI-TruD lacked a dependency on the requirement of 
reducing agent dithiothreitol (DTT), although the presence of DTT enhanced activity 
(Figure 5.4B and Supporting Figure S5.2B). The mechanism of increased activity of 
enzymes fused to its recognition sequences has been proposed to be due a 
conformational change in the enzyme.16,17 The loss of dependency on DTT by the 
RSI-TruD implies that this mechanism maybe related to disulphide linkages in the 

































Figure 4 (A) The mass spectrum of heterocyclization by TruD and RSI-TruD 
on substrate 1 (878.2 Da [M+H]+) leading to heterocyclized product 2 (860.2 
Da [M+H]+ or 882.2 Da [M+Na]+) are shown. The enzyme (1 µM each) was 
used with substrate 1 (50 µM) in optimised reaction mixture for 1 hour. (B) 
The percentage of reaction was calculated based on area of integrated 
chromatograms of each species 1 and 2, and plotted against the different 
conditions. The RSI-TruD in presence of DTT was found to be the most 
efficient reaction condition and used in all subsequent reactions. Each data 
point is an average of duplicate reactions and error bars represent standard 
deviation. The mass spectrum of the same reactions in absence of DTT is 
shown in Supporting Figure 2B. The structures of 1 and 2 is shown in 










Figure 5.4 Heterocyclization po ttranslational modificat on on substrate 1: (A) The 
mass spectrum of h terocyclization by TruD and RSI-TruD on substrate 1 (878.2 Da 
[M+H]+) leading to product 2 (860.2 D  [M+H]+ or 882.2 Da [M+Na]+) are shown. 
Enzyme (1 µM each) was used with 1 (50 µM) in optimized reaction mixture for 1 
hour. (B) The percentage of reaction was calculated based on area of integrated 
chromatograms of each species 1 and 2, and plotted against the different conditions. 
The RSI-TruD in presence of DTT was found to be the most efficient reaction 
condition and used in all subsequent reactions. Each data point is an average of 
duplicate reactions and error bars represent standard deviation. The mass spectrum 
of the same reactions in absence of DTT is shown in Supporting Figure S5.2B. The 





5.2.3 Modularity enables use of the putative AerD product 2 in further 
modifications by PatG and prenylation-methylation by AerMTPT 
The product 2 carries the C-terminal protease/macrocyclase recognition 
sequence RSIII (SYD). The protease domain of the native aer macrocyclase AerG 
shares 65% identity with that from the pat pathway enzyme PatG.18 As with AerD 
and TruD, we expected PatG to be able to process 2 to the macrocyclized product 3, 
the linear product 4, or a mixture of both. But, incubation of 2 in a reaction mixture 
with PatG led to no detection of the expected products (Figure 5.5A). Instead, 
incubation of 2 in a reaction mixture that contained PatG in presence of AerMTPT 
and the isoprene donor dimethylallyl pyrophosphate (DMAPP) led to formation of 
the N-prenylated product 5, and the N-protected PatG proteolysed product 6 was 
observed. This implied that AerMTPT prenyl-transfer occurs first before PatG 
proteolysis, which was shown to be true by sequential addition of AerMTPT (30 
minutes) followed by PatG to the reaction mixture. When a second batch of 
AerMTPT with the methyl donor S-adenosyl methionine (SAM) was added to this 
reaction, the expected methylated product 7 was observed (Figure 5.5B). The 
methylation activity of AerMTPT could also be captured in reaction mixtures of 5 in 
presence of both PatG and AerMTPT (with added DMAPP and SAM) together. The 
structures of each reaction intermediate and products are shown in Supporting 
Figure S5.3A. The addition of isoprene and methyl creates a mass shift of +68 Da 
and +14 Da, respectively, which was used to search for the reaction products. The 
methylation reaction was found to be dependent on SAM concentration with 
increasing SAM leading to increased product (Supporting Figure S5.3B). Control 
reactions for the AerMTPT were carried out in absence of DMAPP and/or SAM and 






the first functional characterization report of a cyanobactin methyl-prenyl 
transferase. 
 
5.2.4 Substrate selectivity rules of AerMTPT 
Before using the native substrate sequence of 1, we had previously tried a 
series of different substrates (1.1 to 1.10) with diverse sequences (Supporting 
Figure S5.4A), but no prenylated products were observed. Analysis of homologous 
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used to search for the reaction products. The methylation reaction was found 
to be dependent on SAM concentration with increasing SAM leading to 
increased product (Supporting Figure 3B). Control reactions for the 
AerMTPT were carried out in absence of DMAPP and/or SAM and also in 
absence of AerMTPT, which led to no product formation in all cases. This is 
the first functional characterization report of a cyanobactin methyl-prenyl 
transferase. 
 
Figure 5 (A) In reaction mixtures with 2 as the starting material PatG 
failed to carry out either macrocyclization or C-terminal proteolysis to the 
expected products 3 or 4, which were not detected in the mass spectrum 
analysis of the reactions. (B) In reaction mixtures with PatG in presence of 
AerMTPT (with DMAPP), the N-prenylated product 5 (928.2 Da [M+H]+) and 
the subsequent PatG proteolysed product 6 (563.2 Da [M+H]+) was observed, 
which could be transformed into the C-methylated version 7 (577.2 Da 





used to search for the reaction products. The methylation reaction was found 
to be dependent on SAM concentration with increasing SAM leading to 
increased product (Supporting Figure 3B). Control reactions for the 
AerMTPT were carried out in absence of DMAPP and/or SAM and also in 
absence of AerMTPT, which led to no product formation in all cases. This is 
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Figure 5 (A) In reaction mixtures with 2 as the starting material PatG 
failed to carry out either macrocyclization or C-terminal proteolysis to the 
expected products 3 or 4, which were not detected in the mass spectrum 
analysis of the reactions. (B) In reaction mixtures with PatG in presence of 
AerMTPT (with DMAPP), the N-prenylated product 5 (928.2 Da [M+H]+) and 
the subsequent P tG proteolysed product 6 (563.2 Da [M+H]+) was observed, 
which could be transformed into the C-methylated version 7 (577.2 Da 






Figure 5.5 PatG proteolysis posttranslational modification reactions: (A) In 
reaction mixtures with 2 as the starting material, PatG failed to carry out either 
macrocyclization or C-terminal proteolysis to the exp ted products 3 or 4 , whi h 
were not detected in the mass spectrum analysis of the reactions. (B) In reaction 
mixtures with PatG in presence of AerMTPT (with DMAPP), the N-prenyla ed 
product 5  (928.2 Da [M+H]+) and the subsequent PatG proteolysed product 6 (563.2 
Da [M+H]+) was observed, which could be transformed into the C-methylated version 
7 (577.2 Da [M+H]+) in presence of AerMTPT and SAM. 			
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AerMTPT genes from genome database shows that in each case, the known native 
substrates of these homologs all carry an N-terminal Phe residue, followed by a 
hydrophobic residue and a Pro or Cys (Supporting Figure S5.4B). Since none of the 
above tested substrates had these features, this implies that the prenylation activity 
of AerMTPT has a preference for a hydrophobic N-terminal end. On the other hand, 
we found that AerMTPT could N-prenylate the non-heterocyclized 1 (forming 
product 8), in addition to the expected native substrate 2 with roughly the same 
efficiency (Figure 5.6), indicating that a heterocycle at the C-terminus does not drive 





























Figure 6 (A) The formation of N-prenylated non-heterocyclized product 8 
(946.2 Da [M+H]+) by AerMTPT (with DMAPP) is shown, which demonstrate 
that the C-terminal heterocycle is not a requirement for N-prenylation. (B) A 
comparison of the relative percentage of reaction completion for AerMTPT on 
the non-heterocyclized substrate 1 (leading to product 8) versus 
heterocyclized version 2 (leading to product 5) showing that both proceed 
with roughly the same efficiency. Reaction mixtures contained each substrate 
(50 µM), AerMTPT (2 µM) and DMAPP (5 mM) and percentage reaction 
completion was calculated from area of integrated chromatogram at a time-
point of 10 minutes. Each data point is an average of duplicate reactions, and 







Figure 5.6 N-prenylation posttranslational modification reaction on substrate 1: 
(A) The formation of N-prenylated non-heterocyclized product 8 (946.2 Da [M+H]+) 
by AerMTPT (with DMAPP) is shown, which demonstrates that the C-terminal 
heterocycle is not a requirement for N-prenylation. (B) A comparison of the relative 
percentage of reaction completion for AerMTPT on the non-heterocyclized substrate 
1 (leading to product 8) versus heterocyclized version 2 (leading to product 5) 
showing that both proceed with roughly the same efficiency. Reaction mixtures 
contained each substrate (50 µM), AerMTPT (2 µM) and DMAPP (5 mM) and 
percentage reaction completion was calculated from area of integrated 
chromatogram at a time-point of 10 minutes. Each data point is an average of 





The methylation activity of AerMTPT was observed only at the C-terminus of 
the thiazoline of the prenylated intermediate 6, and no products were observed from 
other intermediates. This implies that the MT has preference for both the thiazoline 
and prenyl group. Indeed, secondary structure predictions (JPred) showed that the 
AerMT domain shares homology with a methyltransferase that C-methylates 
geranyl pyrophosphate.19 Since recognition might be driven by both isoprene and 
heterocycle, this may explain the remarkable selectivity of the MT domain. 
 
5.2.5 Timing of biosynthesis of the aer pathway 
As shown in Figure 5.1, the first two steps of the pathway are expected to be 
AerD and AerA activity. It is to be noted that although AerMTPT can prenylate the 
non-heterocyclized substrate 1 before putative AerD activity, the AerD homolog 
TruD was unable to heterocyclize the free Cys thiol in this prenylated product 8. 
This supports the proposed biosynthetic route that heterocyclization and N-terminal 
proteolysis precedes prenylation by AerMTPT, in our reconstitution of the pathway 
in vitro. The subsequent prenylation activity of AerMTPT on 2 leading to product 5 
was found to be efficient in that the reaction was almost complete to about 80% in 15 
minutes (Figure 5.7A). The activity of PatG was much slower and continued for a 
period of greater than a single day and never reaching completion. The PatG 
reaction was complete to only 35% after 2 days (Figure 5.7B). If AerMTPT with 
added SAM was present in the reaction mixture, methylation continued along with 
PatG proteolysis over the same time-period (Figure 5.7C). But, the independent 
methylation reaction was found to be comparatively faster. It was found to reach 
40% completion within 3 hours only in contrast to 2 days in presence of PatG in the 


















substrate for the MT. Although it is to be noted, that the results with the 
native aer pathway enzymes may show different reaction efficiencies than 





















Figure 5.7 Posttranslational modification reactions converting 2 to 7 : (A) The 
mass spectrum of reaction of 2 with AerMTPT (in presence of DMAPP) leading to 
product 5 at a 15-minute time-point (top) in comparison to a reaction in absence of 
enzyme (considered as 0 minute time-point). Reaction mixtures contained AerMTPT 
(2 µM), DMAPP (5 mM) in optimized conditions. The substrate was generated in the 
reaction with 1 (50 µM) and RSI-TruD (1 µM) for 1 hour, to lead to the AerMTPT 
substrate 2. (B) PatG (10 µM) was added to a reaction with the same conditions as 
in (A) and the expected product 6 was detected after a period of 1 and 2 days. The 
percentage reaction completion was calculated based on the area of integrated 
chromatograms of each species 5 and 6 and was found to be 35% after 2 days. (C) If 
AerMTPT (2 µM) with SAM (5 mM) was added to the same reaction as in (B), the 
expected methylated product 7 was observed, which was absent if the reaction 
lacked SAM (bottom). The methylation reaction was found to proceed for days and 
was at 40% completion at a time-point of 2 days, since it was tied up with PatG 
release of the substrate 6. In contrast, if the reaction was boiled first after PatG 
activity, followed by addition of AerMTPT and SAM, the methylation reached the 

































































































Figure 7 (A) The mass spectrum of reaction of 2 with AerMTPT (in presence 
of DMAPP) leading to product 5 at a 15 minute time-point (top) in 
comparison to a reaction in absence of enzyme (considered as 0 minute time-
point). Reaction mixtures contained AerMTPT (2 µM), DMAPP (5 mM) in 
optimised conditions. The substrate was generated in the reaction with 1 (50 
µM) and RSI-TruD (1 µM) for 1 hour, to lead to the AerMTPT substrate 2. (B) 
PatG (10 µM) was added to a reaction with the same conditions as in (A) and 
the expected product 6 was detected after a period of 1 and 2 days. The 
percentage reaction completion was calculated based on the area of 
integrated chromatograms of each species 5 and 6 and was found to be 35% 
after 2 days. (C) If AerMTPT (2 µM) with SAM (5 mM) was added to the same 
reaction as in (B), the expected methylated product 7 was observed and the 
reaction was about 40% complete in 2 days (top left). The product 7 was 
absent if the reaction lacked SAM (bottom). The longer time scale of 2 days 
was because the methylation activity was tied up with PatG release of 
substrate 6. In contrast, if the reaction was boiled first after PatG activity, 
followed by addition of AerMTPT and SAM, the methylation reached the 
same 40% completion within 3 hours.  
 
C"





was used with AerMTPT and SAM (Figure 5.7C). This means that with the in vitro 
toolkit setup we have used, AerMTPT activity follows route 2 (Figure 5.1), wherein 
the bi-domain enzyme recognizes two structurally different substrates in two 
separate catalytic steps. It is to be noted that in certain scale-up reactions, we did 
observe trace amounts of the proteolysed tetrapeptide (FFPC*, where C*= 
thiazoline), which was undetectable if prenylation by AerMTPT is present in the 
same reaction mixture due to its faster reaction completion time. 
An implication of the above timing of each biosynthetic step is that it follows 
the tenets of diversity-generating metabolism.20 This type of metabolism exemplified 
by the tru pathway is dedicated to generating a diversity of products. The cause of 
this diversity is dictated by the relative enzyme efficiency of each step of the 
biosynthetic pathway. As the pathway proceeds, the corresponding enzymes 
encounter a greater diversity in substrates. This is dealt with a decrease in reaction 
efficiencies of each succeeding enzyme. For example, activity of the latter step of the 
pathway is slower than each preceding step. The same trend of reaction efficiencies 
was also observed in vitro.20 In other words, the more selective an enzyme is in its 
substrate preference, the more efficient it will be, and vice versa. We notice the same 
tendencies if we compare PatG and AerMTPT activities. PatG is intrinsically 
promiscuous, which is reflected in its lower efficiency in that it takes days to process 
its substrate 5. This is in contrast to AerMTPT activity that is more substrate 
selective in comparison, wherein prenylation is as fast as 15 minutes and 
methylation is complete in a few hours. It is to be noted that it is possible for the 
methylation reaction to be even faster if the thiazoline is oxidized to a thiazole, since 
that is likely to be the native substrate for the MT. Also, the results with the native 
	 82	
aer pathway enzymes may show different reaction efficiencies than those observed 
with our in vitro toolbox enzymes. 
 
5.2.6 Secondary AerMTPT reactions 
We serendipitously discovered secondary reactions of the AerMTPT 
prenyltransferase. In reaction mixtures that were aimed to probe into simultaneous 
prenyl-methyl transfers, the reactions contained both DMAPP (as the prenyl donor) 
and SAM (as the methyl donor), wherein we surprisingly discovered prenylation on 
the SAM molecule. Furthermore, this reaction showed a dependency on SAM 
concentration (Supporting Figure S5.5). Since AerMTPT prenylates the free amino 
N-terminus of Phe residue at the peptide N-terminus, we hypothesized that the free 
amino group at the adenosine ring in the SAM molecule could be the possible site of 
N-prenylation. This was supported by the fact that we also found AerMTPT could N-
prenylate free adenosine (Figure 5.8) and adenine in trace amounts. In contrast, 
AerMTPT could not prenylate the adenosine ring of other molecules like coenzyme A 
or adenosine triphosphate (ATP). Structures resembling prenylated adenine are 
found in plant hormones like zeatin.21 Although this holds future engineering 
potential, the current utility of these secondary reactions is minimal since there was 
extremely low product turnover with only about less than 5% conversion to product, 
and future work will require optimization of reaction conditions or enzyme 

































































































Figure 5.8 The mass spectrum of secondary reaction products of prenylated-SAM 
11 (366.1 Da [M+H]+), prenylated-adenosine 13 (336.1 Da [M+H]+) and prenylated-
adenine 15 (204.1 Da [M+H]+) are shown, along with their possible structures with 
the prenylation modification highlighted in blue. It is to be noted that SAM molecule 
is actually 400.1 Da [M+H]+, but only the fragment 10 (298 Da [M+H]+) was detected 
in the mass spectrum that also corresponded to the fragmented product 11. 
Reactions contained AerMTPT (5 µM), DMAPP (5 mM) with SAM, adenosine and 
adenine (5 mM each) for 18 hours. In all cases, negative control reactions were 






In this study, we report the first functional characterization of a di-domain 
methyl-prenyl transferase fusion enzyme AerMTPT from the cyanobacterium 
Microcystis aeruginosa. This was enabled by the promiscuity and modularity of 
cyanobactin pathways, which allowed the use of non-native aer pathway enzymes 
such as TruD (tru pathway) and PatG (pat pathway) for enzymatic synthesis of the 
AerMTPT substrate. In addition, the concept of recognition sequences was used to 
create the RSI-TruD derivative, wherein TruD was N-terminally tagged with its 
recognition sequence RSI, for increased activity to lead to more substrate material 
for AerMTPT.  
The in vitro reconstitution of elements of the aer pathway showed that with 
our in vitro toolbox of enzymes, the AerMTPT act in two distributive steps. The first 
step comprises prenylation and the subsequent product is released to be the 
substrate for the consecutive PatG enzyme. The product of this activity in turn acts 
as the second step of methylation by AerMTPT. This implies that the fusion enzyme 
accepts two structurally different substrates for its two separate catalytic domains.  
The timing of the prenylation activity showed that it was very efficient in 
that the reaction was almost complete by 15 minutes. This is in contrast to 
prenyltransferase homologs from other cyanobactin pathways. For example, the O-
prenyltransferase TruF1 from the tru pathway takes days to carry out prenylation 
both in vitro and in vivo in an E. coli expression platform.10,20 It is to be noted that 
the fast activity of AerMTPT facilitates production of the linearized product, since 
N-terminal prenylation blocks PatG macrocyclization, which is extremely slow in 
comparison. It is of interest therefore as to the evolution of the N-prenyltransferase 
domain in terms of faster reaction times to enable linearization. 
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The methyltransferase activity was found to be stringent in terms of 
substrate selectivity, which makes it the only non-promiscuous enzyme activity from 
the known cyanobactin enzyme repertoire. In contrast, the prenyltransferase 
activity was found to comparatively more relaxed in that it could accept both 
heterocyclized and non-heterocyclized substrates, and the unexpected secondary 
reactions on adenine, adenosine and the adenosine ring of SAM. Put together, these 
reactions expand the posttranslational toolbox of the cyanobactin enzymes to create 
prenylated and/or methylated small molecules and linear peptides. 
 
5.4 Materials and methods 
5.4.1 Genes and cloning 
The aerMTPT gene was obtained from Genscript in a codon-optimized version. 
The truD and patG genes for the enzymes were obtained as described previously.15,18 
The RSI-TruD gene carried the sequence RLTAGQLSSQLAELSEEALG fused at the 
N-terminus of TruD followed by a tetra Gly-Ser spacer link. 
 
5.4.2 Protein expression, purification and synthesis 
All enzymes were expressed as N-terminal hexa-histidine tagged constructs 
in R2D-BL21 strains of E. coli. They were expressed with 0.1 mM IPTG induction 
overnight at 18°C and purified using nickel affinity chromatography under native 
conditions. The detailed conditions of protein expression and purification have been 
described previously.10 The substrate 1 was synthesized at the University of Utah 




5.4.3 TruD, RSI-TruD and PatG assay conditions 
Heterocyclization assays were carried out with TruD or RSI-TruD in reaction 
mixtures containing buffer Tris pH 7.5 (50 mM), MgCl2 (5 mM), DTT (5 mM), ATP (1 
mM), enzyme (1 µM) and substrate 1 (50-100 µM). Assays with PatG were 
maintained at the same composition except that ATP was not necessary to be added 
and up to 10-20 µM of PatG was used.  
 
5.4.4 AerMTPT assay conditions 
All AerMTPT reactions were carried out in Tris pH 7.5 (50 mM), MgCl2 (5 
mM), DTT (5 mM), substrate (50-100 µM) and enzyme (5 µM). Reactions contained 
DMAPP (1 mM) as the isoprene donor that was chemically synthesized as described 
previously,22 and SAM as the methyl donor that was obtained from Sigma Aldrich. 
Negative control reaction for prenyl-methyl transfers was carried out in the absence 
of DMAPP, SAM and/or enzyme. 
 
5.4.5 Product characterization by mass spectrometric methods 
All product characterization was through liquid chromatography mass 
spectrometry, which was performed on a Micromass Q-TOF Micro Mass 
Spectrometer (Waters) in positive ion mode, on an analytical Agilent Eclipse XDB-
C4 column (4.6 × 150 mm, 5 µm) with a linear gradient of 1%-99% B over 20-minute, 
where the mobile phase comprised solvent A (Optima LC-MS grade water with 
0.05% formic acid) and solvent B was Optima LC-MS grade acetonitrile. Relative 
abundance of each intermediate species (1 to 15), if described, was calculated as a 
function of area, which is an absolute value obtained from the integration of the 
displayed mass peak from the total ion chromatogram of the mass spectrum. 
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Supporting Figure S5.1 Clustal alignment of AerG and PatG. The domain 
represented by blue is the protease/macrocyclase domain of PatG, which as shown 
shares homology to AerG. The letters in red represent the conventional Ser-His-Asp 
catalytic triad for PatG class of serine proteases. The letters in green represent the 
region that binds RSIII of the substrate that contains two helices (underlined). The 
domain boundary for PatG protease was obtained from previously described 































Supporting Figure S5.2 Details of heterocyclization reaction on substrate 1: (A) 
The sequence of RSI-TruD is given, with the RSI element in the N-terminal region of 
the protein construct highlighted in red. This is followed by four Gly-Ser repeats 
before the start of the TruD enzyme. (B) RSI-TruD can function without DTT to lead 
to product 2 (bottom), whereas TruD is unable to function under the same conditions 
without DTT (top). (C) The structures of substrate 1 and its heterocyclized product 2 






















































































Supporting Figure S5.3 Details of posttranslational reactions involved in the 
conversion of 2 to 7 : (A)  The structures of intermediates and products 5, 6 and 7 
are shown, with the modifications of heterocyclization, N-prenylation and C-
methylation highlighted in yellow, blue and green circles, respectively. (B) The 
amount of methylated product 7  formed depends on SAM concentration as shown. 
The percentage reaction completion was calculated from the integrated 
chromatograms of 6  and 7, and was found to be 12.3% complete with lower SAM (1 
mM) in comparison to 43.4% complete with higher SAM (10 mM) and there was no 
reaction in the absence of SAM. The reaction was carried out for a time-period of 18 























































































Supporting Figure S5.4 Details of the N-prenylation substrate selectivity of 
AerMTPT: (A) The following substrates 1.1 to 1.10 were not found to be prenylated 
by AerMTPT (where C* is thiazoline). (B) Putative core sequences proposed to be 
substrates for homologous AerPT domains from other cyanobacteria. All carry an N-
terminus Phe residue, followed by a hydrophobic residue and a Pro or Cys (which is 







Supporting Figure S5.5 The secondary reaction of prenylation on SAM by 
AerMTPT corresponded to SAM concentration. Reactions were carried out in the 
same reaction conditions as given in Figure 5.8, but with varying SAM 
concentrations from 0.01-1 mM SAM (top to bottom). The area of integrated 
chromatograms of 11 is shown on the left, whereas the corresponding mass 
spectrum of the same peak is shown on the right. The area was found to be directly 
proportional to increasing SAM concentration. A negative control reaction in absence 





THE HETEROCYCLASE MYSTERY SOLVED: MECHANISM OF ACTION OF ATP  
 
USAGE BY THE CYANOBACTIN HETEROCYCLASE 
 









A heterocycle is a ring structure that has atoms of at least two different 
elements. The thiazoline ring is a ubiquitous structural feature found in many 
natural products. It contains both sulfur and nitrogen in its ring, and the source of 
sulfur is cysteine, which is modified to the thiazoline ring. Oxazoline is a related 
derivative with the sulfur replaced by an oxygen atom, derived in the same way from 
serine. If threonine undergoes the same modification, it gives rise to methyl 
oxazoline (Figure 6.1A). Often these rings are further oxidized to the thiazole, 
oxazole or methyl oxazole derivatives.  
Heterocyclization often lends bioactivity to the molecule by introducing two 
key features: firstly, locking an amide bond into the heterocycle rigidifies the peptide 
backbone protecting it from proteolytic degradation and secondly, conversion of an 
amide and a polar amino acid to an aromatic ring appends hydrophobicity. This 
often results in increased bioactivity. For example, the heterocycle itself increases 
interactions with proteins (microcin B17), RNA (thiopeptides), DNA (bleomycin A) 
and the added hydrophobicity often allow membrane access (tubulysins). 
Additionally, they also serve as metal complexation sites (patellamides). It also plays 
a major role in acting as a nucleophilic catalyst in biologically important reactions, 
such as in the case of thiamine pyrophosphate that is involved in the generation of 
acetyl CoA.1 With its ubiquitous presence and diverse functions in Nature’s 
medicinal chemistry toolbox, understanding the biosynthesis of heterocycles is a 




























Nature employs two main methodologies to introduce such heterocycles in its 
natural products.2 The first is via nonribosomal peptide synthetases. This can occur 
by aryl carrier protein domains, which loads activated aryl-AMP acyl groups that 
help to start the peptide chain as an aryl-N-capped chain with the heterocycle (as in 
siderophores). Another way is the use of modified condensation, cyclization (Cy) 
domains. The classical condensation domain catalyses the attack of the amino group 
A	
B	
Figure 6.1 The heterocyclization reaction process and its presence in different 
natural products: (A) The conversion of Cys thiols or Ser/Thr hydroxyls to 
heterocyclic ring structures fused with the peptide backbone is shown. The atoms 
involved in this modification reaction are in red. (B) The structures of representative 
natural products carrying heterocycles are shown, with the modification highlighted 
in yellow. 			
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of one thioesterified amino acid to an activated acyl group of an upstream amino acid 
or peptide to form a new peptide bond. The Cy domain then converts the N-acetyl-
cysteinyl bond on the peptidyl carrier protein to the thiazoline ring by cyclizing the 
side chain nucleophile to the newly formed amide (as in epothilone).3-6 Apart from 
this first route via nonribosomal peptide synthetases, the second route to formation 
of heterocycles is via posttranslational modification enzymes after ribosomal 
translation. This is a common feature in many ribosomally synthesized and 
posttranslationally modified peptide (RiPP) natural products.7 An additional route to 
heterocycle generation is seen in the case of the thiazole moiety of thiamine 
pyrophosphate. In E. coli, this involves a complex of six proteins that act in 
coordination for thiamin biosynthesis. One of these proteins called ThiF carries a 
Cys that acts as the sulfur donor for the thiazole ring.8 
Although all of the above routes are involved in the creation of the same 
chemical motif, the biosynthetic machinery responsible for this chemistry as 
described is highly divergent. A standout feature of difference with the RiPP 
heterocycle biosynthesis is the use of ATP in contrast to the other route. The ATP 
requirement was first reported to be absolute necessity in the microcin RiPPs,9 
which was subsequently shown to be true for other RiPPs.10,11 Within the RiPPs, 
such heterocycles are found in the linear azoline peptides (LAPs) that include the 
microcins, goadsporin and plantazolicin, within the cyanobactins, within 
thiopeptides and within bottromycins.7  
The first study delving into the mechanism of ATP hydrolysis for thiazoline 
formation was in the microcin B17 RiPP. The microcin B17 synthetase (McbBCD) 
was shown to be a kinase since ADP was detected as the ATP hydrolysis product. In 
addition, a superstoichiometric usage of ATP led to the proposed hypothesis that 
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ATP is used in a manner analogous to molecular machines.9 Subsequently, studies 
with the cyanobactin RiPP heterocyclase TruD/PatD also reported the enzymes to be 
a kinase based on ADP formation and inhibition by the non-hydrolysable βγ-
methylene-ATP analog that would prevent ADP formation. Stoichiometry studies 
showed that use of ATP and heterocycle formation was 1:1 unlike the Mcb 
synthetase, but ATP was shown to be hydrolysed continuously even after product 
formation, which gave further support to the molecular machine hypothesis in 
thiazoline ring formation.10,12   
The molecular machine hypothesis was subsequently challenged by studies 
on a heterocyclase complex derived from Bacillus sp. Al Hakam (BalhBCD). This 
enzyme belonged to the thiazole-oxazole modified microcin (TOMM) RiPPs that also 
includes microcin B17. It was shown that ATP was hydrolysed to ADP as in the case 
of microcin B17, but isotopic labeling experiments were performed to show that 
there was direct phosphorylation of the amide carbonyl oxygen preceding the 
heterocyclizable residue. Also, stoichiometry of ATP to heterocycle formation was 1:1 
by the Balh enzymes, which was in discrepancy with that reported in the Mcb 
microcin B17 synthetase. This led to a re-investigation of the Mcb synthetase 
experiments with a full-length substrate (McbA) and a tag-free synthetase complex 
(McbB: McbC: McbD) added in a 1:1:1 molar ratio. With this setup, the 
stoichiometric ratio of ATP to heterocycle was indeed 1, in concurrence with the 
Balh enzymes.13 Use of an 18O-labeled substrate with the Balh system and analysis 
of the phosphate-leaving group by 31P-NMR, provided further evidence of direct 
phosphorylation of the amide carbonyl oxygen.14 These two studies called into 
question the molecular machine hypothesis and led to proposal of a phosphorylated 
hemiorthoamide intermediate as the likely mechanism involved in heterocyclization. 
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As mentioned earlier, the cyanobactin heterocyclase TruD/PatD was reported 
to release ADP as the ATP hydrolysis product, similar to the microcin B17 McbBCD 
synthetase and the TOMM BalhBCD enzymes. A subsequent report of the crystal 
structure of the TruD enzyme also analysed the ATP hydrolysis products and 
demonstrated AMP (and not ADP) release during heterocyclization. This led the 
authors to propose that TruD, unlike the other heterocyclases, behaves as an 
adenylase instead of kinase, and the reaction proceeds via an adenylated 
intermediate in contrast.15 This proposal was based solely on the observation of AMP 
as the ATP hydrolysis product, and no other mechanistic routes were investigated. 
Apart from the dissimilarities in ATP hydrolysis products reported, another 
feature of debate among the RiPP heterocyclases had been the identity of the ATP 
binding site. In the TOMM RiPPs, the microcin B17 synthetase consists of three 
components (McbB, McbC, McbD) that need to be associated together to form a 
functional unit. McbB contains two CxxC motifs that bind zinc. McbC is the oxidase 
that converts azolines to azoles. McbD was reported to share weak homology to 
canonical ATP binding sites, but these were not conserved across different enzymes.9 
The Balh heterocyclases also consists of three units (BalhB, BalhC, BalhD), wherein 
BalhB is the oxidase, BalhC and BalhD is homologous to McbB and McbD, 
respectively. Unlike the McbC oxidase, the BalhB oxidase does not need to associate 
with the BalhC-BalhD proteins for function.11 The oxidase in the cyanobactin RiPPs 
shows even a greater degree of independence in that they may be stand-alone or 
fused to a completely different enzyme.16 This allows the heterocyclase to exist as a 
single enzyme with the N-terminus domain corresponding to McbB/BalhC that carry 
the zinc-binding CxxC double motif and the C-terminus domain corresponding to 
McbD/BalhD.10 Since the N-terminus domain of TruD (McbB/BalhC) shows weak 
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resemblance to adenylating enzymes, it was earlier proposed that this domain was 
responsible for ATP binding. The C-terminus domain of TruD (McbD/BalhD) that 
carried a domain of unknown function, YcaO, was proposed to be responsible for 
regulation or scaffolding. This assignment was essentially reversed when the TOMM 
BalhD carrying the YcaO domain was shown to be solely responsible for direct 
activation of the amide bond carbonyl by phosphorylation, establishing the YcaO as 
the catalytic domain.13,14  
Despite the evidence of direct phosphorylation in TOMM RiPPs, within the 
cyanobactin RiPPs, the release of AMP by TruD, coupled with the fact that the N-
terminal domain of TruD showed homology to known adenylases, led to the proposal 
that TruD is structurally divergent and uses its N-terminal domain (instead of the 
YcaO containing C-terminal domain) to adenylate the heterocyclization reaction 
intermediate. This was proposed in spite of contrary evidence that adenylases that 
shared homology with TruD carried an ATP binding site that was not fully 
conserved in TruD, and mutations in corresponding residues still produced 
functional (or in some cases insoluble) enzyme,15 leaving open questions regarding 
the adenylase mechanism. 
The report of the crystal structure of the YcaO domain from E. coli (called Ec-
YcaO) characterized for the first time the actual ATP binding site, which was fully 
conserved among TOMM YcaO’s and vital for heterocyclization by BalhD.17 The 
ATP-binding motif was also fully conserved in TruD-YcaO and homologs, further 
calling into question the role of N-terminal TruD in adenylation. Finally, a recent 
report of the crystal structure of LynD (a TruD homolog) was shown to have the 
same ATP binding site as the TOMM and Ec-YcaO’s. Furthermore, the placing of 
ATP in the LynD-YcaO active site was found to be similar to the Ec-YcaO. There 
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was shielding of the α-phosphate of ATP from the peptide substrate, whereas the γ-
phosphate of ATP was exposed, implying a kinase mechanism to be more likely for 
the cyanobactin heterocyclase and demonstrating the earlier proposed adenylase 
mechanism to be improbable.18 In accordance with a kinase mechanism, the TOMM 
YcaO’s clearly produces ADP and phosphate (Pi). However, one observation with the 
Ec-YcaO and the cyanobactin LynD/TruD-YcaO still remains a mystery, which is the 
fact that both of these produce AMP and pyrophosphate (PPi) instead of ADP and Pi 
as ATP hydrolysis products. Although the Ec-YcaO releases AMP in absence of any 
substrate, and since its native substrate is unknown, it is not possible to infer what 
the actual ATP hydrolysis products will be. However, the observation that the 
cyanobactin heterocyclase produces AMP in presence of its natural substrate led us 
to probe into the intriguing question, how could an enzyme that shows structural 
resemblance to a kinase release AMP/PPi as the ATP hydrolysis products? 
 
6.2 Results and discussion 
6.2.1 Initial ADP formation was an artifact and AMP is the  
detectable hydrolysis product 
As described, both the microcin B17 synthetase and the TruD heterocyclases 
were previously shown to hydrolyse ATP to ADP during product turnover.9,12 
Recently, on the basis of 31P-NMR analysis of TruD reaction, it was shown that AMP 
was the ATP hydrolysis product instead.15 Since this study did not discuss the 
existence of a discrepancy with preceding data, we set out to reinvestigate the TruD 
reaction. First, we repeated the earlier published experiments using TruE2, the 
native substrate for TruD. We used identical methods to those previously reported, 
wherein TruE2 was incubated with TruD in presence of ATP in reaction buffer and 
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the reaction products analysed with ion-exchange separation by HPLC. Again, only 
ADP was observed, with no trace of observable AMP (Supporting Figure S6.1A), in 
concurrence with the previous study.12  
Since the recently reported AMP release was detected in a reaction that used 
an engineered substrate derived from a different cyanobactin pathway instead of the 
native TruD substrate, we set out to look at ATP hydrolysis products from additional 
substrates. In addition to TruE2, we used TruLy2 that is a chimeric substrate with 
the first core belonging to tru and the second core belonging to lyn sequences and a 
previously described leaderless artificial substrate (here called P1), which carries 
the tru core flanked by recognition sequences only without the leader.19 Analysis of 
the reactions showed presence of primarily ADP for TruLy2 (as with TruE2), 
although AMP was clearly detected in reactions with the substrate P1 (Supporting 
Figure S6.1B).  
The substrates TruE2 and TruLy2 are expressed and purified as His-tag 
constructs from E. coli, whereas P1 is a chemically synthesized peptide. This implied 
that P1 would be free of contamination from E. coli enzymes, which may be present 
in the other substrate preparations. This was found to be the case since a series of 
controls led us to identify adenylate kinase from E. coli in the TruLy2 substrate 
preparation. This is an enzyme that transforms two molecules of ADP into AMP and 
ATP in a reversible reaction, such that any AMP formed during TruD 
heterocyclization reaction would combine with ATP to release ADP, which would be 
the final detected hydrolysis product. Since the precursor peptide substrates are 
small in size (around 10-15 kDa), they are expected to be heat-stable. We therefore 
removed the adenylate kinase contamination by autoclaving the TruLy2 peptide 
solution. The autoclaved TruLy2 was confirmed to be a fully functional substrate 
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that could be completely modified by TruD (Supporting Figure S6.1C). When this 
was used to detect ATP hydrolysis products in presence of TruD, we found AMP to 
be released instead of ADP (Supporting Figure S6.1D). This portrays the well-known 
dangers of using certain E. coli-derived protein preparations for analysis of ATP 
utilizing enzymes. Such impurities are often present in low amounts to evade 
detection, but their high activity is enough to perturb observed data. Since the 
cyanobactin precursor peptides does not require stringent shape requirements and is 
exceptionally heat-stable, we could remove the impurities by unconventionally 
extreme methods such as autoclaving.  
With the chemically synthesized P1 substrate, AMP as the hydrolysis product 
was clearly detectable above background hydrolysis in presence of TruD only, which 
formed baseline levels of both ADP and AMP. Additionally, AMP formation was 
coupled to heterocycle formation, with no additional AMP release after completion of 
TruD reaction (Figure 6.2). However, in light of the recent crystal structure of LynD 
(a TruD homolog), which was proposed to support a kinase mechanism,18 implies 
that ADP should be the actual ATP hydrolysis product. Instead, since AMP is being 
observed in concurrence with the previous TruD study,15 this raises questions 
between experimental data and inferences drawn from the crystal structure, which 
led us to probe into the mechanism further by use of non-hydrolysable ATP analogs. 
 
6.2.2 Both αβ-methylene-ATP and βγ-methylene-ATP inhibits heteroc- 
 yclization, but inhibition by βγ-methylene-ATP is stronger 
The initial study on TruD biochemistry had shown that it was inhibited by 
βγ-methylene-ATP (βγ-ATP), which has a methylene bridge at the βγ-phosphate 















Figure 2 (A) The ATP, ADP and AMP species formed in a reaction with P1 
(100 µM) and TruD (1 µM) in presence of ATP (500 µM) were detected by 
HPLC by absorbance at 260 nm. The identity of each chromatogram peak 
was confirmed by mass and the amount of each species was quantified by the 
integrated chromatogram of the ion count from the mass spectrum of each 
species. Control reactions (labeled as -ve) were run in absence of substrate to 
detect background hydrolysis by TruD alone. (B) The percentage product 
formation in the heterocyclization reaction is shown, calculated from the ion 
chromatogram of substrate P1 and its product, showing that the reaction 
progress is coupled with AMP formation, which stagnates as the reaction 
reaches >95% completion. (C) To ensure that ionization differences in the 
mass spectrum do not interfere with quantification, the amount of AMP 
formed was also calculated based on 260 nm UV absorbance in comparison 
with a 1 mM AMP standard solution. As shown, the AMP formation as 
quantified by MS in (A) could be correlated to absorbance, and is roughly 
stoichiometric with the amount of substrate consumed for heterocyclization. 







Figure 2 (A) The ATP, ADP and AMP species formed in a reaction with P1 
(10  µM) and TruD (1 µM) in presence of ATP (50  µM) were detected by 
HPLC by absorbance at 260 nm. The identity of each chromatogram peak 
was confirmed by mass and the amount of each species was quantified by the 
integrated chromatogram of the ion count from the mass spectrum of each 
species. Control reactions (labeled as -ve) were run in absence of substrate to 
detect background hydrolysis by TruD alone. (B) The percentage product 
formation in the heterocyclization reaction is shown, calculated from the ion 
chromatogram of substrate P1 and its product, showing that the reaction 
progress is coupled with AMP formation, which stagnates as the reaction 
reaches >95% completion. (C) To ensure that ionization differences in the 
mass spectrum do not interfere with quantification, the amount of AMP 
formed was also calculated based on 260 nm UV absorbance in comparison 
with a 1 mM AMP standard solution. As shown, the AMP formation as 
quantified by MS in (A) could be correlated to absorbance, and is roughly 
stoichiometric with the amount of substrate consumed for heterocyclization. 







Figure 6.2 MP is the hydrolysis product of ATP du ing TruD h terocyclization: 
(A) The ATP, ADP and AMP species formed in a reaction with P1 (100 µM) and 
TruD (1 µM) in presence of ATP (500 µM) were de ected by HPLC by abs rb nce at 
260 nm. The id ntity of each chromatogram peak wa  confirmed by mass and the 
amount of each species was quantified by the integrated chromatogram of the ion 
count from the mass spectrum (MS) of each species. Control reactions (labeled as -
ve) were run in absence of substrate to detect background hydrolysis by TruD alone. 
(B) The percentage reaction completion of the heterocyclization reaction is shown, 
calculated from the ion chromatogram of substrate P1 and its product, showing that 
the reaction progress is coupled with AMP formation, which stagnates as the 
reaction reaches >95% completion. (C) To ensure that ionization differences in the 
mass spectrum do not interfere with qua tification, the amount of AMP formed was 
also calculated based o  260 m UV absorbance i  comparison with a 1 mM P 
standard solution. As shown, the AMP formatio  as quantified by MS i  (A) could be 
correlated to absorbance, and is roughly s oichiometric ith the amount of substrate 
consumed for heterocyclization. Each data point is an average of duplicate reactions 
and error bars represent standard deviation. 		
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following study years later that showed AMP release instead and claimed TruD to be 
an adenylase, did not discuss the previous inhibition studies with βγ-ATP, or 
attempt to support adenylation by use of the αβ-methylene-ATP (αβ-ATP) analog, 
which has a methylene bridge at the αβ-phosphate bond of ATP that should inhibit 
adenylases15 (Supporting Figure S6.2). This led us to study the inhibition effects of 
these two non-hydrolysable analogs on TruD activity. 
With both P1 and TruLy2 (autoclaved), TruD was unable to utilize βγ-ATP 
(as previously shown with TruD’s native substrate TruE2). In contrast, αβ-ATP was 
a substrate (Figures 6.3A and Supporting Figure S6.3), although less efficient than 
ATP, in that the reaction could not exceed 30% completion even after a prolonged 
time scale of 4 days. To test the level of inhibition, we carried out a series of 
experiments of TruD-P1 reaction with each analog alone and in presence of ATP. It 
was observed that effect of lower turnover efficiency with αβ-ATP could be restored if 
ATP was present. In contrast, with the βγ-ATP analog, the presence of ATP only 
partially restored this inhibition after 5 hours, although the reaction was completed 
in a longer time period of 1 day (Figure 6.3B). Also, the heterocyclization reaction 
could be made to proceed further with the αβ-ATP analog by increasing the TruD 
enzyme concentration (Supporting Figure S6.4).  
Analysis of some of the controls with the non-hydrolysable analogs showed 
that in some cases, ADP instead of ATP could be hydrolysed for product turnover 
(Supporting Figure S6.5A). We carried out a series of controls, and found that the 
ADP standard alone contained a small peak in the mass spectrum corresponding to 
mass of ATP, which if ATP could drive heterocyclization. Another possible 
explanation is that TruD contained very low levels of adenylate kinase activity, 
which could generate some ATP from ADP and drive the reaction (Supporting 
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Figure S6.5B). This is also explained by the fact that the ADP usage was directly 
proportional to TruD concentration as shown in Supporting Figure S6.4. 
Additionally, the amount of ATP and AMP formed from the adenylate kinase 
activity was not equal, implying that TruD could also hydrolyse ADP to AMP in 
absence of any substrate. The AMP formation from ADP was not coupled to 
heterocyclization in presence of the substrate P1. These observations make it 
unlikely that the detected heterocyclization by TruD with ADP is a result of 
functional ADP hydrolysis. 
! 120!
1 day (Figure 3B). Also, the heterocyclization reaction could be made to 
proceed further with the αβ-ATP analog by increasing the TruD enzyme 















Figure 3 (A) The extent of heterocyclization was followed by the percentage 
of heterocyclic product formed in assays with P1 (50 µM), TruD (1 µM) and 
ATP (1 mM) or the analogs αβ-ATP and βγ-ATP (1 mM each). A control 
reaction was run in absence of ATP that resulted in no heterocyclization, but 
presence of ATP led to complete conversion to product and with αβ-ATP the 
completion was about 25% after 1 day (light grey) that slightly increased 
after a longer time period of 2 days (dark grey). There was no product 
turnover with βγ-ATP. (B) Similar reactions were set up as in (A) with αβ-
ATP and βγ-ATP analogs, but in the presence of ATP in the same reaction 
mixture, which completely restored heterocyclization if present with αβ-ATP 
within 3 hours (light grey). But, if present with βγ-ATP, the inhibition was 
stronger by 3 hours (light grey), which could also be completely restored at a 
longer time point of 1 day (dark grey). The percent reaction completion was 
calculated by the integrated ion chromatograms from the MS of substrate P1 
and heterocyclized product. Each data point is an average of duplicate 





Figure 6.3 Inhibition of heterocyclization by non-hydrolysable ATP analogs: (A) 
The extent of heterocyclization was followed by the percentage reaction completion 
in assays with P1 (50 µM), TruD (1 µM) and ATP (1 mM) or the analogs αβ-ATP and 
βγ-ATP (1 mM each). A control reaction was run in absence of ATP that resulted in 
no heterocyclization, but presence of ATP led to complete conversion to product and 
with αβ-ATP, the completion was about 25% after 1 day (light grey) that slightly 
increased after a longer time period of 2 days (dark grey). There was no product 
turnover with βγ-ATP. (B) Similar reactions were set up as in (A) with αβ-ATP and 
βγ-ATP analogs, but in the presence of ATP in the same reaction mixture, which 
completely restored heterocyclization if present with αβ-ATP within 3 hours (light 
grey). But, if present with βγ-ATP, the inhibition was stronger by 3 hours (light 
grey), which could also be c mpletely restored at a longer time point of 1 day (d rk 
grey). The percentage reaction compl tion was calculated by the i egrated ion 
chromatograms f om the MS of substrate P1 and heterocyclized product. Each data 
point is an average of duplicate reactions and error bars represent standard 
deviation. 		
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We sought for further confirmation of αβ-ATP usage for heterocyclized 
product turnover by searching for the αβ-ADP hydrolysis product by HPLC/ESI-MS. 
Although the αβ-ADP mass was detected in correlation with UV absorbance at 260 
nm in a TruD reaction with αβ-ATP, a standard solution of αβ-ATP was also found to 
contain trace amounts of αβ-ADP (Supporting Figure S6.6). To ensure that TruD 
does not utilize αβ-ADP, a reaction was run with the same for up to 3 days with 
substrate P1, and no heterocyclized product was observed (data not shown).  
Another potential route could be that TruD utilizes ATP in a complex two-
step process as seen in apyrases, also known as ATP diphosphohydrolases.20 It first 
hydrolyses ATP to ADP, which is then hydrolysed further to AMP, resulting in two 
Pi overall. In both the steps, TruD would attack the γ-phosphate. This could explain 
all the above observations of the possible use of ADP, the partial use of αβ-ATP and 
the observed AMP release. The hydrolysis of αβ-ATP would yield αβ-ADP, which 
cannot be utilized in the second step to produce AMP. This was tested by adding 
ADP to the αβ-ATP reaction with TruD, in which case, the ADP would help replace 
the use of the non-functional αβ-ADP product. This was found to not be the case 
since addition of ADP (up to 10 mM) failed to increase the product from the αβ-ATP 
reaction (Supporting Figure S6.7). Additionally, the earlier study on TruD structure 
had reported PPi release from heterocyclization, which would make this route 
unlikely. Coupled with the biochemical data presented here, this ruled out a complex 
kinase mechanism of TruD involving a two-step ATP hydrolysis.  
The complete inhibition of TruD by βγ-ATP analog supports the TruD enzyme 
to be a kinase similar to the other RiPP heterocyclases,9,14 and as inferred from the 
crystal structure of its homolog LynD.18 This is also supported by use of the αβ-ATP 
analog, which can drive heterocyclization, implying breakage at the βγ-phosphate 
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linkage attacked by classical kinases. The puzzle still remained that TruD 
hydrolysed ATP to AMP and not ADP. Hydrolysis to AMP is not supported by ability 
to use the αβ-ATP analog, which blocks hydrolysis at the αβ-phosphate linkage of 
ATP. Thus, use of the non-hydrolysable analogs still gave no conclusive answers to 
the mystery of TruD’s mechanism and led us to probe further by use of isotopic 
labeling of the P1 substrate. 
 
6.2.3 Isotopic labeling of P1 to determine identity of leaving  
group from reaction intermediate 
The peptide P1 was isotopically labeled at the carbonyl preceding the 
heterocyclizable cysteine by a method slightly modified from a previously described 
protocol (18O-P1) (Supporting Figure S6.8).14 First, we used 31P-NMR to help detect 
the fate of the 18O-label. The results were inconclusive, calling into the requirement 
of the need for more 18O-labeled material. We then resorted to using mass 
spectrometric-based methods. An 18O-labeled species would result in a mass increase 
of +2 Da. Since the Pi/PPi species are small, we first tried a gas-chromatographic 
mass spectrometry approach, but failed to detect any labeled species despite several 
attempts. We reasoned this could be due to the extreme tri-methylsilyl 
derivatization protocol of samples that involves prolonged heating prior to gas 
chromatography. 
We then developed a liquid-chromatographic mass spectrometry approach 
(HPLC/ESI-MS) to analyze ADP and AMP. As described in methods, ammonium 
acetate coupled with acetonitrile mobile phase was used on a reverse-phase column 
that clearly resolved ATP, ADP and AMP, which could be used to follow reaction 
progress. Using this method, no label was detected on either the AMP or ADP 
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species in a reaction with 18O-P1/TruD. A control reaction was carried out with 
unlabeled P1, and the absence of 18O-AMP in reactions with 18O-P1 conclusively 
rules out a direct adenyl transfer at the carbonyl preceding the heterocyclizable 
residue by TruD with biochemical evidence (Figure 6.4). 
Apart from adenylation of the amide carbonyl directly involved in 
heterocyclization, other mechanistic possibilities of ATP usage could be adenylation 
of a carbonyl elsewhere in the peptide backbone, as seen in microcin C7 biosynthesis, 
wherein the adenylated intermediate is a precursor to N-P bond formation.21 In the 
case of TruD, such a route would require water to act as a nucleophile to release the 
activated phosphate containing species. This was tested by performing a TruD 
reaction with unlabeled P1 in presence of labeled H218O, which would add an 18O 
label to the peptide, but there was no evidence of such a route since a resultant +2 
Da mass increase was not observed in the heterocyclized product (Supporting Figure 
S6.9).  
The failure to detect a labeling source could arise also from a possibility of an 
alternative mechanistic route, such as the molecular machine mechanism or the less 
common pyrophosphoryl transfer mechanism. In the molecular machine route, water 
is the leaving group from the heterocyclization reaction intermediate, and ATP 
hydrolysis only serves as a mechanical driving force for the enzyme, as observed in 
ATP-dependent chaperones.22 This mechanistic route has been ruled out in the 
TOMM heterocyclases and since the same ATP binding motif is conserved in the 
cyanobactin heterocyclase, it is unlikely to be a possibility. Absence of 18O-AMP at 
the reaction intermediate and the rarity of pyrophosphoryl transfers led us to 
explore this possibility yet again.  
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To test this, we employed variants of substrate P1. The first was P1.1, which 
is a truncated version of P1 with the tru core without the TruD recognition sequence. 
This was expected to be a fully functional substrate for TruD, since unlike other 
heterocyclases, a unique feature of natural cyanobactin heterocyclases is that they 
can process leaderless core sequences.15,19,23 The second was P1.2, which is the same 
as P1.124 except the tru core cysteine was replaced with a proline instead such that 
it would not be a substrate for TruD. The formation of AMP was indeed tightly 
coupled to presence of a functional heterocyclizable substrate, wherein AMP 
Figure 6.4 The AMP formed from reactions with TruD (1 µM), P1 or 18O-P1 (100 
µM) and ATP (500 µM) was detected by HPLC-ESI/MS. A comparison with a 1 mM 
standard solution of AMP was carried out to confirm both mass and elution time 
based on UV absorbance at 260 nm. With the labeled 18O-P1, there was no +2 Da 
mass shift in AMP mass (red arrow). A control reaction was run with unlabeled P1. 			
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formation was more with P1 and comparatively lower with P1.1, since P1.1 is a 
poorer substrate than P1 due to absence of TruD recognition sequence motif of 
LAELSEEAL. With the substrate P1.2 that carried no heterocyclizable residue, 
there was negligible AMP formation. These results combined implied a molecular 
machine route to be unlikely (Supporting Figure S6.10). Further support disfavoring 
this route is provided by the observations earlier presented that AMP is used in 
roughly stoichiometric amounts coupled to heterocycle formation and hydrolysis to 
AMP did not continue after thiazoline formation (Figure 6.2). 
With the above possibilities ruled out, the remaining alternative could be 
pyrophosphorylation of the reaction intermediate since AMP is the hydrolysis 
product, although pyrophosphoryl transfers are known to be rare with only a few 
examples known.25 In support of this route, we had serendipitously observed that 
PPi inhibits TruD, whereas Pi does not (Supporting Figure S6.11). To test this 
mechanistic route, it is necessary to search for 18O-PPi in a heterocyclization reaction 
with 18O-P1. A number of failed attempts to detect PPI by 31P-NMR and GCMS led us 
to use a directed infusion ESI-MS approach.26 A similar approach was used in the 
LynD crystal structure studies, and an 18O label was detected not only in PPi but 
also in Pi,18 allowing no definitive conclusions to be drawn. In our hands, the +2 Da 
mass increase of PPi and Pi was observed in pure standards of both species when 
present in the TruD reaction mixture, under various capillary and cone voltage 
parameters for direct infusion. This background meant that any 18O-labeled PPi/Pi 
data derived from a labeled 18O-P1 reaction with TruD might be unreliable in the 
setup we used. Since an HPLC-ESI/MS detection of AMP, ADP and ATP was by far 
the most definitive method to probe into the identity of the reaction intermediates, 
we coupled the TruD heterocyclization reaction with an enzyme that would use PPi 
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to make products that would be clearly detected by LCMS. Any +2 Da label in this 
new product would identify the source of the 18O-label to arise from PPi. 
For detection of labeled PPi, we coupled the TruD reaction ATP sulfurylase 
(ATPS),27 which uses PPi to convert adenosine 5’-phosphosulfate (APS) to ATP. This 
means that if the PPi were labeled with 18O, it would result in 18O-labeled ATP 
(Supporting Figure S6.12A). Although this reaction is reversible leading to 
breakdown of the ATP again, it is to be noted that equilibrium favors ATP formation 
by a factor of 108.25 We ran control ATPS reactions in presence of reaction mixture 
conditions to ensure that the equilibrium to ATP formation is maintained and in 
presence of TruD enzyme only to ensure absence of pyrophosphatase contamination 
that would degrade any PPi.  
Indeed, a +2 Da increase in mass label was detected in the ATP mass peak 
when 18O-P1 was used in a reaction with TruD, in comparison to reactions with P1. 
The peak height of the labeled isotope was found to be directly proportional to 
labeled peptide 18O-P1 concentrations. Control reactions were run firstly in absence 
of the ATPS enzyme, which would disable the formation of 18O-ATP. Secondly, the 
TruD reaction was subjected to a pyrophosphatase (PPase) before addition of the 
ATPS enzyme. This would breakdown any 18O-PPi, disabling the formation of the 
18O-ATP species (Figure 6.5). In both cases, there was no labeled 18O-ATP detected in 
comparison to a complete reaction with the 18O-P1 substrate coupled with ATPS
(Supporting Figure S6.12B-D). The detection of the +2 Da label is represented as a 
function of the ratio of the peak heights of the labeled isotope peak corresponding to 
507.8 Da [M+H]+ with the preceding peak of 506.8 Da arising from unlabeled ATP
mass of 505.8 Da [M+H]+, demonstrating that the labeling was observed only in 










Figure 6.5 The isotopic labeling on ATP (18O-ATP) is indicated as a function of the 
ratio of the peak heights of the 18O-ATP labeled peak at [M+H]+ 507.8 Da and the 
preceding peak at 506.8 Da arising from unlabeled ATP. A series of reactions were 
run in different conditions as given. The black bars on the left are from control 
reactions of ATP standard only, a positive control reaction with ATPS and APS in 
presence of added PPi leading to ATP formation, and a negative control reaction of 
APS and added PPi without ATPS, resulting in no ATP formation. The light grey 
bars in the center are from reactions with P1 without TruD, with TruD and with 
reactions treated with PPase. Similarly, the dark grey bars on the right are from 
reactions with 18O-P1 in absence of TruD, with TruD, with TruD and higher 
concentration of 18O-P1 (200 µM) and reactions treated with PPase. Reactions with 
P1 or 18O-P1 do not contain added PPi and the TruD reaction is the source of PPi. As 
shown; only reactions with intact PPi arising from labeled 18O-P1 show the +2 Da 
mass shift as calculated from increased peak height of [M+H]+ 507.8 Da. This peak 
height is increased further with higher substrate concentration, and disappears if 
the reaction is treated with PPase. All reactions were run with substrate (100 µM), 
TruD (1 µM) and ATP (500 µM) in reaction buffer for 2 hours. This was then treated 
with ATPS (1 µM) and APS (5 mM) for 20 minutes. If mentioned, PPase (1 µM) 
treatment for 20 minutes was done before ATPS addition. Additional data with the 
mass spectrum of each reaction are given in Supporting Figure S6.12. 
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indicating a unique mechanistic route for TruD involving a pyrophosphoryl transfer 
that would result in a pyrophosphorylated reaction intermediate. 
Pyrophosphoryl transfer indicates that the reaction intermediate nucleophile 
attacks the β-phosphate of ATP. This is in contrast to kinases that attack the γ-
phosphate and adenylases that attack the α-phosphate of ATP (Figure 6.6). The 
release of AMP as the ATP hydrolysis product and detection of PPi as the leaving 
group involved in heterocyclization confirms a pyrophosphoryl transfer mechanism. 
It also explains the inhibitory effects of the non-hydrolysable αβ-ATP and βγ-ATP 
analogs, since both involve a methylene at the β-phosphate, which might hinder 
attack at the position. The fact that TruD can process αβ-ATP with low product 
turnover implies that with this ATP analog, TruD can attack the γ-phosphate 
instead and Pi  (or the ADP moiety) is the leaving group from the reaction 
intermediate. A reaction with labeled 18O-P1 with αβ-ATP did not lead to labeling on 
the αβ-ADP hydrolysis product (Supporting Figure S6.13), indicating the 
involvement of Pi as the reaction intermediate with this particular ATP analog. 
 
6.3 Conclusions 
Although pyrophosphate linkages are widespread in biology, there are only a 
few pyrophosphoryl transfers known to date. The first type of transfer reactions is 
involved in the synthesis of pyrophosphate containing molecules, as in thiamine 
pyrophosphate synthetase, which catalyses the attack of a substrate hydroxyl to β-
phosphate of ATP that adds on the pyrophosphate group to thiamine. In the second 
type of transfer reactions, as seen in pyruvate dikinase, the pyrophosphate does not 
end up in the final product; instead, the reaction involves a pyrophosphorylated 












enzyme intermediate that transfers this phosphate to pyruvate.25 Unlike both of the 
above routes, TruD catalyzes the formation of a pyrophosphorylated reaction 
intermediate that acts as a precursor to the final reaction product, in this case a 
thiazoline that is formed as an effect of the pyrophosphate leaving group, making 
TruD a unique pyrophosphoryl transferase enzyme. 
The rarity of pyrophosphoryl transfers is due to the fact that the alternatives 
of adenylation or phosphorylation are more favored in biology. A question that arises 
is what is the evolutionary significance for cyanobactin heterocyclases such as TruD 
(and LynD) to function as a pyrophosphoryl transfer enzyme in contrast to other 
RiPP heterocyclases that behave as phosphoryl transferases (or in other words, 
Figure 6.6 A summary of the possible nucleophilic attack sites on an ATP molecule 
is shown. The nucleophile is the reaction intermediate carbonyl oxygen that 
precedes the Cys residue undergoing heterocyclization. Classical kinases and 
adenylases attack at the γ-phosphate and α-phosphate of ATP, respectively, whereas 
the data presented here support the hypothesis that TruD attacks at the β-
phosphate of ATP, which would classify TruD as a pyrophosphoryl transferase 
enzyme. 			
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kinases). One reason could be that the substrate tolerance of TruD is much more 
relaxed than the other characterized RiPP heterocyclases. For example, TruD can 
accept a much greater diversity of sequences with little or no restrictions regarding 
the position of the heterocyclization in the core sequence.23 On the other hand, the 
Balh and Mcb synthetases have more constrained sequence limitations within the 
core with regard to regioselectivity.9,11 
In the crystal structure of the Ec-YcaO, the α-phosphate of ATP was shielded 
and the γ-phosphate exposed to attack, which supported the proposed kinase route 
for other RiPP heterocyclases. Additionally, the authors stated that surprisingly, 
two Mg2+ ions were found in the nucleotide-binding pocket coordinating opposite 
sides of the β- and γ-phosphates.17 The subsequent LynD crystal structure had the 
same features as the previously published Ec-YcaO structure, in that ATP was 
bound in an identical homologous location with the α-phosphate shielded, the β-
phosphate coordinated by two Mg2+ ions and the γ-phosphates exposed. The 
shielding of α-phosphate and functional analysis of enzyme constructs of mutations 
of key residues ruled out the first proposed adenylase mechanism for TruD. 
Hydrolysis to AMP and PPi was still observed with LynD (as with TruD) and no 
biochemical evidence was provided to support the scenario of adenylation. 
Additionally, isotopic labeling studies that involved direct detection of PPi/Pi species 
by direct infusion mass spectrometry detected 18O labeling in both PPi and Pi, 
leading to inconclusive interpretations. Based on the exposed γ-phosphate in the 
crystal structure and the release of AMP, a complex kinase mechanism was 
proposed instead, in contrast to the earlier proposed adenylase mechanism.18 
To probe into both the earlier proposed contradictory hypotheses, we 
reinvestigated the reaction mechanism of TruD with the use of non-hydrolysable 
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ATP analogs and isotopic labeling. We probed into different possible mechanistic 
routes using a combination of methods. Here, we report biochemical evidence 
against adenylation, and with the use of a coupled enzymatic route, we detected 18O-
labeling on the PPi species. Any efforts to detect 18O-labeling on the Pi species might 
be unreliable in contrast, since the TruD enzyme preparation alone has ATPase 
activity, and additionally, any released PPi from the heterocyclization reaction can 
break down to Pi, transferring the label to the Pi species. Therefore, we sought to add 
confirmation to the labeling on the PPi species by use of pyrophosphatase, which was 
found to eliminate the detection of the 18O-label as expected. Put together, these 
results support a pyrophosphoryl transfer mechanism for TruD. This implies attack 
at the β-phosphate of ATP, which is supported by inhibition of the non-hydrolysable 
ATP analogs, both of which carry a methylene bridge around the β-phosphate. The 
use of the αβ-ATP analog for low product turnover also implies that in certain 
instances when the β-phosphate is less prone to nucleophilic attack, the TruD 
mechanism can proceed via a phosphorylated reaction intermediate at very low 
efficiency. We speculate that the Mg2+ ion coordination at the β-phosphate reported 
in the crystal structures of related enzymes could have a role to play in the proposed 
pyrophosphoryl transfer mechanism of TruD. 
 
6.4 Materials and methods 
6.4.1 Protein synthesis 
TruD was synthesized as described previously.12 This involved expression as 
histidine tagged construct in pET28(b) and purification by nickel affinity and size 
exclusion chromatography. The peptides P1 and P1.2 were synthesized at the 
University of Utah peptide core facility. The peptide P1.1 was obtained by 
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proteolytic cleavage of P1 carried out by the cyanobactin protease PatA as described 
previously,24 followed with purification by reverse phase liquid chromatography. 
 
6.4.2 Heterocyclization reaction conditions 
Reactions were carried out with TruD (1 µM), substrates (50-100 µM) or as 
specified in optimized reaction mixtures containing Tris pH 7.5 (50 mM), 
dithiothreitol DTT (7.5 mM) and MgCl2 (5 mM) along with 1 mM ATP in a final 
reaction volume of 50-100 µL. For reactions involving quantification of ATP 
hydrolysis products, the concentration was lowered to 500 µM. Reactions were 
incubated at varying time-points at 37°C in a MJ Research Minicycler. Typically, 
reactions with ATP (500 µM) were complete by 2 hours. All ATP analogs of αβ-ATP, 
βγ-ATP, ADP or AMP (1 mM) if used, were incubated for longer time period starting 
from 3 hours to up to 4 days as specified. ATP and analogs were obtained from 
Sigma Aldrich. If necessary, reactions were quenched by boiling for 10 minutes, 
centrifuged and the supernatant subjected to analysis. In all cases, controls were 
run to ensure boiling did not alter observed profiles. 
 
6.4.3 Isotopic labeling protocol for substrate P1 
Isotopic labeling of P1 was carried by a protocol adapted from a previously 
described method.14 The substrate P1 was first heterocyclized by TruD in reaction 
conditions as described above. The product was subsequently purified by reverse 
phase HPLC and fractions with absorbance maxima with 255 nm shoulders 
(corresponding to thiazoline) were collected and lyophilized to remove water. The 
dried peptide was then redissolved in 97% H2O18 (Cambridge Isotope Labs) in an 
acidic solution of 0.5% formic acid and left overnight at room temperature. The ring-
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opened peptide was recovered by further lyophilization. Confirmation of O18-labeling 
was provided by mass spectrometry. The labeled peptide was quantified by 
absorbance at 280 nm, since it carries a tyrosine residue. 
 
6.4.4 Reaction conditions for coupled assay leading to ATP formation 
The enzyme ATP sulfurylase (ATPS) was obtained from New England 
BioLabs and APS from Sigma Aldrich. To heterocyclization reaction mixtures as 
described above, ATPS (1 µM) was added along with APS (400 µM) and incubated at 
37°C for 20 minutes. If specified, E. coli inorganic pyrophosphatase that was 
obtained from New England BioLabs was added to reaction mixtures (1 µM) for an 
additional 20 minutes before addition of ATPS and APS to degrade any PPi. All 
coupled reactions were analysed the same way as TruD reactions. 
 
6.4.5 Product characterization by ion-exchange chromatography 
As described previously,11 certain reactions were analysed by ion-exchange 
chromatography using a Vydac 302IC4.6 column in a Hitachi LaChrom Elite HPLC 
system. A linear gradient of 100% buffer A (45 mM formic acid adjusted to pH 4.5 
using with NaOH) to 100% buffer B (500 mM NaH2PO4 adjusted to pH 2.5 with 
formic acid) was run over 12 minutes using a flow-rate of 2 mL min-1 and 10 µL 
injection volume. A saturated solution of 1 M urea was added to each reaction, and 
the supernatants were analysed by HPLC. Controls were run to ensure that addition 
of urea did not alter elution profiles of ATP, ADP and AMP. Pure standards of ATP, 
ADP and AMP were run in optimized reaction mix to determine elution time of each. 
Estimation of ADP and/or AMP formed was done by manually integrating area of 
peaks corresponding to each nucleoside and plotted versus time.  
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6.4.6 ATP hydrolysis product characterization by reverse phase HPLC/ESI-MS 
Reactions were analysed by reverse phase chromatography using a Luna 5 
µm C18 column (Phenomenex) with 150 ✕ 4.6 mm specification. A linear gradient 
from 97% A (20 mM NH4OAc pH 4.5) to 95% B (acetonitrile) was run over 15 
minutes using a flow-rate of 1 mL min-1. Standard solutions of ATP and analogs 
were run to determine elution time and confirmation was provided by mass 
spectrometry connected to a Micromass Q-TOF Micro Mass Spectrometer (Waters) 
in negative ion mode. The amounts of ATP hydrolysis products were quantified 
based on the integrated chromatogram peak obtained at 260 nm absorbance, or the 
integrated ion counts from the chromatograms obtained from the mass spectrum. 
 
6.4.7 Peptide product characterization by HPLC/ESI-MS 
Peptide product characterization was performed on a Micromass Q-TOF 
Micro Mass Spectrometer (Waters) in positive ion mode, on an analytical Agilent 
Eclipse XDB-C4 column (4.6 × 150 mm, 5 µm) with a linear gradient of 1%-99% B 
over 20 minutes, where the mobile phase comprised solvent A (Optima LC-MS grade 
water with 0.05% formic acid) and solvent B was Optima LC-MS grade acetonitrile.  
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Supporting Figure S6.1 AMP, and not ADP, is released during TruD 
heterocyclization: (A) Reaction of TruD (1 µM) with native substrate TruE2 (20 µM) 
in presence of ATP (1 mM) was followed at different time-points by ion-exchange 
HPLC, showing the formation of ADP. (B) Reaction of TruD (1 µM) with P1 (20 µM) 
showed AMP (red arrow) formation. (C) TruLy2 was found to carry adenylate kinase 
activity, which could be removed by autoclaving (left). The autoclaved substrate was 
found to be fully functional and could be heterocyclized (TruLy2*). The mass 
spectrum is shown, with fully intact TruLy2 present, TruLy2 with loss of first 
methionine and a carbamylated adduct with urea. (D) Reactions of autoclaved (left) 
and non-autoclaved (right) TruLy2 (20-40 µM) with TruD (1 µM) in presence of ATP 
(1 mM) showing formation of AMP for the former and ADP for the latter. 
Background reactions were carried out in absence of substrate or as specified. The 
identity of ATP, ADP or AMP species was determined by comparing with pure 
standards (dotted lines).  Red arrows show the detected ATP hydrolysis product 
above background. The SDS-PAGE gel on the bottom right shows conversion of 



















































































Supporting Figure S6.2 The structure of ATP is shown and possible nucleophilic 
attack routes at the α, β and γ-phosphates of ATP indicated. An attack at the αβ-
linkage will yield AMP and PPi, which would correspond to an adenylase or 
pyrophosphoryl transferase mechanism. Alternatively, an attack at the βγ-linkage 
will yield ADP and Pi, which would correspond to a kinase mechanism for TruD. The 
analogs αβ-ATP and βγ-ATP blocks hydrolysis at the corresponding phosphate 


















































Supporting Figure S6.3 Inhibition of heterocyclization by non-hydrolysable ATP 
analogs: (A) The MS of reactions of P1 (50 µM), TruD (1 µM) and ATP analogs (1 
mM) is shown. There was heterocyclization with the αβ-ATP analog (blue box). The 
mass of P1 is 1273.1 Da ([M+2H]2+) and its TruD product (indicated by *) is 1264.1 
Da ([M+2H]2+). A negative control reaction was run in the absence of TruD. (B) The 
autoclaved TruLy2 (30 µM) was partially heterocyclized by TruD (1 µM) as shown in 
the deconvoluted MS by loss of 18 Da in the three forms of TruLy2 (see Supporting 
Figure S6.1) as indicated by arrows. MS/MS fragmentation analysis localized the 18 
Da losses to Cys of the first core of TruLy2. The sequence of the full substrate 
(bottom) is given with the core sequence in blue, heterocyclizable residues in red and 
the site of heterocyclization indicated by *. The reaction was also followed by SDS-



























Supporting Figure S6.4 The percentage of heterocyclization of P1 (25 µM) with 
increasing concentrations of TruD (1x= 0.5 µM; 2x= 1 µM; 3x= 1.5 µM) in presence of 
ATP and analogs is given. Reactions with the αβ-ATP analog are boxed in blue, 
showing increased product formation with increasing enzyme. The percentage was 
calculated based on integrated ion counts of P1 and its heterocyclized product from 
the mass spectrum. Each data point is an average of duplicate reactions and error 













































Supporting Figure 4 he percentage of heterocyclization of P1 (25 µM) 
with increasing concentrations of TruD (1x= 0.5 µM; 2x= 1 µM; 3x= 1.5 µM) 
in prese e of ATP and analogs is give . Reactions with t  αβ-ATP analog 
re boxed in blue, showing increased product formation with increasing 
enzyme. The percentage was calculated based on integrated ion counts of P1 
and its heterocyclized product from the mass spectrum. Each data point is an 






































Supporting Figure S6.5 TruD enzyme preparation is capable of hydrolyzing 
ADP: (A) The percentage of heterocyclization of P1 (50 µM), TruD (1 µM) and ATP, 
ADP or AMP (1 mM) is shown, indicating that ADP alone could result in product 
formation. The percentage was calculated based on integrated ion counts of P1 and 
its heterocyclized product from the mass spectrum. Each data point is an average of 
duplicate reactions and error bars represent standard deviation. (B) Ion-exchange 
HPLC of control reactions with P1/TruD, TruD only and P1 only in presence of ADP 
indicated minor adenylate kinase contamination in TruD since there was formation 
of ATP and AMP (shown by arrows). The TruD enzyme preparation also showed 
ADPase activity in that a greater amount of AMP was formed. The identity of ATP, 
ADP or AMP species was determined by comparing with the elution time of 
standards. Shown on the right are controls where the 260 nm UV absorbance 
chromatograms of different combinations of TruD is given, wherein the mass 
corresponding to each absorbance peak was confirmed to belong to ATP, ADP or 
AMP by comparison with standards, showing that TruD alone carried neither of 
these species, TruD had low ATPase activity and there was no degradation of AMP 












Supporting Figure 5 (A) The percentage of heterocyclization of P1 (50 
µM), TruD (1 µM) and ATP, ADP or AMP (1 mM) is shown, indicating that 
ATP alone could result in product formation. The percentage was calculated 
based on integrated ion counts of P1 and its heterocyclized product from the 
mass spectrum. Each data point is an average of duplicate reactions and 
error bars represent standard deviation. (B) Ion-exchange HPLC of control 
reactions wit  P1/TruD, TruD only and P1 only in presence of ADP indicated 
minor ade yl e kin s  contamination in TruD since there was ormation of 
ATP and AMP (shown by arrows). The TruD enzyme preparation also showed 
ADPase activity in that a greater amount of AMP was formed. The identity of 
ATP, ADP or AMP species was determined by comparing with the elution 
time of standards. Shown on the right are controls where the 260 nm UV 
absorbance chromatograms of different combinations of TruD is given, 
wherein the mass corresponding to each absorbance peak was confirmed to 
belong to ATP, ADP or AMP by comparison with standards, showing that 
TruD alone carried neither of these species, TruD had low ATPase activity 























Supporting Figure S6.6 The chromatogram from 260 nm UV absorbance showed 
that a standard solution of αβ-ATP carried a trace amount of αβ-ADP, which was 
confirmed by running a αβ-ADP standard in tandem, and by the mass spectrum. A 
reaction of P1, TruD and αβ-ADP led to no product formation (data not shown), 
indicating that this contamination in the αβ-ATP solution was not the source of the 















Supporting Figure S6.7 A potential route of TruD mechanism could be use of 
ATP in two subsequent steps, wherein ATP is hydrolysed first to ADP that is 
hydrolysed again to AMP. This would explain low product turnover with αβ-ATP 
since the αβ-ADP cannot be hydrolysed further (left). This route was ruled out by 
following P1 (50 µM) and TruD (1µM) reactions with ADP (1-10 mM) added 3 hours 
after αβ-ATP reaction, which led to no signifucant product increase (blue box). 
Control reactions were run with ATP, αβ-ATP and ADP (1 mM each). The total 
reaction time was 18 hours. The percentage was calculated based on integrated ion 
counts of P1 and its heterocyclized product from the mass spectrum. Each data point 

















Su porting Figure 6 chromatogram from 260 nm UV a sorbance 
showed that a standard solution of αβ-ATP ca ri d a trace amount of αβ-ADP, 
which was confirmed by running a αβ-ADP standard in tande , and by the 
mass spectrum. A reaction of P1, TruD an  αβ-ADP led to no product 
formation (data not shown), indicating that this contamination in the αβ-ATP 
solution was not the source of the heterocyclization product turnover with the 
αβ-ATP analog. 
 
Su porting Figure 7 A potential route of TruD mechanism could be use of 
ATP in t o t ATP is hydrolysed first o ADP that is
hydrolysed again to AMP. This would explain low product turnover with αβ-
ATP since the αβ-ADP cannot be hydrolysed further (left). This ro te was 
ruled out by following P1 (50 µM) and TruD (1µM) reactions with ADP (1-10 
mM) added 3 hours after αβ-ATP reaction, which led to no signifucant 
product increase (blue box). Control reactions were run with ATP, αβ-ATP 
and ADP (1 mM eac ). The total reaction time was 18 hours. The percentage 
of product formed was calculated based on integrated ion counts of P1 and its 
heterocyclized product from the mass spectrum. Each data point is an 





























Supporting Figure S6.8 Protocol for peptide labeling with 18O: (A) The method 
followed to add 18O label to P1 is shown with a stretch of sequence, with the atoms 
involved in heterocyclization in red. The TruD product is ring opened under acidic 
conditions with H2O18 to label the peptide (see methods for details). (B) The MS 
chromatograms of 18O-P1 in comparison with a P1 standard showed an increase 




















Supporting Figure S6.9 A reaction of TruD (1 µM) with P1 (100 µM) in H2O18 led 
to no labeling on the heterocyclized peptide product ([M+2H]2+ = 1263.5 Da) when 
compared to a reaction carried out in H2O, as detected from the MS (right). This 
indicated that there was no direct activation of a carbonyl by ATP away from the 



















Supporting Figure S6.10 The amount of AMP formed from reactions of TruD (1 
µM) and ATP (1 mM) with each substrate P1, P1.1 or P1.2 (100 µM) is shown. The 
percentage reaction completion was calculated from the integrated ion 
chromatograms of the substrates and products. AMP formation is coupled to the 
level of successful heterocyclization. Each data point is an average of duplicate 
reactions and error bars represent standard deviation. The sequence of each 


































Supporting Figure S6.11 A heterocyclization reaction with 18O-P1 would yield 
18O-PPi if there were nucleophilic attack at the β-phosphate of ATP (top). In a 
reaction time of 20 minutes, during the initial phase of heterocyclization, a control 
reaction of P1 (100 µM), TruD (1 µM) and ATP reached about 40% completion. 
Within the same time frame, similar reactions with externally added pyrophosphate 
or phosphate salt solutions (1 mM) showed significant inhibition or no effect, 
respectively. The percentage reaction completion was calculated from the integrated 
ion chromatograms of the substrates and products. Each data point is an average of 







































Supporting Fig re 11 A heterocyclization reaction with 18O-P1 would 
y eld 18O-PPi if there were nucleophilic attack at the β-phosphate of ATP 
(top). In a reaction ti e of 20 minutes during th  initial ph s of 
heterocycliza ion when a control reaction with P1 (100 µM), TruD (1 µM) and 
ATP reached about 40% completion, we found that within the same time 
frame, similar reactions with externally added pyrophosphate (1 mM) showed 
significant inhibition, whereas with externally added phosphate (1 mM) there 
was no effect. The percentage of product formation was calculated from the 
integrated ion chromatograms of the substrates and products. Each data 















Supporting Figure S6.12 Detection of pyrophosphate release by the coupled 
ATPS assay: (A) ATP sulfurylase (ATPS) reaction is shown that converts APS and 
PPi to ATP. If the released PPi were isotopically labeled, it would lead to isotopic 
labeling on ATP. (B) The mass spectrum of ATP is shown in all cases. 18O-ATP 
species has a mass of 507 Da ([M+H]+) in comparison to pure ATP that has a mass of 
505 Da ([M+H]+). Positive control reactions with ATPS (1 µM), APS (400 µM) and 
externally added PPi salt (400 µM), and the same reaction in presence of TruD (1 
µM) led to formation of detectable ATP. A negative control reaction in absence of 
ATPS (left) had background level of the ATP mass. If the ion count was less than 
100, the amount of ATP formed was regarded as none, which was further confirmed 
by absence of UV absorbance at 260 nm. In comparison, ion counts of ATP standard 
(500 µM) was greater than 1000. (C) Reactions with TruD (1 µM), ATP (500 µM) and 
in which the source of PPi was from heterocyclization with (i) P1 (100 µM), (ii) 18O-
P1 (100 µM) and (iii) 18O-P1 (200 µM). In reactions with 18O-P1 only, the +2 Da mass 
shift in ATP was observed, which was increased with higher substrate concentration 
(red arrows). Control reactions with 18O-P1, TruD and ATP were run in absence of 
ATPS (iv) and when ATPS was added after pyrophosphatase (PPase) treatment (v). 
In both cases, the increased peak height of 507 Da had disappeared. TruD reactions 
were carried out for 2 hours, ATPS for 20 minutes and PPase if used was also for 20 
minutes before addition of ATPS. (D) The LC chromatograms of the same reactions 
is shown wherein the elution time of ATP was considered as 3.5-4.5 minutes based 


































































Supporting Figure S6.13 Reactions with TruD (1 µM), P1 or 18O-P1 (100 µM) 
and αβ-ATP for 18 hours are shown, wherein the mass spectrum of the αβ-ADP 
hydrolysis product is given at the bottom ([M+H]+ = 423.9 Da in negative ion mode) 
in comparison with a standard. In both cases, no 18O on αβ-ADP was observed, 
implying that the label ends up in the Pi species, indicating that with this particular 
analog, TruD attacks at the γ-phosphate with the involvement of a phosphorylated 
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Combinatorial biosynthesis of RiPPs: docking
with marine life
Debosmita Sardar and Eric W Schmidt
Ribosomally synthesized natural products are found in all
forms of life. Their biosynthesis uses simple ribosomally
synthesized peptides as starting materials that are
transformed into complex structures via posttranslational
modifications, enriched with elaborate chemical scaffolds that
make them desirable as pharmacological tools. In addition,
these natural products often exhibit combinatorial
biosynthesis, making them attractive targets for engineering.
An increasing knowledge of their biosynthetic machinery has
provided key insights into their fascinating chemistry. Marine
organisms have been a rich source of this class of natural
products and here we review the lessons learned from marine
life that enables exploitation of their potential for combinatorial
engineering, opening up new routes for peptide-based drug
discovery.
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Introduction
The combinatorial nature of secondary metabolites, and
their potential for combinatorial biosynthesis has long
been recognized [1,2]. In nature, dedicated pathways
carry the enzymatic machinery responsible for the bio-
synthesis of natural products. The question arises wheth-
er such biosynthetic pathways exhibit modularity,
wherein each module can be used multiple times in
different combinations with other modules, to enable
combinatorial chemistry. If so, what are the degrees of
freedom in their chemistry that can be exploited?
These questions have recently been addressed with the
ribosomally synthesized and posttranslationally modified
peptide (RiPP) class of natural products. RiPPs begin as
precursor peptides that usually contain leader (or some-
times follower) and core peptide sequences. The leader
peptide is cleaved off in the course of biosynthesis while
the core directly encodes the natural products (Figure 1).
Depending upon the RiPP, the leader and other non-core
elements encode diverse functions, such as signal
sequences dictating localization, enzyme recognition ele-
ments, and others [3]. Diverse posttranslational modifica-
tions (PTMs) decorate the core peptides to produce an
astounding array of natural products [4], which are often
bioactive and amenable to peptidomimetics in vivo and in
vitro [5–13].
The marine environment has played an important role in
RiPP engineering. Marine-derived RiPPs provided the
first examples of four important concepts that make RiPP
combinatorial chemistry a possibility: firstly, core peptide
hypervariability; secondly, natural broad-substrate path-
ways; thirdly, enzyme recognition sequences; and fourth-
ly, modularity of posttranslational elements (Figure 2). In
addition, many novel PTMs were first observed in marine
organisms. Below, we discuss how these features diversify
RiPPs enabling combinatorial synthesis.
Strategy one: introduce variety (by core
peptide hypervariability)
Hypervariability in protein sequences allows organisms
to adapt. For example, pathogens often exhibit hyper-
variability in cell-surface molecules that likely help to
evade host immune responses [14]. Likewise, hyper-
variability of RiPP core peptide sequences creates
natural product diversity. The phenomenon of hyper-
variability was first described in marine cone snail
toxins, the conopeptides [15]. Hypervariability exists
only in the core sequence, which allows the cone snail
to produce an army of mature toxins or ‘cabals’ that act
synergistically to paralyze prey by targeting different
ion channels simultaneously [16].
While some core peptides were known to be hypervari-
able, the question remained as to whether the corre-
sponding PTM enzymes were similarly hypervariable.
This question was answered with marine peptides, the
cyanobactins [17]. In a series of cyanobactin pathways
encompassing diverse core peptides from across the trop-
ical Pacific Ocean, essentially sequence identical
enzymes were found, implying that libraries of com-
pounds can be created using the same set of enzymes.
Indeed, with the cyanobactins later engineering evidence
revealed that certain pathways could produce potentially
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millions of derivatives [18]. Another example lies in the
highly mutable marine lanthipeptide pathway to pro-
chlorosins that was discovered by genome mining, and
in vitro work reconstituted all the observed variants
[19,20]. More recently, similar RiPP hypervariability is
also starting to be discovered in terrestrial organisms
[21!], implying that this feature may be widespread.
However, there are limitations to this strategy since some
pathways carry cores that are less mutable. For example,
unlike the cyanobactin tru pathway that is mutable for
PTMs at all positions excepting the C-terminal residue
[22], the linear azoles/azoline peptide (LAP) family of
RiPPs that include the microcins and plantazolicin are
more restricted in their core sequence [23,24]. Neverthe-
less, in many RiPP pathways hypervariability has been
exploited extensively to create unnatural natural product
libraries. For example, not only have RiPPs been engi-
neered with sequences not found in nature, but also
highly engineered derivatives carrying non-proteinogenic
amino acids can be encoded as has been successfully
demonstrated in the lanthipeptides [25!], cyanobactins
[26] and more recently in the lasso peptides [27].
Strategy two: pair variety with promiscuity
(using broad-substrate pathways)
Enzymes are often remarkably selective, with strong
affinities for their native substrates. But, this is not true
for the hypervariable RiPPs, which necessitates the PTM
enzymes to be promiscuous to be functional. Coupled
with hypervariability, such broad substrate-tolerance of
the PTM enzymes allows combinatorial synthesis in
nature [15,17,19]. Since most RiPP pathways are multi-
step, the noteworthy feature that stands out here is that
due to the substrate variability ensuing each PTM event,
it is not one PTM enzyme, but every PTM enzyme in the
pathway that is promiscuous. Thus, the entire multi-step
pathway as a whole unit displays remarkable promiscuity.
This has led to successful creation of artificial compound
libraries by heterologous expression of the entire RiPP
pathways as in the microviridins [28], lasso peptides [11],
thiopeptides [12] and cyanobactins [18] among others, in
addition to libraries carrying non-canonical amino acids,
already detailed above.
The question of how promiscuity is evolutionarily favored
in broad-substrate enzymes was elegantly investigated in
the study of the promiscuous marine lanthionine synthe-
tase ProcM from the prochlorosin pathway, which can
install lanthionines on 29 different substrates [19]. A
comparison of ProcM with its narrower substrate tolerant
counterpart LanM showed that ProcM pays a ‘kinetic
price’ for its relaxed specificity [29!!]. Another example
lays in cyanobactin biosynthesis that has been known to
carry upto six or more PTMs. The initial enzymatic steps
encounter comparatively similar substrates due to the
presence of the leader, and exhibit comparatively faster
reaction completion times in vitro, which is in contrast to
the latter PTM steps that are progressively slower as the
enzymes encounter greater structural diversity [22,30!!].
16 Biocatalysis and biotransformation
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posttranslational
modifications
A simple schematic representation of RiPP biosynthesis, showing that the biosynthetic machinery is genetically encoded. The precursor peptide
substrate gene is shown in black, which is flanked by multiple posttranslational modification enzymes and other proteins (shown in grey)
responsible for the transformation of the precursor peptide substrate into the final product. The precursor peptide itself can be differentiated into
the core sequence (that matures into the final product) and a leader/follower sequence that often carry enzyme recognition elements among
others.




Strategy three: provide roots to promiscuous
partnership (through conserved recognition
sequences)
The molecular basis of PTM promiscuity relies on the use
of recognition sequences (RSs). In this strategy, short
sequence motifs (RSs) within the precursor peptide sub-
strate act as docking sites for the PTM enzymes. The idea
that enzymes dock with substrates at specific sequence
motifs is well known and has been documented for a large
number of proteases, kinases, and methyltransferases,
among others [31].
Within RiPPs, the presence of RSs is widespread [4].
Because of the unique evolutionary strategy employed
in several marine cyanobactin biosynthetic pathways,
conserved peptide sequence elements could be directly
observed, leading to the concept of RSs in RiPP pathways
[7]. Reports of crystal structures of many RiPP PTM
enzymes have confirmed presence of specific contacts
between the enzyme and RS [32–34]. Interestingly, homo-
logs of certain RSs motifs are sometimes found in
completely unrelated RiPP pathways, but carrying the
same PTM, suggesting that the RS is likely serving the
same purpose. For example, a homolog of the cyanobactin
heterocyclization RS is also found in the bottromycin
family of RiPPs, which contain the same type of hetero-
cycles [35].
The conservation of RSs allows PTM enzymes to be fairly
well conserved in function between different pathways.
Marine RiPP engineering and biosynthesis Sardar and Schmidt 17
Figure 2
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Features of RiPP pathways that enables combinatorial chemistry: (1) core peptide hypervariability (represented by variation in color of the core
sequences), which allows to diversify the RiPP pathway products by simple mutations in the core sequence only; (2) broad-substrate pathways,
which requires the respective PTM enzymes (shown in blue and green shapes corresponding to distinct PTMs) to be promiscuous enabling them
to accept the diversity in the core substrate; (3) recognition sequences (shaded in blue and green boxes along with their respective PTM
enzymes), which provide docking sites for these promiscuous enzymes, thus preserving chemistry, despite the susbtrate diversity; (4) pathway
modularity, wherein certain units of the pathway act as modules that can be interchanged with other distinct pathways further diversifying PTM
chemistry. For instance, recognition sequences from one pathway can be interchanged with PTM enzymes from another (represented by
differently colored PTM enzymes deviant from the original) to generate new modifications (shown by stars) in the same core sequence.




Although, hypervariability of substrate core sequences
implies that the substrates are rapidly evolving. This
phenomenon of substrate evolution, wherein core pep-
tide hypervariability is coupled with conservation of RSs,
has allowed RiPP pathways to diversify the final natural
products they encode, which in turn may endow evolu-
tionary advantages [36!]. Substrate evolution is yet an-
other mechanism that has enabled creation of both
natural and artificial combinatorial biosynthesis, exam-
ples of which have already been discussed.
This has further enabled in vitro engineering of indi-
vidual PTM steps, wherein many approaches such as
use of non-native cores, non-proteinogenic cores, chi-
meric substrates among others have been extensively
exploited [12,22,36!,37–39]. In addition, these short
RSs are portable, wherein the RS only without the
leader can be imported to non-native sequences, and
still function to recruit the expected PTM [36!]. More
recently, engineered PTM enzymes fused to RSs could
also successfully modify stand-alone core peptides.
This was first shown in the lanthionine synthetase
LctM [40!!] and later in the cyanobactin heterocyclase
LynD [41], although cyanobactin heterocyclization is
capable of proceeding without its RS altogether at the
price of lower efficiencies [36!,42,43!!]. Interestingly,
such ‘leaderless’ PTMs that do not require RSs outside
the core sequence have also been reported in the
cyanobactin prenyltransferases [44] and more recently
in a lanthipeptide dehydrogenase [45].
Strategy four: swap partners (by pathway
modularity)
RiPP pathways are often modular, which was not appre-
ciated before studies in marine organisms. In nature, a
clear example of modularity is observed between the pat
and tru cyanobactin pathways [46]. Both encode very
different cyanobactins; the patellamides from the pat
pathway are thiazole–oxazole carrying cyclic peptides,
whereas the tru pathway produces thiazoline containing
prenylated cyclic peptides called patellins. The only
major differences between their gene clusters lie in
regions that encode specific PTM enzymes, which are
responsible for the structural differences between them.
Otherwise, they share about 98% gene sequence identity
over half of their gene clusters, implying that pat and tru
elements maybe interchangeable.
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Representatives of novel PTMs observed in marine derived RiPPs. Shown in grey circles are all PTMs present in the particular structure, whereas
shown in blue circles are specific PTMs first observed in marine RiPPs.




This implied that by maintaining the same core
sequences, different PTM enzymes between pathways
could be swapped (as long as the RSs are preserved),
leading to hybrid natural products. This was recently
demonstrated in the multi-step cyanobactin pathways,
wherein swapping PTM enzymes from unrelated
pathways at each step led to complete in vitro reconsti-
tution of both natural and unnatural products. Addi-
tionally, different combinations of PTM enzymes
were used to create an unnaturally large macrocycle
[30!!].
Strategy five: achieve novelty (creating unique
PTMs)
Structurally, RiPP diversity is limited due to the con-
straint of only 20 possibilities from the amino acid pool.
Nonetheless, the structural complexity of RiPPs often
rivals those of the nonribosomal peptides due to the
presence of extensive posttranslational processing [5].
RiPPs are rich in such novel PTM chemistry [4], and
detailed below are a few examples of PTMs discovered in
marine organisms (Figure 3).
The combination of N-C peptide macrocyclization with
the presence of azol(in)es was observed first in the cya-
nobactin RiPPs from tunicates living in coral reefs [47], in
addition to dimethylallylation or geranylation of a peptide
side-chain [44,48] and prenylation of a peptide amino
terminus [49]. The microviridins from limnal cyanobac-
terial blooms of Japan were the first to show presence of
ester and amide linkages via functional groups of lysine or
aspartate/glutamate, leading to rigid cage-like cyclic pep-
tides with lactones and lactams [50]. Halogenation of
tryptophan residues was first reported in the conopeptides
[51]. Among recently discovered RiPPs, the most striking
example of novel PTMs was reported in the new family of
proteusins represented by the giant natural products
polytheonamides derived from marine sponge associated
symbiosis. They carry up to 48 PTMs, including an
unprecedented N-terminal acyl unit derived from threo-
nine [52!!,53]. Other marine peptides too exist that
resemble RiPPs structurally, but their biosynthetic route
is unknown, an interesting example of which is the
lanthionine carrying vitilevuamide, isolated from marine
ascidians [54].
Much ongoing research is aimed at understanding the
PTM machinery of RiPPs. Such knowledge will further
the engineering efforts for the creation of these enzymes
as tools to generate PTM diversity in artificial combina-
torial libraries. For example, ProcM was manipulated to
act as a kinase instead of lanthionine synthetase, using
principles of RiPP RSs [55!]. Since many PTMs resemble
those found in nonribosomal pathways in terms of com-
plexity or structure, knowledge of RiPP enzymes will aid
the increasing repertoire of chemical scaffolds for design-
er peptide motifs [5].
Conclusions and perspectives
Questions of specific biological problems in the oceans
has led to the discovery of many of the principles of RiPP
evolution and design described above. When taxonomic
relationships are close, precise evolutionary relationships
develop. For example, cone snails synthesize the con-
otoxin family of RiPPs to paralyze their prey. Research
into these peptides was initiated to discover the active
principles behind these ecological interactions, leading to
the FDA approved drug Prialt. Because cone snails are
closely related to each other and occupy different eco-
logical niches, a compelling evolutionary story came to
light that greatly impacted the design and discovery of
conopeptides and analogs [56].
Similarly, compounds in a wide range of organisms con-
tain close chemical relationships that were proposed to be
of use in biosynthetic engineering [57]. Although most of
these compounds are not RiPPs, examples of applying
this evolution/function strategy have focused on the
RiPPs. More recently, such features are beginning to
emerge in cases such as the cyclotides, found in plants
[21!]. As sequencing data continues to arise, these and
other stories will continue to enable the designed enzy-
matic synthesis of modified peptides.
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The cyanobactin biosynthetic machinery is an intriguing unit of novel 
chemistry. The first point of interest is that the biosynthetic enzymes exhibit 
remarkable substrate tolerance in that diverse substrate sequences can be fully 
processed, leading to enrichment with different chemical motifs. The second point of 
interest lies in these chemical motifs themselves, which are structurally elaborate 
with the potential of lending important biological properties to peptide scaffolds. For 
example, single cyanobactin pathways have been known to carry up to five types of 
peptide modification reactions. This dissertation was aimed to investigate deeper 
into these two features, and the questions we started out with were the following: 
First, what is the biochemical basis of the observed substrate tolerance of the 
biosynthetic machinery? And second, if we understand the fundamentals of this 
phenomenon, can we use the set of rules we learn for the creation of peptide motifs 
encoding both diversity of sequence and chemically elaborate structures?  
By definition, enzymes are known to be specific for select substrates, which is 
the route followed in conventional metabolic pathways. In contrast, the cyanobactin 
pathway enzymes are inherently not specific for substrate sequences, allowing them 
to create product diversity, exemplifying diversity-generating metabolism.1 The 
biochemical basis for this promiscuity lies in the use of recognition sequences, which 
serve as docking sites for recruiting the different posttranslational enzymes. This 
means the actual site of recognition for these enzymes is highly conserved. On the 
other hand, the site of catalysis is separated and lies in the core sequence encoding 
diversity. Classically, enzyme evolution comprises technologies that engineer the 
enzyme itself for broader substrate selectivity or new chemistry.2 However, herein 
lies a natural technology, where the enzyme is unchanged, and the substrates evolve 
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to encode diversity in the core sequence. Substrate evolution also ensures that the 
site of recognition is conserved instead through the use of homologous recognition 
sequences. This natural phenomenon was exploited biochemically by demonstrating 
the discrete and portable nature of the recognition sequences for the various 
posttranslational enzymes, providing answers to the first question about enzyme 
promiscuity.  
Since both the recognition sequences and the corresponding posttranslational 
enzymes across different pathways are homologous, this implied that elements from 
across pathways could be interchanged to create chemistry. This is the concept of 
modularity in the cyanobactin pathways, which implies different elements across 
multiple pathways act as modules that can be mixed and matched for combinatorial 
in vitro synthesis of peptide motifs. The set of rules provided by recognition 
sequences coupled with the feature of modularity of pathways gives us a tool kit of 
enzymes and recognition elements for the creation of peptide motifs. The successful 
use of this toolkit addresses the second question asked in this dissertation.  
A third theme that covers these questions is the introduction of new 
chemistry in the created peptide scaffolds. One way to achieve this is by exploiting 
modularity of the pathways by the creation of hybrid natural products. A second way 
is to characterize new enzymology from newly discovered cyanobactin pathways and 
incorporate them into peptide scaffolds. One such example has been provided in this 
dissertation by characterization of new enzymology from a cyanobactin pathway. 
Additionally, the cyanobactin biosynthetic machinery is a source of unique enzyme 
mechanisms, an example of which has also been studied here, providing new 
insights into ATP utilizing systems.  
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In summary, this dissertation explores the three features of promiscuity, 
modularity and unique chemistry from the cyanobactin pathways. The lessons we 
learn from this study enabled us and will enable future efforts to expand nature’s 
chemical inventory for the creation of new molecules with drug-like properties, 
holding potential in the field of peptide-based drug discovery.  
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